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CHAPTER 1
INTRODUCTION
1.1

Parkinson’s disease
Parkinson’s disease (PD) is a slowly progressing neurodegenerative disorder, which was

initially described as “Paralysis agitans” by James Parkinson in 1817 in an essay on shaking
palsy. He described tremors, postural instability, rigidity, festinating gait, sleep disturbances, and
constipation as hallmark features of the disease in his essay (Parkinson 2002). Five out of six
cases described by James Parkinson were subjects with age range from fifty to seventy two
years. This implied aging as a common cause of the disease, which has been well established
now (Shulman, De Jager et al. 2011). Afterwards, Jean-Martin Charcot described this disease in
greater detail and named it after James Parkinson as Parkinson’s disease. Surprisingly, all the
symptoms of PD described by Parkinson and Charcot are still considered main clinical features
for diagnosis purpose. Most of the patients with PD are diagnosed at a stage when their motor
symptoms (tremors, postural instability, and rigidity) appear. However, it has been established
now that non-motor symptoms of the disease such as sleep disturbances, constipation
(dysautonomia), and loss of olfactory sense appear as early as 20 years before the appearance of
cardinal motor symptoms (Hawkes 2008). After the discovery of dopamine (DA) as a
neurotransmitter in 1957 (Carlsson, Lindqvist et al. 1957, Carlsson, Lindqvist et al. 1958),
research in PD field has grown exponentially and wide variety of pathological targets have been
identified. Significant therapeutic and surgical interventions have been developed after
understanding the pathophysiology of PD. Also, various diagnostic tools have been developed to
diagnose the progressive disorder in advance, which may help in disease intervention during its
early phase.
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1.2

Statistics, epidemiology and risk factors
Currently, PD is the second most common neurodegenerative disease after Alzheimer’s

disease. Approximately 10 million people worldwide are living with the disease, 1 million of
which are Americans. Every year around 60,000 Americans are diagnosed with PD. Total direct
and indirect expenses in United States because of PD are estimated to be nearly $25 billion per
year.
1% people over age of 65 and 5% people over age of 85 suffer from PD. Aging is the
most common risk factor associated with sporadic PD. Men are one and half times more likely to
get PD than women (Van Den Eeden, Tanner et al. 2003, de Lau and Breteler 2006). Exposure to
environmental toxins such as MPTP (meperidine analog), herbicide (paraquat) and pesticide
(rotenone) has been shown to increase the risk of PD. Cigarette smoking and coffee consumption
have been shown to reduce the risk of PD. Gene mutations are usually responsible for an early
onset of PD and approximately 90% cases of PD are sporadic in nature. European ancestry
increases the risk of PD because of genetic causes (Shulman, De Jager et al. 2011).

1.3

Pathophysiology of Parkinson’s disease

1.3.1

Dopamine and Parkinson’s disease
Interestingly, reserpine administration into animals and humans produce Parkinson’s

motor symptoms, and reserpine is a widely used toxin in Parkinson’s animal models to induce
immobility (Carlsson 1959). As reserpine was known to cause depletion of 5-hydroxytryptamine
(serotonin), initial hypothesis for PD implicated depletion of brain serotonin as a culprit.
However, restoration of serotonin levels in brains of reserpinized animals by administration of 5hydroxytryptophan (a brain penetrable precursor of serotonin) did not change Parkinson’s motor
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symptoms, whereas, administration of 3,4-dihydroxyphenylalanine (L-DOPA), a precursor of
catecholamines (dopamine, adrenaline and noradrenaline) caused almost complete reversal of
reserpine’s effects temporarily (Carlsson, Lindqvist et al. 1957).
Historically, DA was shown to be a neurotransmitter by Arvid Carlsson (Carlsson,
Lindqvist et al. 1958, Carlsson 1959). Further investigations showed that high concentration of
DA was localized to corpus striatum, an area of brain which is extrapyramidal motor center and
controls motor functions (Carlsson 1959). Finally, studies by Hornykiewicz and workers showed
that Parkinson’s patients had depleted levels of DA in caudate nucleus and putamen (parts of
striatum), the regions where nigrostriatal dopaminergic neurons from substantia nigra terminate
(Birkmayer and Hornykiewicz 1961, Birkmayer and Hornykiewicz 1998). It was proposed that
PD may result

from imbalance between serotonin and catecholamines on one hand, and

histamine and acetylcholine on the other (Barbeau 1962). Current hypothesis suggests the loss of
dopaminergic neurons in substantia nigra pars compacta (SNPc) as a main pathological feature
of PD (figure 1-1).
Various pathological assessments have clearly established that PD patients have
significant dopaminergic neuronal degeneration in SNPc, which forms nigrostriatal tract.
Nigrostriatal dopaminergic system is essential for motor co-ordination and its degeneration in PD
results in cardinal motor symptoms which are tremors and postural instability. Unfortunately,
Parkinson’s motor symptoms do not appear until around ~60% of the dopaminergic neurons in
SNPc have degenerated, which translates to around ~80% of dopamine depletion (Hornykiewicz
and Kish 1987, Dauer and Przedborski 2003). Therefore, the disease is diagnosed at very
advanced stage when significant neurodegeneration has already taken place.
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Figure 1-1. Neuropathology of Parkinson’s disease.
A. Normal nigrostriatal pathway, where dopaminergic neurons from SNPc project to
caudate and putamen. (dopaminergic neurons are melanized and thus appear black
colored); B. Nigrostriatal pathway in Parkinson’s disease patient, where dopaminergic
neurons projecting from SNPc to putamen have significantly degenerated and there is a
moderate loss in projection from SNPc to caudate. Also, note the depigmentation of SNPc
due to loss of dopaminergic neurons (Dauer and Przedborski 2003).
1.3.2 Iron and Parkinson’s disease
PD patients show an increase in iron(III) accumulation and ferritin expression (iron(III)
storage protein) in SNPc but not in substantia nigra pars reticulata (SNPr) (Jellinger, Paulus et al.
1990). Patients with advanced stage PD have significant accumulation of iron(III), whereas,
cases with mild PD do not show increased accumulation in SNPc (Zecca, Youdim et al. 2004).
Post-mortem analysis and non-invasive methods such as magnetic resonance imaging (MRI)
have revealed age-related increase in iron concentration in various brain regions. Neuromelanin
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in nigral dopaminergic neurons has a strong tendency to bind to iron(III) and it might be
responsible for higher content of iron(III) in SNPc than any other brain regions (Bharath, Hsu et
al. 2002). Highest amount of iron-melanin complex is observed in patients with
Alzheimer’s/Parkinson’s disease (Jellinger, Kienzl et al. 1992). Iron(III) deposits have been
shown to be present in microglia, astrocytes, and oligodendrocytes in the SNPc of patients with
PD. Neuromalanin-iron complex has been shown to activate microglia (inflammatory mediators)
in-vitro, which leads to release of various inflammatory mediators (Zecca, Youdim et al. 2004).
Iron misregulation/accumulation can result in the demise of dopaminergic neurons only in case
of genetic disorders. More than 90% cases of PD have very low amount of iron build-up. Thus,
the neurotoxicity in PD may result from complex interactions between iron and other
pathological factors involved in pathogenesis of PD.
There is an inverse relationship between DA concentration and iron(III) concentration in
the putamen (dopaminergic neuron terminal site), but not in the substantia nigra (dopaminergic
neuron origination site), which indicates that the neurodegeneration may be a retrograde process.
This implies that the neurodegeneration may initiate at dopaminergic neuronal terminal site
(striatum) and may proceed in retrograde path to permanently degenerate its origination site in
the substantia nigra.
1.3.3 Lewy bodies and Lewy neurites in Parkinson’s disease
Post-mortem analysis of PD patient brain reveals accumulation of intra-cytoplasmic
protein rich inclusions, which stain positive for ubiquitin (figure 1-2). In 1912, Fritz Jacob
Heinrich Lewy described these cellular inclusions in various brain parts of patients with
neurogenerative disorders. Afterwards, in 1919 Tretiakoff et al. reported the presence of these
inclusions (termed “Lewy bodies”) in the substantia nigra of PD (Goedert, Spillantini et al.
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2013). Lewy body pathology has been implicated as a cause of PD by promoting
neurodegeneration. Surprisingly, Lewy body pathology in PD doesn’t only restrain to central
nervous system, but it also extends to peripheral nervous system and enteric nervous system.

Figure 1-2. Immunostained Lewy bodies in SNPc dopaminergic
neurons of Parkinson’s disease
Immunostaining with an antibody against α-synuclein reveals intensely immunoreactive
central core surrounded by faintly reactive peripheral zone. Whereas, staining with
ubiquitin reveals diffused immunostaining throughout lewy body (Dauer and Przedborski
2003).
In 1997, two research findings on α-synuclein protein brought substantial change in the
Lewy body research in PD field (Polymeropoulos, Lavedan et al. 1997, Spillantini, Schmidt et al.
1997). One of these studies identified α-synuclein mutations in some familial cases of PD
(Polymeropoulos, Lavedan et al. 1997). Immediately following this finding, Spillantini et al.
showed that in idiopathic PD, Lewy bodies and Lewy neurites exhibited strong staining for αsynuclein protein (figures 1-2, 1-3). Later, it was shown by electron microscopy that Lewy
bodies and Lewy neurites are made of unbranched α-synuclein filaments, with a length of 200600nm and width of 5-10 nm and stain very strongly compared to traditional staining with
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ubiquitin (Spillantini, Crowther et al. 1998). Now, it has been established that α-synuclein forms
the major filamentous portion of Lewy bodies and Lewy neurites in PD.

Figure 1-3. Substantia nigra from Parkinson’s disease patient stained for α-synuclein
(a) Shows two pigmented nerve cells, each containing an α-synuclein positive Lewy bodies
(thin line). Lewy neurites (thick line) are also immunopositive, (b) shows two α-synucleinpositive Lewy bodies in single pigmented cell, and (c) shows α-synuclein positive
extracellular Lewy body (Spillantini, Schmidt et al. 1997).
Missense and gene dosage mutations in SNCA (α-synuclein gene) are related to familial
PD. However, 90% cases of PD are sporadic in nature. α-synuclein pathology has been shown to
spread in a prion-like manner, originating from small number of nerve cells (Goedert,
Clavaguera et al. 2010). α-synuclein positive Lewy bodies and Lewy neurites emerge in
predictable order and Braak et al. have established a staging scheme for sporadic PD progression
(Braak, Del Tredici et al. 2003) (figure 1-4).
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Figure 1-4. Spread of idiopathic Parkinson’s disease pathology
Lewy body pathology may arise from peripheral/enteric nervous system, possibly in
gastrointestinal tract, and transfer to the brain stem via the glossopharyngeal and vagus
nerves. Finally, it spreads to the cortex at a later stage of disease progression (red arrows).
Alternatively, the pathology may start at the olfactory bulb and anterior olfactory nucleus
and spread to the midbrain and cortex regions (orange arrows) (Hansen and Li 2012).
According to the staging scheme, Lewy pathology spreads in PD patient in six
distinguishable stages. Lewy pathology spreads to substantia nigra in 3rd stage. Staging scheme
corroborates the findings that non-motor symptoms of PD appear before the motor symptoms.
Schapira et al. have proposed that the detection of incidental Lewy bodies can be an early
predictor of neurodegeneration and can help significantly in disease intervention in early stage of
PD (Schapira and Tolosa 2010).

9

1.3.4 Oxidative stress and Parkinson’s disease
Human brain is highly susceptible to oxidative stress because of four reasons,
i. High concentration of polyunsaturated fatty acids (PUFA), which are substrates for lipid
peroxidation,
ii. Brain utilizes the maximum amount of oxygen among all body parts and under chronic stress
there is more probability of mitochondrial dysfunction,
iii. Brain possess low concentrations of anti-oxidant protective mechanisms such as catalase,
glutathione, glutathione peroxidase, tocopherol etc. than other body parts,
iv. Iron is present at high concentration in specific brain regions which can catalyze various
reactions that can cause generation of free radicals or hydroxyl ion (Olanow 1990).
Post-mortem analysis of PD brain show significant increase in oxidation of various
biomolecules in substantia nigra, which implies involvement of free radicals and reactive oxygen
species (ROS) in the pathology of PD. It has been suggested that exposure to environmental
toxin or an endogenous toxic process might initiate generation of free radicals and promote
vicious cycle of oxidative stress (Jenner, Dexter et al. 1992). However, the intimate relationship
of oxidative stress with many other pathological factors involved in PD pathogenesis suggests
that it is very difficult to conclude whether oxidative stress is responsible for initiation of PD or
not, but it surely is responsible for the progression of PD (Jenner 2003). In PD, dopaminergic
neuron milieu and increased iron accumulation can strongly promote excessive generation of free
radicals, which can cause increased oxidative burden. In addition, mitochondrial dysfunction can
result in increased generation of ROS. The extent of change in the oxidative stress in the
substantia nigra suggests that the oxidative stress is not just limited to dopaminergic neurons but
should also be taking place in other non-neuronal cells of substantia nigra. Early compensatory
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changes in the turnover of DA because of nigral dopaminergic neuron degeneration may initiate
an increase in oxidative stress and oxidative metabolites of DA.
Initially, the presence of neuromalanin (a product of DA oxidation) in nigral neurons
attracted significant interest. Auto-oxidation of DA, formation of semiquinone, and
polymerization of DA has been extensively studied as sources of oxidative stress (figure 1-5).
DA auto-oxidation and its metabolism by monoamine oxidase-B (MAO-B) generate hydrogen
peroxide. Under normal conditions, the generated hydrogen peroxide is neutralized by cellular
anti-oxidant machinery (particularly glutathione system). However, in PD, overburden of
oxidative species can compromise cellular anti-oxidant systems and result in excessive hydrogen
peroxide accumulation.

Figure 1-5. Dopamine metabolism by enzymatic reaction and autooxidation
Enzymatic metabolism of dopamine by MAO-B liberates hydrogen peroxide. Autooxidation of dopamine results in formation of semi-quinones, free radicals which enter
vicious cycle of oxidative stress by reacting with dopamine to liberate hydrogen peroxide
and free radicals. Hydrogen peroxide generated by both reactions is neutralized by
glutathione system in cells (Lotharius and Brundin 2002).
Iron-melanin complexes have been shown to be elevated in PD substantia nigra
(Jellinger, Kienzl et al. 1992). Iron(III) accumulation may selectively occur in melanized
dopaminergic neurons because of melanin’s high affinity to interact with iron(III). In PD
substantia nigra, there is a shift in iron(II)/iron(III) ratio in favor of iron(III) and a subsequent
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increase in iron(III)-binding protein ferritin (Riederer, Sofic et al. 1989). Iron can catalyze two
different biochemical reactions which can cause generation of ROS and free radicals, increasing
the oxidative burden in PD. Fenton reaction and Haber-Weiss reactions are known to be
catalyzed by iron(II) in cells under physiological environment. Haber-Weiss reaction is very
slow but can be catalyzed by iron(III) (figure 1-6). These reactions can convert the hydrogen
peroxide generated by DA metabolism or by superoxide dismutase enzyme to highly toxic
hydroxyl radical, which can result in increased oxidative stress in PD substantia nigra.

Figure 1-6. Iron(III) catalyzed reactions
Superoxide ions generated in cells are usually converted to hydrogen peroxide by
superoxide dismutase enzyme (anti-oxidant enzyme) and the hydrogen peroxide is
neutralized by glutathione system. However, higher oxidative burden can generate
excessive superoxide ions which get converted into highly reactive hydroxyl radical by
Haber Weiss reaction or Fenton reaction. Haber Weiss reaction is very slow at
physiological conditions and superoxide dismutase is shown to neutralize superoxide before
the reaction can take place. However, Fenton reaction is the mechanism which can
generate hydroxyl radicals from hydrogen peroxide (Olanow 1990).
Energy for various cellular processes is provided by ATP, which are generated by
mitochondria of cells. Aging, various environmental factors (toxins) and genetic risk factors
associated with PD cause mitochondrial dysfunction by influencing the bioenergetics, dynamics,
transport and quality control of mitochondria (Exner, Lutz et al. 2012). Mitochondrial oxidative
phosphorylation generates ATP for various cellular processes and it depends on both
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mitochondrial and nuclear DNA-encoded proteins for its function (figure 1-7). Systemic
dysfunction of mitochondrial complex-I enzyme has been shown to be present in substantia
nigra, platelets, skeletal muscles and frontal cortex of patients with PD (Exner, Lutz et al. 2012).
Mitochondrial DNA has been also shown to undergo age dependent mutations and deletions,
which can contribute to mitochondrial dysfunction in age related PD. Substantia nigra
dopaminergic neurons are more susceptible to mitochondrial DNA mutations, as neurons from
other regions of brain do not show high levels of mitochondrial DNA mutations.
Mitochondrial complex-I inhibition, which is widely used to model PD in various cell
culture and animal models (discussed later) has been shown to cause decreased ATP production
and increased formation of reactive oxygen species. This process can further damage
mitochondrial DNA and trigger vicious cycle of mitochondrial impairment and oxidative stress
(Lin and Beal 2006). Genes associated with PD have been also shown to be involved in
inhibition of mitochondrial complex-I (discussed later).
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Figure 1-7. Mitochondrial Electron Transport System (ETS)
The ETS is located on inner mitochondrial membrane and has 4 membrane spanning
enzyme complexes, which efflux protons out and generate protomotive force. These protons
again enter mitochondrial inner membrane through Complex V and generate ATP from
ADP. Parkinson’s disease patients have significant decrease in their mitochondrial
complex-I activity. Surprisingly, this decrease in not only limited to substantia nigra but it
is widespread and shown to be present in platelets, skeletal muscles and frontal cortex
(Abou-Sleiman, Muqit et al. 2006).
Excessive generation of reactive oxygen species or their inadequate clearance by antioxidant systems can lead to the oxidation of biomolecules in the substantia nigra. Because of
unstable nature of superoxide, hydroxyl and other free radicals, they instantaneously react with
surrounding lipids, proteins and DNA of substantia nigra cell population.
PUFA levels are significantly high in brain, which means there is high amount of lipids
available as a substrate, which can undergo lipid peroxidation. Various studies have shown that
the PUFA content in the PD substantia nigra is significantly reduced and simultaneously there is
significant increase in Malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) levels which
are late end-stage byproducts of lipid peroxidation (Dexter, Carter et al. 1989) (figure 1-8). Lipid
hydroperoxides, which are early stage products of lipid peroxidation are shown to be present in
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even higher concentration in PD substantia nigra (Jenner, Dexter et al. 1992). This implies that in
PD substantia nigra, significant amount of PUFA undergo lipid peroxidation, which results in
decrease in total PUFA available. One of the reasons for lipid peroxidation in PD substantia
nigra may be excessive iron accumulation, which can catalyze chemical reactions to generate
hydroxyl radical. The resulting 4-HNE is highly reactive and can form stable adducts with thiol
and amine groups of proteins resulting in their damage.
Increase in the level of 8-hydroxy-2’-deoxyguanosine (8-OHG) (guanine oxidation
product) and parallel decrease in the levels of FAPy-guanine (guanine reduction product) have
been reported in PD, which indicates oxyradical-mediated damage to the nuclear DNA (Alam,
Jenner et al. 1997). 8-OHG and FAPy-guanine have a common intermediate precursor, which
when oxidized yields 8-OHG and when reduced gives FAPy-guanine. This suggests that the
DNA damage may not be actually because of oxidative stress, but possibly because of change in
redox status in the diseased tissue (Jenner 2003) (figure 1-9).
DNA damage is even more pronounced in mitochondria, as the DNA isolated from
mitochondria showed 10 times high levels of 8-OHG (Mecocci, MacGarvey et al. 1993). It has
been suggested that hydroxyl radical may not be involved in DNA damage as it can generate
many diverse oxidation products of DNA, which are not observed in post-mortem PD substantia
nigra. However, peroxyl radicals from lipid peroxidation could selectively damage guanine and
they could be potentially involved in DNA damage in PD (Shigenaga, Aboujaoude et al. 1994).
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Figure 1-8. Lipid peroxidation process in presence of free radicals
Model of peroxidation of Arachidonic acid, where initial reaction with hydroxyl radical
generates reactive intermediate which reacts with O2 to give lipid hydroperoxides. Lipid
hydroperoxides react further to give MDA and 4-HNE (VanderJagt, Harrison et al. 2001).
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Figure 1-9. Products of guanine oxidative damage via the intermediate
C8-OH adduct radical
Guanine under various oxidative conditions can form C8-OH-adduct radical, which can
get converted to 8-OHG under oxidizing environment or can convert into FAPy guanine
under reducing environment. It is postulated that the damage to DNA might be not due to
radical attack but due to oxidizing environment in Parkinson’s disease (Alam, Jenner et al.
1997).
Index
Total iron concentration

Brain region
Substantia nigra
Cortex

Percentage of control
129%
100%

Superoxide dismutase

Substantia nigra
Cerebellum

133%
95%

Lipid peroxidation

Substantia nigra
Cortex

135%
94%

Protein oxidation

Substantia nigra
Frontal cortex

~200%
~100%

DNA oxidation

Substantia nigra
Cerebellum

238%
110%

Table 1.1. Evidence of oxidative stress in Parkinson’s disease.
Oxidation of lipid, protein and DNA is dramatically elevated in the substantia nigra
specifically. Iron accumulation in the substantia nigra of patients with Parkinson’s disease
results in Fenton reaction which causes ROS generation. Anti-oxidant enzyme levels reflect
oxidative burden in substantia nigra compared to other brain regions (Lotharius and
Brundin 2002).
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Oxidative stress associated damage to proteins is also reported in patients with advanced
stage PD (Floor and Wetzel 1998) (figure 1-10). Surprisingly, protein carbonyls have been
shown to be elevated not only in the substantia nigra of advanced stage PD brain, but also in all
other brain regions. Protein carbonyl levels in various brain areas of PD are independent of
iron(III)/iron(II) level and thus iron might not play a primary role in generation of protein
carbonyls. Also, protein carbonyl levels are not found to be changed in incidental Lewy body
disease, which is considered presymptomatic PD. L-DOPA therapy (which can act as prooxidant) and/or more widespread effects of oxidative stress in advanced stage of the disease in
PD patients could cause a generalized increase in protein carbonyl levels in brain (Fahn 1996,
Alam, Daniel et al. 1997). Protein carbonylation is an irreversible and unrepairable process.
Additionally, PD patients have dysfunctional ubiquitin-proteasome system, which increases the
possibility of protein carbonyls forming higher molecular weight aggregates that may be
cytotoxic. Damage to proteins which are responsible for dopaminergic neurotransmission (αsynuclein, DAT, VMAT2, v-SNARE, t-SNARE, and dopamine receptors) may cause direct
damage in PD.

Figure 1-10. Carbonylation of protein amino acid side-chain
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Increased oxidative stress in PD can overburden the anti-oxidant systems of cells.
Unfortunately, as mentioned before, brain has less amount of catalase, tocopherol, glutathione,
glutathione reductase, and glutathione peroxidase (key anti-oxidant defense systems in cells)
compared to peripheral organs. Dysfunction of anti-oxidant systems in cells can result in
decreased clearance of oxidative species and increased oxidative environment. Significant
decrease in levels of reduced glutathione and total glutathione are reported in substantia nigra of
patients with PD and there is no corresponding increase in oxidized glutathione (Perry, Godin et
al. 1982, Sofic, Lange et al. 1992). Decrease in glutathione levels may reduce the clearance of
H2O2 (generated from dopamine auto-oxidation and metabolism) and promote the formation of
hydroxyl radical in a reaction catalyzed by iron in substantia nigra.
Interestingly, the extent of glutathione depletion correlates well with the severity of PD
(Jenner and Olanow 1996). Also, glutathione depletion has been shown to precede the loss of
dopaminergic neurons as well as accumulation of “Lewy bodies” in PD patients. In patients with
incidental Lewy body disease (ILB), glutathione is depleted to similar levels as PD patients.
However, ILB patients do not show elevated levels of iron or impaired activity of mitochondrial
complex-I. Thus, glutathione depletion may be an earliest biochemical marker for nigral
neurodegeneration. Various studies have concluded that the glutathione depletion is not only
limited to neuronal population, but glial cells of substantia nigra are also significantly depleted of
glutathione because of huge amount of glutathione levels they possess. Corresponding increase
in oxidized glutathione hasn’t been observed because glutathione is shown to be effluxed by cells
under persistent oxidative stress. No significant changes in glutathione system enzymesglutathione reductase, glutathione peroxidase, γ-glutamylcysteine synthetase (rate-limiting
enzyme in glutathione synthesis) and glutathione transferase have been reported. However, two
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fold increase in an enzyme- γ-glutamyl transpeptidase (γ-GTP) has been reported (Sian, Dexter
et al. 1994). γ-GTP is a cell membrane enzyme responsible for degradation and translocation of
glutathione. Conjugation of glutathione and its amino acid (cysteine) with oxidized products of
DA, L-DOPA, DOPAC (dopamine metabolite), and other catecholamines has been also
suggested to result in decrease in reduced glutathione levels (Shen and Dryhurst 1996, Spencer,
Jenner et al. 1998, Linert and Jameson 2000). Figure 1-11 demonstrates the synthesis pathway
of glutathione and its role in various detoxification processes in the cellular system.
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Figure 1-11. Glutathione synthesis and metabolism in the central nervous system
Both astrocytes and neurons can synthesize glutathione, but astrocytes also play important
roles in substrate supply to neurons. Glutathione synthesized in astrocytes is exported in
the extracellular space, where ectoenzyme γ-GTP (1) transfers the glutamyl group onto
amino acid acceptor, creating cysteinylglycine, which is broken down into its constituents,
cysteine and glycine. Glutathione is synthesized in two steps: first, glutamyl cysteine is
formed from cysteine and glutamate, catalyzed by GCL (2), then glycine is added by
glutathione synthase (3). Glutathione has many roles in detoxification and maintenance of
redox equilibrium. The majority of these processes generate GSSG, which is reduced back
to GSH by glutathione reductase and NADPH from pentose phosphate shunt (4). 1. γ-GTP,
2. GCL, 3. glutathione synthase, 4. glutathione reductase, 5. glutathione peroxidase, 6.
glutaredoxin, 7. GST (Martin and Teismann 2009).
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1.4

Etiology of Parkinson’s disease

1.4.1 Environmental factors
Specific etiology of PD is not known. However, numbers of epidemiological studies and
an accidental finding have concluded potential environmental factors that can significantly
increase the risk of PD. The risk factors include exposure to pesticides, herbicides, well water,
industrial chemicals, wood pulp mills, farming and living in rural environment.
Current hypothesis implicates exposure to dopaminergic and mitochondrial toxins as a
risk factor for PD. MPTP (meperidine analog), rotenone (insecticide) (Betarbet, Sherer et al.
2000) and paraquat (herbicide) (Liou, Tsai et al. 1997) are known to induce PD. In fact,
accidental exposure to MPTP induced chronic parkinsonism in human subjects (Langston,
Ballard et al. 1983), which led to its use as in-vitro and in-vivo model of PD. Surprisingly, all the
toxins mentioned above cause mitochondrial dysfunction in cells, particularly they damage
mitochondrial complex-I, whose activity has been shown to be decreased in PD patients.
Generation of pyridinium metabolite has been shown to cause PD symptoms in MPTPinduced Parkinsonism (Markey, Johannessen et al. 1984). MPTP is highly lipophilic and crosses
the blood-brain barrier within minutes of administration. Afterwards, MPTP is oxidized by
MAO-B (located in glial cells and serotonergic neurons only) to 1-methyl-4-phenyl-2,3-dihydropyridine (MPDP+). It is then converted to MPP+ (probably by spontaneous oxidation), the
toxic metabolite, which is substrate for DAT. MPP+ enters dopaminergic neurons and can cause
damage by three possible mechanisms,
i) Bind to VMAT-2 which can translocate MPP+ to synaptosomal vesicles,
ii) Concentrate in mitochondria and block electron transport chain by inhibiting
complex-I activity,
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iii) Can remain in cytosol to interact with cytosolic enzymes, especially the one carrying
negative charge (figure 1-12).

Figure 1-12. Representation of intracellular pathways of MPP+ toxicity
(Dauer and Przedborski 2003)
Paraquat is a herbicide structurally similar to MPP+ and found to be present in
environment (figure 1-13). It doesn’t penetrate blood-brain barrier easily (Shimizu, Ohtaki et al.
2001). Paraquat has been shown to produce toxicity by inhibition of mitochondrial complex-I
and by generation of superoxide radicals. Systemic administration of Paraquat in mice leads to
selective degeneration of SNPc dopaminergic neurons with appearance of “Lewy bodies”
containing α-synuclein aggregates (McCormack, Thiruchelvam et al. 2002). Surprisingly,
Paraquat induced dopaminergic neurodegeneration doesn’t reflect similar loss of DA levels in
animal models. It has been suggested that paraquat might selectively damage dopaminergic
neuronal cell bodies, sparing the neuronal terminals. Tyrosine hydroxylase activity in paraquat
treated animals is also shown to be increased, which suggests some compensatory changes taking
place after paraquat induced neurodegeneration (McCormack, Thiruchelvam et al. 2002).
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Figure 1-13. Structural similarity between MPP+ and Paraquat

Rotenone is a naturally occurring compound found in roots of Leguminosa plant species.
It is used as an insecticide and to kill unwanted fish. It has been shown to selectively inhibit
mitochondrial complex-I activity, without affecting complex-II and complex-IV activity.
Rotenone is highly hydrophobic and can easily cross biological membranes. It doesn’t require
dopamine transporter to be taken up into dopaminergic neurons. MPTP induces dopaminergic
neuronal complex-I inhibition, whereas in PD, complex-I inhibition is observed systemically.
Rotenone has been shown to induce systemic partial defect in complex-I, which is enough to
produce behavioral, neurochemical and neuropathological symptoms of PD (Betarbet, Sherer et
al. 2000). Selective damage of dopaminergic neurons by rotenone suggests that the dopaminergic
neurons may be more vulnerable than other cell population to mitochondrial complex-I
inhibition.

1.4.2 Genetic factors
PD was earlier thought as sporadic disorder in nature and not related to genetic
inheritance. However, numerous findings in last two decades have implicated various genes that
may increase the susceptibility to PD. Genetic inheritance has been shown to be significantly
involved in the cases of young-onset PD. 10-30% PD patients report a positive family history.
Additionally, first-degree relatives of subjects with PD were shown to have two to seven-fold
increase in relative risk of PD (Shulman, De Jager et al. 2011). Initially, linkage analysis which
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analyzed multiple family members affected by Mendelian PD revealed rare genetic variant which
have high penetrance effect. On the other side, Genome wide association analysis compared
control and case subjects and identified statistically significant genetic variants with incomplete
penetrance responsible for sporadic PD. Surprisingly, both approaches yielded some genes which
overlap. Thus, now PD is considered to be a complex disease resulting from interaction of
environment/gene and/or gene/gene.
More than 13 loci and 9 genes are associated with autosomal dominant or autosomal
recessive form of PD (Lesage and Brice 2009) (table 1-2). Identified genes can be divided into
two types: causal genes and associated genes. Causal gene alone without the influence of other
genes or environmental factors causes PD in person who inherits it, whereas, associated gene
does not cause PD but increases the possibility of developing it. Associated gene’s interaction
with other genes or environmental factors can trigger PD in the person who inherits it. SNCA,
PARK2, and PARK7 are causal genes, whereas, LRRK2 is an associated gene.
SNCA (α-synuclein) has been clearly shown to be involved in pathophysiology of
familial and sporadic PD. It is the major component of Lewy bodies and Lewy neurites found in
PD patients. Three missense mutation in SNCA: A30P (Kruger et al. 1998), E46K (Zarranz,
Alegre et al. 2004), and A53T (Polymeropoulos, Lavedan et al. 1997, Spira, Sharpe et al. 2001)
are extremely rare. However, all the patients with missense mutations have early onset of disease
and dementia with Lewy bodies. Duplication (Chartier-Harlin, Kachergus et al. 2004) and
triplication (Singleton, Farrer et al. 2003) of the locus containing SNCA support the hypothesis
that the increase in α-synuclein concentration is toxic. Early stage patients with SNCA
duplication resemble patients with “idiopathic” PD. Interestingly, patients with SNCA
triplication have earlier onset, faster disease progression, marked dementia, and frequent
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dysautonomia (Ross, Braithwaite et al. 2008). This further corroborates the dosing effect of
SNCA gene.

PARK Loci

Gene

Forms of PD

Mutations

PD- associated loci and genes with conclusive evidence

PARK1/PARK4

SNCA

EOPD AD and
sporadic

A30P, E46K, A53T
Genomic duplications/triplications
40 missense variants, >7 of them
pathogenic, including the common
G2019S

PARK8

LRRK2

LOPD AD and
sporadic

PARK2

Parkin

Juvenile and EOPD
AR and sporadic

>100 mutations (point mutations, exonic
rearrangements)

PARK6

PINK1

ARPD

>40 point mutations, rare large deletions

PARK7

DJ-1

EOPD AR

>10 point mutations and large deletions

PARK9

ATP13A2

Juvenile AR Kuforrakeb syndrome and
EOPD

>5 point mutations

Table 1-2. Loci, genes and susceptibility factors involved in Parkinson’s disease
EO, Early onset; LO, Late onset; AD, Autosomal dominant; AR, Autosomal recessive; PD,
Parkinson’s disease; SNCA, α-synuclein; LRRK2, Leucine-Rich Repeat Kinase-2; PINK1,
PTEN-induced kinase 1(Lesage and Brice 2009).
α-synuclein is a small, 140 amino acid protein that contains an amphipathic amino
terminal, a hydrophobic central core [termed “non-amyloid component” (NAC region)] and
negatively charged c-terminus (figure 1-14). It is expressed homogenously throughout the
nervous system. It is enriched at presynaptic nerve terminals, where it is found in association
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with synaptic vesicular membranes. The physiological role of α-synuclein is not well understood.
Some studies suggest that it may be playing a critical role in neurotransmitter release and
synaptic vesicle recycling (Lotharius and Brundin 2002). Brundin et al. have proposed that the
mutant forms of α-synuclein (A30P, E46K, A53T) might have a loss of normal function. Effect
of toxic function of mutant protein may prevent the sequestration of DA into synaptic vesicles.
Therefore, it may cause increased cytoplasmic concentration of DA, which may result in
increased oxidative stress because of excessive DA metabolism and DA auto-oxidation in PD
(Lotharius and Brundin 2002). Full length α-synuclein normally occurs as a natively unfolded
monomer. However, at higher concentrations, it can form oligomers (SDS-sensitive, noncovalently bound, soluble), which are termed “protofibrils”. Protofibrils can seed in a nucleation
dependent manner to form fibrils (SDS-sensitive, non-covalently bound, insoluble) present in
Lewy bodies (figure 1-14). A30P and A53T mutations of α-synuclein increase the tendency of
the protein to form protofibrils (Conway, Harper et al. 2000). Initial study by Lansbury et al.
established that the protofibrils (oligomers) may be responsible for neuronal toxicity (Goldberg
and Lansbury 2000). It may be possible that the fibrillar inclusions (Lewy bodies) may sequester
the toxic species and/or divert α-synuclein from toxic assembly pathways and protect neurons. It
is further supported by the fact that the neuronal cells of post-mortem PD patients showing Lewy
bodies appear healthy.
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Figure 1-14. Aggregation and functional domains of α-synuclein
α-synuclein natively occurs as an unfolded monomer, which at higher concentration or in
presence of point mutations or by interaction of dopamine can aggregate to form oligomers
(“protofibrils”), oligomers can seed in a nucleation-dependent manner to produce fibril
structure (β-sheet rich structure) found in Lewy bodies [except for dopamine-induced
oligomers] (a). Two point mutations A53T and E46K are genetically linked to Parkinson’s
disease and speed up the process of oligomerization. Whereas, third point mutation A30P
causes fragmentation of fibrils, which then accelerates the seeding process forming new
fibrils. The amphipathic N-terminal region of α-synuclein forms α-helices when it
associates with lipid membranes. This region and the hydrophobic NAC domain of protein
are important for oligomerization. Synuclein can be phosphorylated at Ser129 by several
different polo-like and casein kinases, however fibril form is usually found in
phosphorylated form than the monomer form (Hansen and Li 2012).
Surprisingly, dopamine-quinone generated by auto-oxidation of DA can form covalent
adduct with α-synuclein and prevent the conversion of oligomers (SDS-resistant, covalently
bound, soluble) to β-sheet bearing fibrillar structure (Conway, Rochet et al. 2001). Specifically 3
DA molecules under oxidizing condition have been shown to bind per α-synuclein monomer,
which yields its highly extended state (Illes-Toth, Dalton et al. 2013). It has been established that
the “protofibrils” involved in the process of fibrillization are more toxic than the mature fibrils
themselves (Goldberg and Lansbury 2000, Bucciantini, Giannoni et al. 2002, Li, Lin et al. 2005).
It has been suggested that because of strong oxidizing environment in dopaminergic neurons
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“protofibrils” do not convert into fibrils rapidly when compared to environment in other neurons.
The slower conversion may cause selective toxicity of protofibrils in dopaminergic neurons. Covalently modified oligomeric form of α-synuclein has been shown to be able to attack and disrupt
the biological membranes easily (Rochet, Outeiro et al. 2004). These oligomeric forms can
further damage DA containing vesicles and increase the cytoplasmic levels of dopamine, which
in turn can lead to vicious cycle of oxidative stress and dopamine-α-synuclein adduct formation.
In addition, protofibrillar form of α-synuclein has also been shown to transfer to other
neighbouring neurons in prion-like manner (Prusiner 2012). This has been shown by presence of
α-synuclein containing Lewy bodies in patients grafted with fetal human mesencephalic
dopaminergic neurons (Li, Englund et al. 2008) (figure 1-15).

Figure 1-15. Aggregation and functional domains of α-synuclein
α-synuclein positive Lewy bodies in host substantia nigra and grafted dopaminergic
neurons in Parkinson’s disease patient (Li, Englund et al. 2008).
Mutations in PARK8 have been shown to be involved in sporadic as well as autosomal
dominant familial Parkinson’s disease. PARK8 codes for leucine rich repeat kinase-2 (LRRK2)
protein. The most common and best studied LRRK2 variant is G2019S, which is found in 1% to
4% in PD patients with European descent. However, populations with LRRK2 mutation has been
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found to be developing PD symptoms after the age of 60 or in some cases found to be normal.
Thus, additional genetic and environmental factors must be interacting to cause the disease onset.
Mutations in PARK2 have been shown to be involved in development of autosomal
recessive juvenile PD. Patients with PARK2 mutations show degeneration of dopaminergic
neurons without the presence of Lewy bodies. PARK2 encodes for Parkin, which is a E3ubiquitin-protein ligase. Mutant Parkin from autosomal recessive PD patient doesn’t have the
E3-ubiquitin-protein ligase activity. Thus, it might result in accumulation of proteins which may
cause dopaminergic neuronal demise. The onset of PD in population with PARK2 mutations is
around 30 years of age.
Mutations in PINK-1 is the second most common cause of autosomal recessive juvenile
PD. PINK-1 encodes a serine-threonine kinase that is widely expressed in mitochondria. Some
data from animal models suggest that PINK-1 and Parkin may function coordinately (Exner,
Lutz et al. 2012). Mutations in PARK7, which encodes DJ-1 is a rare cause of autosomal
recessive juvenile PD. DJ-1 is a ubiquitously expressed protein with unknown function.
However, it has been known to translocate to mitochondria in response to oxidative stress and
may have protective role. Mutations in ATP13A2 have been shown to cause loss of function of
ATP13A2 protein (lysosomal type 5 P-type ATPase). It has been suggested that there may be a
link between aggregation of mutant protein in endoplasmic reticulum and proteasomal or
lysosomal function (Ramirez, Heimbach et al. 2006).

30

1.5

Therapeutic interventions for Parkinson’s disease
As discussed above, PD is a multi-factorial disorder for which the exact etiology is not

known. Variety of interactions between aging, environmental factors, and genetic components
may be potentially involved in dysfunction of the dopaminergic system of brain by increasing the
oxidative burden and mitochondrial dysfunction selectively in the dopaminergic neurons.
Unfortunately, PD motor symptoms, which are the cardinal features for diagnosis of PD, appear
after significant dopaminergic neurodegeneration has already taken place and are currently used
for diagnosis purpose. Most clinically used PD therapeutics are targeted towards restoring the
normal dopaminergic function in the brain. Currently available therapeutics are either precursor
of DA, DA receptor agonists or inhibitors of enzymes responsible for DA metabolism.
Surprisingly, L-DOPA which was discovered immediately following the discovery of DA
still remains the gold standard to relieve motor deficits of PD (Birkmayer and Hornykiewicz
1961). L-DOPA is a prodrug of DA, which converts to DA through decarboxylation process by
aromatic amino acid decarboxylase (AADC) enzyme. L-DOPA is combined with other drugs
such as peripheral dopa decarboxylase inhibitors (DDC) or catechol-O-methyl-transferase
(COMT) inhibitors or monoamine oxidase-B (MAO-B) inhibitors to either avoid its peripheral
conversion to dopamine or to prevent its breakdown into dopamine metabolite in CNS (figure 116). Combination therapy helps in increasing the duration of action of L-DOPA. However, LDOPA use results in production of dyskinesia and its long-term use results in sudden “on-off”
effects (Marsden and Parkes 1976). DA receptor agonists such as pramipexole and ropinirole are
also widely used. DA receptor agonists bind post-synaptic dopaminergic receptors to mimic
response(s) similar to that produced by DA.
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Figure 1-16. Mode of action of current Parkinson’s disease therapeutics
Levodopa is a gold-standard drug to relieve motor symptoms of Parkinson’s disease. It is
usually combined with other drugs such as peripheral dopa decrboxylase inhibitors or
COMT inhibitors to prevent its peripheral breakdown. Levodopa is also combined with
MAO-B inhibitors, which inhibit the breakdown of dopamine generated by levodopa.
Dopamine agonists are also widely used to mimic effects of dopamine at post-synaptic
dopaminergic receptors.
Present PD therapeutics only provide symptomatic relief and are very useful in early
stage of the disease. The critical issue that needs be addressed is that none of the clinically used
drugs prevent the progression of neurodegeneration or resolve the underlying cause of the
disease. Thus, over the course of disease, drug’s effect diminishes and disease pathology leads to
more complications. In addition, there is some evidence that L-DOPA increases oxidative burden
and enhances PD progression (Basma, Morris et al. 1995, Fahn 1996). Table 1-3 mentions
clinically used PD therapeutics with their mechanisms of action.
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Drug Class

Brand Name

Mechanism of Action

(Generic name)

Dopamine replacement
therapy
(Carbidopa/Levodopa

Levodopa is a precursor of dopamine, which
Sinemet

is usually combined with Carbidopa

Carbidopa/Levodopa controlled
release

Sinemet CR

(peripeheral aromatic amino acid

Carbidopa/Levodopa/Entecapone

Stalevo

decarboxylase inhibitor) or Entecapone

Carbidopa/Levodopa Orally
disintegrating tablet)

Parcopa

(COMT-inhibitor) to increase its CNS
bioavailability and prevent its peripheral
breakdown and resulting side-effects.

Dopamine Agonist
(Pramipexole

Mirapex

Ropinirole

Requip

Rotigotine

Neupro

Pergolide

Permax

Bromocriptine)

Parlodel

Simulates the effect(s) of dopamine at postsynaptic dopamine receptors site.

Table 1-3 continued on next page
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Drug Class

Brand Name

Mechanism of Action

(Tolcapone

Tasmar

Entecapone)

Comtan

COMT inhibition increases levodopa
bioavailability in CNS by decreasing
peripheral levodopa metabolism

(Generic name)

COMT inhibitors

MAO-B inhibitors
(Selegeline

Eldepryl

Selegeline ODT

Zelapar

Rasagiline)

Azilect

Irreversible inhibitor of MAO-B which is
responsible for breakdown of dopamine in
CNS

Table 1-3. Current Parkinson’s disease therapy
Ideal PD therapeutic should have the ability to halt or slow the progression of
neurodegeneration in the disease process. Currently available PD therapeutics suffer a major
drawback that they were designed to act on one of the many pathological targets responsible for
PD. As PD is a multi-factorial disease involving complex sequence of events in its
pathogenesis/progression, PD treatment can either include combination of drugs that act on
different pathological targets (polypharmacy), or a single drug should be designed to possess the
ability to act on multiple pathological targets involved in disease pathology (multifunctional
drug) (Youdim 2010). Drug’s ability to act on multiple targets associated with disease
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progression/pathogenesis can potentially provide disease-modifying effect, which is highly
desired to prevent or slow down the progression of PD.
Currently, there isn’t any drug in market that was designed to aim at multiple
pathological targets in PD. However, some clinically used drugs have been serendipitously found
to possess ability to act on multiple pathological targets. Pramipexole and Rasagiline have been
shown to possess some neuroprotective property in addition to their DA receptor agonist and
MAO-B inhibition property respectively (Hall, Andrus et al. 1996, Dooley and Markham 1998).
Rasagiline has been shown to have not only neuroprotective, but also neurorestorative property
in MPTP and lactacystin-induced degeneration of nigrostriatal dopaminergic neurons (Sagi,
Mandel et al. 2007, Zhu, Xie et al. 2008). In addition, Rasagiline is the only drug that may
possess disease-modifying activity as shown by clinical trials (Olanow, Rascol et al. 2009).
Thus, it seems more appealing to design drugs that can aim at multiple pathological targets
involved in PD to yield disease-modifying therapeutics. In fact, Youdim et al., who contributed
significantly in development of Rasagiline as a PD therapeutic, have designed some structurally
modified moieties based on Rasagiline (MAO-B inhibitor), which possess multifunctional
activity (Zhu, Xie et al. 2007, Youdim 2013). Youdim et al. targeted iron and MAO-B to design
multifunctional therapeutics and one of their compounds M30 has been shown to possess
significant disease-modifying activities in animal models of PD (Youdim 2013). As iron
accumulation has been shown to be critical in pathogenesis of PD, it is ideal to have drugs with
iron-chelator property. Other pathological targets that can be aimed at include dopamine
receptors, COMT, α-synuclein aggregation modifiers, and anti-oxidants.
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CHAPTER 2
HYPOTHESES
Global Hypotheses
We hypothesized that as PD is a complex disorder resulting from interaction of multiple
pathological factors, the ideal way to target the disease process is to design and develop a
potential therapeutic that can act on various pathological factors responsible for PD. In fact, there
is vast literature evidence that some of the clinically used drugs for PD have broad mechanisms
of action rather than selectivity for one particular pathological target of PD (Shoulson 1998,
Ramirez, Wong et al. 2003, Olanow, Rascol et al. 2009). Hence, we aimed to design therapeutics
which can target more than one pathogenesis factors involved in PD progression. Initially, we
developed some hybrid ligands that can preferentially target dopamine D2 and/or D3 receptors
(Biswas, Hazeldine et al. 2008, Li, Biswas et al. 2010, Johnson, Antonio et al. 2012).
Afterwards, we further optimized their structures to incorporate iron-chelation, anti-oxidant or αsynuclein aggregation inhibition property (Ghosh, Antonio et al. 2010, Gogoi, Antonio et al.
2011, Johnson, Antonio et al. 2012). Our quest to develop multifunctional PD therapeutic
yielded some versatile compounds, which exhibited quite promising results as multi-functional
compounds in animal models and cell-culture models (Ghosh, Antonio et al. 2010, Gogoi,
Antonio et al. 2011, Santra, Xu et al. 2013). As shown in figure 2-1, we designed our
compounds based on Pramipexole pharmacophore to retain DA receptor activity and
incorporated additional moieties to generate multifunctional properties.
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Figure 2-1. Design of potential multifunctional compounds for Parkinson’s disease
Our efforts to generate multifunctional PD therapeutics yielded an interesting compound
D-512 ((-)19), which showed potent agonist activity at D2 and D3 receptors (non-preferential
agonist) (Johnson, Antonio et al. 2012). D-512 showed exceptional anti-oxidant activity. D-512
also showed ability to reverse hypolocomotion in long-lasting manner induced by reserpine in rat
model of PD.
Project hypotheses
First hypothesis of my dissertation study was that as D-512 exhibited neuroprotective
effects in a cell-line devoid of dopaminergic receptors (Santra, Xu et al. 2013), D-512 is a nonpreferring DA D2/D3 receptor agonist, and D-512 also possess a potent anti-oxidant property as
shown by DPPH assay (Johnson, Antonio et al. 2012), it should exhibit robust neuroprotection
activity if evaluated in a cell-culture model which simulates dopaminergic neurons. In addition, I
also hypothesized that as D-512 has been shown to be an antioxidant, it must act on oxidative
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stress producing machinery and its related pathways in the cell culture system. Thus, D-512
should be able to prevent cell-death and provide neuroprotection in a cell-culture model by DA
receptor dependent and independent mechanisms.
Second hypothesis of my dissertation study was that as some polyphenolic compounds
have been shown to inhibit the aggregation of α-synuclein (Li, Zhu et al. 2004, Zhu, Rajamani et
al. 2004, Li, Lin et al. 2005), the compounds inspired from similar structural features (D-240, D436, and D-520) should also be able to inhibit α-synuclein aggregation (figure 2-2). In addition,
if such compounds inhibit the aggregation of α-synuclein, they should also be able to prevent
cytotoxicity in dopaminergic cell line because of modulation of α-synuclein aggregation. Thus,
our compounds should possess α-synuclein aggregation inhibition property in addition to their
dopaminergic receptor agonist potency.
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Figure 2-2. Structures of known α-synuclein aggregation inhibitors
and some lead compounds from our lab

STUDY DESIGN AND RATIONALE
The main objective for first part of my project was to use various biochemical assays for
evaluating neuroprotective and anti-oxidant activities of D-512 against PD cell-culture model.
Main focus of my project was to evaluate the ability of D-512 to rescue PC12 cells from
oxidative stress generated by 6-hydroxydopamine (6-OHDA). We determined to use 6-OHDA as
a toxin, as it has been shown to be elevated in PD patients and also various animal models have
been developed based on intra-striatal injections of 6-OHDA, which causes selective
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degeneration of dopaminergic neurons. In addition, it has been demonstrated by various
independent studies that 6-OHDA exerts its toxic effects by generation of various reactive
oxygen species, which are also known to be major reason for progression of PD. As our main
objective was to determine D-512’s effectiveness as an anti-oxidant, 6-OHDA was appropriate
toxin to be used. As we were previously able to verify D-512’s neuroprotective as well as antioxidant activities in dopaminergic cell-line devoid of dopaminergic receptors, it was ideal to
choose PC12 cell-line, which expresses various dopaminergic neuronal markers (dopamine D2
receptor, dopamine transporter, tyrosine hydroxylase and dopamine) and hence should be able to
mimic dopaminergic neurons.
As discussed in the introduction, PD patients show significant dopaminergic neuronal
degeneration and changes in various oxidative stress markers. An ideal PD therapeutic should be
able to provide protection from dopaminergic neuronal degeneration and also alter oxidative
stress induced changes in cells. As shown in figure 2-3, excessive oxidative stress can damage
critical cellular biomolecules such as DNA, proteins and lipids. In addition, oxidative stress can
also alter anti-oxidant machinery present in cells making them more vulnerable to cell death.

Figure 2-3. Imbalance in reactive oxygen species generation and elimination
(Lotharius and Brundin 2002)
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To achieve the specific aims of this project, I evaluated D-512’s ability to protect PC12
cells against cytotoxicity induced by 6-OHDA. Furthermore, I performed various biochemical
assays to evaluate oxidation status of biomolecules following exposure of PC12 cells to 6OHDA and ability of D-512 to reverse or prevent such oxidative stress induced changes. To
accomplish the objectives, I proposed to:
 Test the hypothesis that D-512 has an ability to protect/reverse the cell-death induced
by oxidative stress produced by 6-OHDA in PC12 cell-line.
This analysis was crucial to carry out further experiments, as D-512’s ability to protect
PC12 cells against cell-death would establish that it is neuroprotective in nature. As D-512 also
possesses dopamine receptor agonist activity, the neuroprotective ability would ensure that it
may be a potential disease-modifying PD therapeutic.

 Test the hypothesis that D-512 has an ability to prevent free radical and ROS induced
damage to various biomolecules in cell culture system and/or capability to act on antioxidant system in PC12 cells. I proposed to perform analysis of changes in oxidized
and reduced glutathione levels to determine effect of D-512 on anti-oxidant system in
PC12 cells using buthionine sulfoximine (BSO) and 6-OHDA. For determining D512’s anti-oxidant activity against free radicals, I proposed to perform lipid
peroxidation assay, DNA fragmentation assay, and nuclear condensation assay using
6-OHDA (or similar oxidizing agents) in PC12 cells.
The rationale behind performing glutathione assays was that if D-512 shows
neuroprotective ability against 6-OHDA, it should have an ability to alter oxidative changes
induced by 6-OHDA in PC12 cells. Interestingly, glutathione levels have been shown to be
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significantly depleted in patients with PD. 6-OHDA has been shown to alter level of glutathione
in cells including PC12 cells. Therefore, we wanted to evaluate whether D-512 is able to alter 6OHDA induced changes in PC12 cells in order to provide anti-oxidant effect. We planned to
carry out analysis of free glutathione levels, because free glutathione is responsible for
neutralizing various ROS and toxins generated by abnormal cellular metabolism. We also
analyzed levels of total glutathione as they would provide us the redox status of cells. As the
mechanism by which glutathione is depleted in PC12 cells by 6-OHDA hasn’t been fully
elucidated, we determined to use BSO, which has been known to inhibit γ-glutamylcysteine
synthetase and deplete cellular glutathione levels. Thus, we tested D-512’s ability to restore
changes in glutathione levels induced by 2 different toxins, in order to assure its capability to act
on anti-oxidant system of cells.
The rationale behind performing DNA fragmentation and nuclear condensation assays
was to understand the mechanism by which D-512 and 6-OHDA act on PC12 cells. Cells can
undergo cell death by two different mechanisms, necrosis or apoptosis. It has been shown that 6OHDA induces cell death in dopaminergic neurons by apoptosis (Ochu, Rothwell et al. 1998).
The cells undergoing apoptosis display some characteristic features such as membrane blebbing,
cell

shrinkage, nuclear condensation, fragmentation of DNA, phopsphotidyl

serine

externalization. Therefore, it was important to evaluate the effect of 6-OHDA on PC12 cells by
performing nuclear condensation and DNA fragmentation assays. Furthermore, it was crucial to
understand the ability of D-512 to rescue PC12 cells from 6-OHDA induced apoptotic cell death.
Therefore, we tested anti-apoptotic effects of D-512 against 6-OHDA induced apoptotic cell
death.
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 Test the hypothesis that D-512 should alter some critical cell signaling pathways at
earlier time-point following exposure to oxidative stress (6-OHDA) which may be
potent molecular mechanism(s) by which D-512 has an ability to confer
neuroprotection.
The rationale behind performing analysis of cellular signaling molecules was based on
the fact that cell fate is determined by balance between various signaling molecules. Imbalance
in various signaling cascades of cells following exposure to variety of stimuli can influence
cellular decisions such as cell survival, cell proliferation, cell differentiation, cell migration, cell
death, etc. Sustained activation of mitogen activated protein kinase signaling molecule,
extracellular signal regulated kinases (ERK1/2), has been shown in PC12 following exposure to
6-OHDA. ERK1/2 activation has been shown to be a key event responsible for cell death in
PC12 cells. In addition, another type of mitogen activated protein kinase signaling molecule, cJun N-terminal kinases (JNKs) respond to various stress-related stimuli, such as cytokines,
inflammatory signals and increase in oxidative stress. JNK has also been shown to be activated
following exposure of PC12 cells to 6-OHDA. Therefore, we evaluated the ability of D-512 to
alter the changes in ERK1/2 and JNK following exposure of PC-12 cells to 6-OHDA. As
signaling molecules are the early determinants of cellular fate, understanding their modulation by
D-512 would help understand the mechanism of D-512 at molecular level.
The main objective of the second part of my project was to assess the ability of some of
our lead compounds to inhibit α-synuclein aggregation. As discussed in the introduction, αsynuclein has been shown to be responsible for PD pathology. Duplication or triplication of
SNCA locus, several point mutations of α-synuclein, and interaction with dopamine and/or iron
can result in generation of aggregates of α-synuclein. Lewy bodies have been shown to be a
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characteristic feature of PD pathology. Lewy bodies contain significant amounts of aggregated
forms of α-synuclein. Hence, it is critical to address the issue of α-synuclein aggregation, as it
may be a significant pathological factor involved in PD progression and/or initiation. My project
focused on generating variety of α-synuclein aggregates using chemicals which have been
known to be responsible for PD pathology and α-synuclein aggregation. For generating αsynuclein aggregates, I employed cell-free system approach to understand direct interactions
between known factors responsible for α-synuclein aggregation. I used DA, iron, or higher
concentration of α-synuclein to generate various types of α-synuclein aggregates. I also
evaluated the extracellular toxicity of α-synuclein aggregates (formed in a cell-free system) in
PC12 cells, as it has been shown that such aggregates can transfer from one neuron to another in
a prion-like manner to cause damage. I used PC12 cells to simulate dopaminergic neuronal
system. To establish a standard to evaluate the effect of our lead compounds, I used a known αsynuclein aggregation inhibitor rifampicin. I carried out various experiments in cell-free system
with lead compounds and rifampicin to compare their relative ability to prevent the aggregation
of α-synuclein. Several studies have shown that co-valent modification of α-synuclein by DA
generarates α-synuclein oligomers, which are potentially toxic species for dopaminergic neurons.
Oxidation of DA into dopamine quinone is shown to be responsible for formation of oligomers.
Therefore, in experiments involving dopamine, I included a potent anti-oxidant ascorbic acid. To
achieve the objective of my project, I proposed to:
 Test the hypothesis that different chemicals interact with α-synuclein to generate
aggregates of α-synuclein which have distinct structural features. I proposed to
perform the cell-free system based aggregation assays using α-synuclein alone, αsynuclein in presence of DA, and α-synuclein in presence of iron. I proposed to
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analyze the formed aggregates using SDS-PAGE followed by silver-staining method,
Thioflavin-T assay (ThT) and transmission electron microscopy.
The rationale behind these experiments was to simulate PD conditions. Abnormal
accumulation of iron takes place in PD. In addition, some studies also show presence of products
of abnormal dopamine metabolism. Hence, it was necessary to understand the contribution of
iron or DA in the process of α-synuclein aggregation. The formed aggregates can be co-valently
modified or non-covalently modified by chemicals. Polyacrylamide gel electrophoresis of
samples in presence of SDS can help differentiate co-valently modified forms of protein from
non-covalently modified form, as non-covalent forms break apart in presence of SDS. Silverstaining of the fractionated samples can help visualize various forms of aggregates which are
resistant to SDS. I planned to evaluate the aggregates by thioflavin-T, as the dye has an ability to
bind to β-sheet structure of protein, which can form by modification of α-synuclein by chemicals
used in this experiment. It is crucial to know the structure of α-synuclein as fibrillar forms of
protein show strong ThT activity, whereas, oligomeric forms (co-valently modified by
dopamine) do not exhibit strong ThT activity. In addition, transmission electron microscopy was
employed to physically visualize the protein aggregates, as there wasn’t comparable robust assay
method that would have helped us understand the aggregate morphology more clearly.

 Test the hypothesis that potent anti-oxidant (ascorbic acid) and our lead compounds
(potent anti-oxidants) should be able to alter DA induced aggregation of α-synuclein.
I proposed to carry out cell-free system experiments with α-synuclein and DA, αsynuclein and DA with ascorbic acid, α-synuclein and DA with rifampicin, αsynuclein and DA with D-436, α-synuclein and DA with D-520. I proposed to
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analyze the formed aggregates using SDS-PAGE followed by silver-staining method,
transmission electron microscopy, and size-exclusion chromatography.
The rationale behind this experiment was that as dopamine quinones (which are oxidized
species of DA) generate toxic oligomers of α-synuclein, anti-oxidant such as ascorbic acid
should be able to prevent/slow down the generation of dopamine quinones. Therefore, ascorbic
acid should decrease/inhibit the generation of oligomeric species of α-synuclein. As our lead
compounds also possess anti-oxidant activity, they should also be able to exhibit similar activity
towards DA induced α-synuclein aggregation. It was critical to evaluate the formed aggregates
using SDS-PAGE followed by silver-staining, as it was critical to understand the modulation of
different compounds on dopamine-quinone induced co-valent modification of α-synuclein.
Transmission electron microscopy helped us physically visualize the aggregates to understand
the structural alterations of α-synuclein upon incubation with various compounds. Furthermore,
size-exclusion chromatography helped us understand the differences in various dimensions of
aggregates from different experiments.

 Test the hypothesis that our lead compounds should be able to alter the aggregation of
α-synuclein such that they would prevent or reduce the extracellular toxicity of αsynuclein aggregates in cell culture system. Initially, I proposed to evaluate the
extracellular toxicity of aggregates formed using cell-free system assay with αsynuclein alone (at high concentration) or α-synuclein and dopamine in PC12 cells in
a time dependent manner. After determining the maximum toxicity of aggregates, I
proposed to carry out cell-free system experiments with our lead compounds to
determine their ability to prevent or alter α-synuclein aggregation. The extracellular
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toxicity of various types of aggregates formed was evaluated using PC12 cells. The
structure of the formed aggregates was confirmed by ThT assay. We also carried out
transmission electron microscopy to evaluate the physical characteristics of
aggregates.
The rationale behind the cell-free system experiments was to understand the influence of
known compounds on the aggregation of α-synuclein. Our initial experiments using aggregates
formed by α-synuclein alone or α-synuclein and DA would help us understand which type of
aggregates can cause more toxicity when incubated extracellularly with PC12 cells. These
experiments could probably reflect upon a fact that which α-synuclein aggregates might be
involved in dopaminergic cell death induced in PD. Once it would be determined that which
types of aggregates are more toxic when incubated with PC12 cells extracellularly, we would
carry out assays to assess the ability of our lead compounds to prevent the toxicity and
aggregation of α-synuclein. The rationale behind these assays was that if our lead compounds
could prevent/alter the process of α-synuclein aggregation, they can potentially prevent the
extracellular toxicity of α-synuclein aggregates in PC12 cells. Thus, we would simulate the
extracellular toxicity of α-synuclein aggregates on dopaminergic neurons and the influence of
our lead compounds to alter the toxicity. We conducted ThT assay to understand the structural
characteristics of the aggregates formed under various conditions. Our transmission electron
microscopy results helped us understand the influence of our lead compounds and standards on
process of α-synuclein aggregation.
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CHAPTER 3
MATERIALS AND METHODS: ANTI-OXIDANT EFFECTS OF LEAD MOLECULE
3.1

Materials
Chemicals: Poly-L-lysine, 6-hydroxydopamine hydrochloride, dimethyl sulfoxide

(DMSO), methanol, methyl thiazolyl blue tetrazolium bromide (MTT), reduced L-glutathione,
buthionine sulfoximine (BSO), sulfosalicylic acid, dithio-bis-nitrobenzoic acid (DTNB),
glutathione reductase, NADPH, thiobarbituric acid, dulbecco’s phosphate-buffered saline (1X
PBS), ribonuclease A, proteinase K, and triton-X-100 were purchased from Sigma-Aldrich (St.
Louis, MO, USA). Ethanol, Hoechst 33342, ethidium bromide, tris, EDTA, BCA protein assay
kit and bovine serum albumin were purchased from Fisher scientific (New Jersey, USA). 10X
tris-glycine solution, 10X tris-glycine-SDS solution, 10X TBS solution (tris-buffered saline),
tween-20, 20% SDS solution, 10% TGX-mini protean gels, 12% TGX- mini protean gels, and
PVDF membranes were purchased from Biorad (Hercules, CA, USA). Sodium nitroprusside and
isopropanol were purchased from Acros organics (New Jersey, USA). Agarose was purchased
from invitrogen (Grand Island, NY, USA). Ammonium acetate was purchased from G
biosciences (St.Louis, MO, USA). 4% paraformaldehyde solution was purchased from Electron
Microscopy Sciences (Hatfield, PA, USA). ECL-Plus reagent was obtained from Perkin-Elmer
(Waltham, MA, USA). Glutathione fluorescence detection kit was purchased from arbor assays
(Ann arbor, MI, USA). D-512 mesylate was synthesized in our lab as described in a recent
publication by Johnson et al. (Johnson, Antonio et al. 2012).
Antibodies: Antisera directed against phospho-ERK1/2, phospho-JNK, total ERK1/2,
total JNK, and GAPDH were from Cell signaling technology (Danvers, MA, USA). Anti-mouse
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and anti-rabbit IgG-horseradish peroxidase conjugates were from MP biomedicals (Santa Ana,
CA, USA).
Cell-culture and treatments: PC12 Adh (ATCC® CRL1721.1™) cells, a rat adrenal
pheochromocytoma cell line, were purchased from ATCC. Stock solutions of D-512 (100 mM)
and 6-OHDA (0.5M) were prepared in DMSO and aliquots were stored at -20°C and -80°C
respectively. Stock solution of reduced glutathione standard (10 mM) and BSO (10 mM) were
prepared in distilled water and aliquots were stored at -20°C. Stock solution of sodium
nitroprusside was prepared fresh in distilled water before treatment.
PC12 cells were cultured in T-75 flask (Sarstedt Inc, Newtown, NC, USA) and
maintained in RPMI 1640 medium supplemented with 10% heat-inactivated horse serum, 5%
fetal bovine serum, penicillin (100 units/mL), and streptomycin (100 µg/mL) at 37°C in 5% CO2
atmosphere.
3.2

Measurement of cell viability
To determine the neuroprotective effect of D-512 on 6-OHDA induced cell death,

quantitative and colorimetric MTT assay was used. PC12 cells were plated at 17000 cells/well
density in 100µL media in 96 well plates for 24 hours to allow their attachment. Adhered PC12
cells were treated with different concentrations of 6-OHDA or different doses of D-512 to
determine their direct effect on cell viability and to determine the optimum concentration of 6OHDA to use in neuroprotection experiments. Neuroprotection experiments were conducted by
treating adhered PC12 cells for 24 hours with different concentrations of D-512 followed by their
treatment with 75 µM 6-OHDA alone (pre-treatment only) or with 75 µM 6-OHDA and different
concentrations of D-512 for another 24 hours (pre-treatment and co-treatment). After incubation,
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10 µL 5 mg/mL MTT was added to the cells and the plate was further incubated at 37°C in 95%
air/5% CO2 atmosphere for 3 hours to produce dark blue formazan crystals. Afterwards, the plate
was centrifuged at 1500 rpm for 10 minutes and the supernatants were carefully removed. The
formazan crystals were dissolved by adding 100 µL of DMSO/methanol (50:50) mixture to each
well and shaking the plate gently at room temperature at 400rpm for 30 minutes at room
temperature using a Thermomix R shaker (Eppendorf, Hamburg, Germany). The absorbance
values were measured using Epoch microplate reader (Biotek, Winooski, VT, USA) at 570 nm
with background correction done at 690nm. Data from at least 3 experiments were analyzed
using Graphpad software (Version 4, San Diego, USA). Cell viability was defined as a
percentage reduction in absorbance compared to untreated controls.
3.3

Measurement of total glutathione levels
To determine the potential effect of D-512 on cellular antioxidant mechanisms, total

glutathione levels were evaluated using quantitative and colorimetric assay (Tietze 1969). For all
experiments, PC12 cells were seeded at 2X105 cells/well density in 2 mL media in 12 well plates
for 24 hours to allow their attachment. Adhered PC12 cells were treated with different
concentrations of buthionine sulfoximine (BSO) or 6-hydroxydopamine (6-OHDA) for 6 hours
or 24 hours to determine their optimum concentration for neuroprotection experiments.
Neuroprotection experiments were performed by pre-treating adhered PC12 cells for 24 hours
with different concentrations of D-512 followed by their co-treatment with 1.56 µM BSO or 25
µM 6-OHDA and various concentrations of D-512 for 6 hours or 24 hours. After incubation,
cells were scraped with rubber policeman, centrifuged, and washed with 1X PBS. Cells were
resuspended in 25 µL 5% sulfosalicylic acid. Resuspended cells were subjected to 2 freeze-thaw
cycles. Cell lysate was incubated on ice for 10 minutes. Cell debris were removed by
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centrifugation at 14000 rpm for 10 minutes at 4°C. 10 µL of supernatant was added to 96 well
plate. Total glutathione levels were measured by adding 150 µL mixture of dithionitrobenzoic
acid (1.5 mg/mL) and glutathione reductase (~ 6 units/mL) and starting the color formation by
addition of 50 µL NADPH (0.16 mg/mL) after 5 minute incubation at room temperature. Color
formation because of formation of nitrobenzoic acid was measured after 5 minutes at 412 nm by
Synergy microplate reader (Biotek, Winooski, VT, USA). Total glutathione levels for samples
were calculated by generating standard curve with known glutathione standards prepared using
reduced glutathione. Total glutathione levels were expressed as percentage of control cells.
3.4

Measurement of free glutathione levels
To delineate the influence of D-512 and 6-OHDA on free and oxidized glutathione levels,

free glutathione levels were measured using glutathione fluorescent detection kit. For all
experiments, PC12 cells were seeded at 5X105 cells/well density in 2 mL media in 6 well plate
for 24 hours to allow their attachment. Adhered PC12 cells were treated with different
concentrations of D-512 for 24 hours followed by their co-treatment with 25 µM 6-OHDA and
various concentrations of D-512 for 6 hours or 24 hours. After incubation, cells were scraped
with rubber policeman, centrifuged, and washed with 1X PBS. Cell pellets were resuspended in
50 µL 5% sulfosalicylic acid. Resuspended cells were subjected to 2 freeze-thaw cycles. Cell
lysate was incubated on ice for 10 minutes. Cell debris were removed by centrifugation at 14000
rpm for 10 minutes at 4°C. Supernatant was diluted 1:5 with assay buffer to make the final
concentration of sulfosalicylic acid 1%. 50 µL of diluted sample was incubated with 25 µL of
thiostar reagent for 15 minutes. Free glutathione levels of samples were obtained by reading
fluorescence at 370 nm excitation and 510 nm emission wavelengths using synergy microplate
reader (Biotek, Winooski, VT, USA). Afterwards, total glutathione levels of same samples were
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determined by incubating samples for 15 minutes with 25 µL reaction mixture (containing
glutathione reductase and NADPH) and obtaining the fluorescence signal at 370 nm excitation
and 510 nm emission wavelength. Both free and total glutathione levels of samples were
calculated by generating standard curve with known glutathione standards. Free and total
glutathione levels were expressed as percentage of control cells.
3.5

Hoechst staining
To qualitatively evaluate the ability of D-512 to protect against nuclear condensation, a

feature of apoptotic cell death induced by 6-OHDA, Hoechst 33342 staining was done. PC12
cells were seeded at 2X105 cells/well density in 12 well plate. Cells were allowed to adhere for
24 hours, old medium was taken out from each well, and 1.5 ml of fresh medium containing
10µM D-512 was added. Following 24 hours of pretreatment with the drug, 75 µM 6-OHDA
was added to treatment wells and co-treatment was continued for 16 hours. The medium was
removed and the cells were washed twice with 1X PBS. The cells were fixed with 1 ml 4%
paraformaldehyde solution (EM sciences) for 15 min at room temperature followed by washing
twice with 1X PBS. The cells were stained with 0.5 mM Hoechst 33342 (Thermo)/ 0.15% tritonX-100 (Sigma) solution 1 ml for 15 min at room temperature followed by washing twice with 1X
PBS. Cell imaging was performed using fluorescence microscopy at 40X magnification (EVOS
FL digital Inverted microscope, AMG) at 357 nm excitation and 447 nm emission wavelength.
3.6

DNA fragmentation assay
To semiquantitatively evaluate the ability of D-512 to protect against nuclear damage, a

feature of apoptotic cell death induced by 6-OHDA, DNA ladder assay was performed. 4X106
cells were plated in 100 mm petri-dish in 10mL media and they were allowed to adhere to the
surface for 24 hours. Adhered cells were pre-treated with different concentrations of D-512 for
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24 hours. The pre-treated cells were co-treated with 75 µM 6-OHDA and different
concentrations of D-512 for another 24 hours. Upon completion of the treatment, media was
collected and 1 ml trypsin was added to 100 mm dishes to dissociate the cells. Cells were scraped
and media was added back to stop the trypsin activity. Cells were centrifuged (2000 rpm, 5 min),
and washed with 1X PBS (2000 rpm, 5 min). The cell pellets were lysed using 100 µL lysis
buffer (0.1% Triton-X-100 in 20 mM EDTA, 50 mM Tris-HCl, pH 7.5) for 5 minutes with
intermittent pipetting. Cell debris were removed by centrifugation (3,000 rpm, 5 min) and
supernatant was treated with 10 µL of 10% SDS solution. The lysate was treated with 10 µL of
50 mg/mL RNaseA for 2 hours at 56°C. Afterwards, lysate was treated with 12.5 µL of 20
mg/ml proteinase K for 2 hours at 37°C. The resulting lysate was treated with 65 µL 10M
ammonium acetate and 250 µL ice-cold isopropanol. After vigorous shaking, isopropanol
precipitation was performed by incubating lysate at -20°C for 3 days. Precipitated DNA was
collected by centrifugation at 12000 rpm for 20 minutes. DNA was washed with 200 µL 80%
ice-cold ethanol and air-dried for 10 min at room temperature. DNA was dissolved in 50 µL trisEDTA buffer. 4 µg of DNA from each sample was separated using 1.2% agarose gel (containing
0.5 µg/mL ethidium bromide) at 5V/cm for 4 hours using horizontal agarose gel electrophoresis
cell (BIORAD). Agarose gel image was taken using Biorad Gel Doc XR+ imaging system.
3.7

Lipid peroxidation
To determine the free radical quenching ability of D-512, lipid peroxidation assay was

performed on PC12 cells and MN9D cells using sodium nitroprusside. For all experiments, PC12
cells were plated at 2X105 cells/well density in 2 mL media in 12 well plates. PC12 cells were
allowed to adhere to the surface for 24 hour. For optimization experiments, adhered PC12 or
MN9D cells were treated with different concentrations of sodium nitroprusside for 8 hours to
determine the concentration to use for inducing appropriate lipid peroxidation. For other
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experiments, adhered PC12 cells were pre-treated with different concentrations of D-512 for 24
hours followed by their co-treatment with 200 µM sodium nitroprusside and D-512 for 8 hours.
Cells were harvested using rubber policeman, centrifuged, and washed with 1X PBS. Cell pellet
was resuspended in 120 µL 1X PBS. Suspended cells were sonicated 3 times for 5 seconds using
ultrasonicator (Branson Inc, Danbury, CT) at 30% amplitude. Whole cell lysate was used to
determine thiobarbituric acid (TBA) reactive species (TBARS). 100 µL 1% SDS and 100 µL
whole cell lysate were mixed with 4mL color reagent (The color reagent was prepared by mixing
320 mg TBA dissolved in 30 mL 0.1M sodium hydroxide and 30 mL diluted acetic acid).
Mixture was boiled for 1 hour at 100°C in dark and the fluorescence was read at 520 nm
excitation and 550 nm emission wavelength using synergy microplate reader (Biotek, Winooski,
VT, USA). Fluorescence was plotted after subtracting blank (which was prepared using 100 µL
1X PBS, 100 µL 1% SDS, and 4 mL color reagent) and considering control (which consisted of
100 µL cell lysate without any treatment, 100 µL 1% SDS, and 4mL color reagent) fluorescence
as 100%.
3.8

Western Blot Analysis
To understand the molecular mechanisms associated with neuroprotection conferred by

D-512 against 6-OHDA induced cell death, expression levels of various phopsphoprotein
signaling molecules were evaluated at earlier time point. PC12 cells were plated at 5X10 5
cells/well density in 6 well plate and they were allowed to adhere for 24 hours. Adhered PC12
cells were pre-treated with 10 µM D-512 for 24 hours. Afterwards, PC12 cells were co-treated
with 75 µM 6-OHDA for 30 minutes, 2 hours and 4 hours. 40 µg of proteins were separated on
10% tris-glycine gel by SDS-PAGE. Afterwards, proteins were transferred to PVDF membrane
(BIORAD). Membrane was blocked with 5% Bovine Serum Albumin (BSA) in TBST (Tris-
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buffered saline with Tween-20) for 2 hours. Blocked membrane was incubated overnight with
primary antibody against phospho-ERK1/2, phospho-JNK, total ERK1/2, total JNK, and
GAPDH (1:1000 dilution) in 5% BSA in TBST. Afterwards, membrane was incubated with
appropriate HRP-conjugated secondary antibody (anti-mouse or anti-rabbit) (1:4000 dilution) in
1% BSA in TBST. The image was visualized using ECL-Plus reagent (PerkinElmer, Waltham,
MA, USA) and ImageQuant LAS 4000 imager (GE Healthcare Biosciences, Pittsburgh, PA,
USA). Densitometric analysis was performed using ImageJ software.
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MATERIALS AND METHODS
α-SYNUCLEIN AGGREGATION MODIFICATION PROPERTIES
OF LEAD MOLECULES
3.9

Materials
Chemicals: α-synuclein was purchased from rpeptide (Bogart, GA, USA). Dopamine

hydrochloride, ammonium iron(II) sulphate hexahydrate, ascorbic acid, rifampicin, sodium
thiosulphate, silver nitrate, sodium hydroxide, formalin (36.5-38% formaldehyde in water), and
thioflavin-T (ThT) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Sodium
carbonate, methanol, HPLC grade acetonitrile, and HPLC grade water were purchased from
EMD Millipore (Billerica, MA, USA). Glacial acetic acid, sodium phosphate, LB broth (Miller),
glycerol, ethanol, and sodium chloride were purchased from Fisher scientific (New Jersey,
USA).

400 mesh copper grids with carbon/formvar coating, uranyl acetate and 4%

paraformaldehyde solution were purchased from Electron Microscopy Sciences (Hatfield, PA,
USA). Ammonium acetate was purchased from G-biosciences (St. Louis, MO, USA).
Trifluoroacetic acid was purchased from Oakwood chemicals (West Columbia, SC, USA).
Streptomycin sulphate was purchased from Calbiochem (Billerica, MA, USA). Ammonium
sulphate was purchased from Research organics (St. Louis, MO, USA). Ampicillin and isopropyl
thiogalactoside (IPTG) were purchased from Gold Biotechnology (St. Louis, MO, USA). ECLplus reagent was purchased from Perkin-Elmer (Waltham, MA, USA).
Analytical columns and standards: Size-exclusion chromatography was performed
using BIOSEP-SEC-S2000 column from Phenomenex (Torrance, CA, USA). Reverse phase
chromatography was performed using C4-Jupiter 300A column from Phenomenex (Torrance,
CA, USA). Gel-filtration standard containing mixture of known globular proteins from Biorad
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(Hercules, CA, USA) was used for size-exclusion chromatography. α-synuclein purification was
performed using 5mL pre-packed Q-sepharose HP column purchased from GE lifesciences
(Pittsburgh, PA, USA).
Antibodies: Antisera directed against wild-type α-synuclein was purchased from BD
biosciences (San Jose, CA, USA). Anti-mouse IgG-horseradish peroxidase conjugate was from
MP biomedicals (Santa Ana, CA, USA).
Cell-culture and treatments: PC12 Adh (ATCC® CRL1721.1™) cells, a rat adrenal
pheochromocytoma cell line, were purchased from ATCC. RPMI 1640, heat-inactivated horse
serum, fetal bovine serum, penicillin-streptomycin, and trypsin were purchased from GIBCO
(Grand Island, NY, USA).
PC12 cells were cultured in T-75 flask (Sarstedt Inc, Newtown, NC, USA) and
maintained in RPMI 1640 medium supplemented with 10% heat-inactivated horse serum, 5%
fetal bovine serum, penicillin (100 units/mL), and streptomycin (100 µg/mL) at 37°C in 5% CO2
atmosphere.
Plasmid and bacteria: E.coli BL21(DE3) strain was purchased from Invitrogen (Grand
Island, NY, USA). pET-3a plasmid containing amino acid sequence for wild-type α-synuclein
was kindly provided by Dr. Suzanne Scarlatta (Stony Brooke University).

3.10

Generation of α-synuclein aggregates using cell-free system
For cell-free system experiments, all solutions were prepared in 1X PBS. Shaking

experiments were conducted on Thermomix R shaker (Eppendorf, Hamburg, Germany) at 1400
rpm and 37°C. 1mg α-synuclein was dissolved in 576.3 µL 1X PBS to generate 120 µM stock
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solution of protein (protein concentration was also verified by BCA protein assay). 400 µM
dopamine hydrochloride was made by dissolving 2mg dopamine hydrochloride in 26.36 mL 1X
PBS. 35 µM ammonium iron(II) sulfate hexahydrate was prepared by diluting 350 µM
ammonium iron(II) sulfate hexahydrate, which was prepared by dissolving 2.05mg ammonium
iron(II) sulfate hexahydrate in 15mL 1X PBS.
Protocol A: Generation of dopamine-induced, SDS-resistant α-synuclein oligomers
α-synuclein oligomers were generated by shaking α-synuclein (17.5 µM) and dopamine
(200 µM) solution for 10 days. 115 µL (35 µM) α-synuclein and 115 µL (400 µM) dopamine
hydrochloride were mixed and 30 µL aliquot was removed for day 0. 30 µL aliquots were
removed for day 2, day 4, day 6, day 8 and day 10 after starting the shaking. The aliquots were
used for silver-staining (10 µL), ThT assay (10 µL), and in some cases for transmission electron
microscopy (10 µL).
Protocol B: Generation of α-synuclein fibrils using high concentration of α-synuclein
α-synuclein fibrils were generated by shaking α-synuclein (70µM) solution for 10 days.
230 µL (70 µM) α-synuclein was prepared and 30 µL aliquot was removed for day 0. 30 µL
aliquots were removed for day 2, day 4, day 6, day 8 and day 10 after starting the shaking. The
aliquots were used for silver-staining (10 µL), ThT assay (10 µL), and in some cases for
transmission electron microscopy (10 µL).
Protocol C: Generation of iron-induced, SDS-sensitive α-synuclein fibrils
α-synuclein fibrils were generated by shaking α-synuclein (17.5 µM) and iron(II) (17.5
µM) for 6 days. 110 µL of 35 µM α-synuclein and 110 µL of 35 µM ammonium ferric citrate
were mixed and 30 µL aliquot was removed for day 0. 30 µL aliquots were removed for day 1,
day 2, day 3, day 4, day 5, and day 6 after starting the shaking. The aliquots were used for silver-
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staining (10 µL), ThT assay (10 µL), and in some cases for transmission electron microscopy (10
µL).

3.11

Assessment of potential lead compounds’, standards’ and anti-oxidant’s ability to
modify α-synuclein aggregation kinetics in cell-free system
We evaluated the effects of ascorbic acid (anti-oxidant), rifampicin (known α-synuclein

aggregation inhibitor), and 2 of our lead compounds (D-436 and D-520) on dopamine-induced αsynuclein oligomerization employing cell-free system. All solutions were prepared in 1X PBS.
Shaking experiments were conducted on Thermomix R shaker (Eppendorf, Hamburg, Germany)
at 1400 rpm and 37°C. 1 mg α-synuclein was dissolved in 266 µL 1X PBS to generate 260 µM
stock solution of protein (protein concentration was also verified by BCA protein assay). 260 µM
α-synuclein was diluted to 70 µM protein solution. 800 µM dopamine hydrochloride was
prepared by dissolving 2 mg dopamine hydrochloride in 13.18 mL 1X PBS. 800 µM ascorbic
acid was made by dissolving 1.4 mg ascorbic acid in 10 mL 1X PBS. 800 µM rifampicin was
prepared by dissolving 1mg rifampicin in 1.52 mL 1X PBS. 800µM D-436 was prepared by
dissolving 2.6 mg D-436 trifluoroacetate in 4 mL 0.1X PBS. 800 µM D-520 was prepared by
dissolving 4.2 mg D-520 hydrobromide in 7 mL 1X PBS (containing 1% DMSO).
Protocol for ascorbic acid experiment
62.5 µL α-synuclein (70 µM) was mixed with 62.5 µL dopamine hydrochloride (800
µM). To this mixture, 125 µL ascorbic acid (800 µM) was added to get total volume of 250 µL.
This resulted in final concentration of 17.5 µM α-synuclein, 200 µM dopamine and 400 µM
ascorbic acid. 30 µL of day 0 aliquot was removed and the mixture was shaken for 10 days.
30µL aliquots were collected at day 2, day 4, day 6, day 8, and day 10. The aliquots were used
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for silver staining (10 µL), size-exclusion chromatography (10 µL), and in some cases for
transmission electron microscopy (10 µL).
Protocol for rifampicin experiment
62.5 µL α-synuclein (70 µM) was mixed with 62.5 µL dopamine hydrochloride (800
µM). To this mixture, 125 µL rifampicin (800 µM) was added to get total volume of 250 µL.
This resulted in final concentration of 17.5 µM α-synuclein, 200 µM dopamine and 400 µM
rifampicin. 30 µL of day 0 aliquot was removed and the mixture was shaken for 10 days. 30 µL
aliquots were collected at day 2, day 4, day 6, day 8, and day 10. The aliquots were used for
silver staining (10 µL), size-exclusion chromatography (10 µL), and in some cases for
transmission electron microscopy (10 µL).
Protocol for D-436 experiment
62.5 µL α-synuclein (70 µM) was mixed with 62.5 µL dopamine hydrochloride (800
µM). To this mixture, 125 µL D-436 (800 µM) was added to get total volume of 250 µL. This
resulted in final concentration of 17.5 µM α-synuclein, 200 µM dopamine and 400 µM D-436.
30 µL of day 0 aliquot was removed and the mixture was shaken for 10 days. 30 µL aliquots
were collected at day 2, day 4, day 6, day 8, and day 10. The aliquots were used for silver
staining (10 µL), size-exclusion chromatography (10 µL), and in some cases for transmission
electron microscopy (10 µL).
Protocol for D-520 experiment
62.5 µL α-synuclein (70 µM) was mixed with 62.5 µL dopamine hydrochloride (800
µM). To this mixture, 125 µL D-520 (800 µM) was added to get total volume of 250 µL. This
resulted in final concentration of 17.5 µM α-synuclein, 200 µM dopamine and 400 µM D-520.
30 µL of day 0 aliquot was removed and the mixture was for 10 days. 30 µL aliquots were
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collected at day 2, day 4, day 6, day 8, and day 10. The aliquots were used for silver staining (10
µL), size-exclusion chromatography (10 µL), and in some cases for transmission electron
microscopy (10 µL).
3.12

Visualization of α-synuclein aggregates by silver-staining
Aliquots collected on different days from cell-free system experiments were fractionated

on 12% tris-glycine-SDS gel to separate protein aggregates according to their molecular weight.
After fractionation, the gel was fixed using fixation solution (50% methanol, 12% glacial acetic
acid, 0.05% formalin) for 2 hours. Fixed gel was washed thrice for 30 minutes with washing
solution (35% ethanol). Gel was sensitized using 0.02% sodium thiosulphate for 2 minutes.
Afterwards, the gel was washed thrice with distilled water for 5 minutes. The gel was stained
using silver staining solution (0.2% silver nitrate and 0.076% formalin) for 20 minutes. Stained
gel was washed twice with distilled water for 1 minute. The gel was developed using silverstaining developer solution (6% sodium carbonate, 0.05% formalin, and 0.0004% sodium
thiosulphate). The developer reaction was stopped by adding stop solution (50% methanol, 12%
acetic acid) for 5 minutes. Gel image was taken using Biorad Gel Doc XR+ imaging system.

3.13

Confirmation of β-sheet positive protein structure by Thioflavin-T assay
ThT assay was performed to evaluate the impact of chemicals or protein concentration on

protein’s structure. 40 µM ThT was prepared by diluting 500 µM ThT, which was prepared by
dissolving 1.1 mg Thioflavin-T in 7 mL 1X PBS. Afterwards, 10 µL of protein aliquot and 10 µL
ThT (40 µM) were mixed together and transferred to 384 plate. Fluorescence generated was read
using Synergy microplate reader (Biotek, Winooski, VT, USA) at 440 nm excitation and 485 nm
emission wavelengths. Control consisted of 10 µL 1X PBS mixed with 10 µL ThT (40 µM).
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3.14

Evaluating the size-distribution of protein aggregates using size-exclusion
chromatography
Aliquots collected from different time points were analyzed for residual protein monomer

left and higher molecular weight aggregates of protein formed using size-exclusion
chromatography. Samples (10 µL) were loaded into Biosep-SEC-S2000 column attached to
Waters HPLC system to measure hydrodynamic dimensions of eluted species (Stokes radius, Rs)
(Li et al. 2004). The mobile phase consisted of 20 mM sodium phosphate buffer, pH 7. Flow rate
was set to 1 mL/minute. Eluted species of protein were detected using UV detector set at 215 nm
wavelength (ideal for monomer detection) and 275 nm wavelength (ideal for oligomer
detection). Single chromatographic run was set to 15 minutes. 10 µL mixture of globular protein
standards (Biorad laboratories) with known Rs values was also injected using same protocol to
estimate the apparent molecular weight of protein species eluted from experimental samples.
3.15

Detection of monomeric and higher molecular weight structures of protein using
reverse-phase chromatography
Aliquots collected from different time points were analyzed for monomer and higher

molecular weight aggregates of protein formed using reverse-phase chromatography. 10 µL
sample was loaded into reverse phase chromatography column (C4, Phenomenex Jupiter, 300A,
5 µM) attached to Waters HPLC system. Gradient elution was carried out using acetonitrile
(containing 0.085% trifluoroacetic acid) versus water (containing 0.1% trifluoroacetic acid):
from 5% to 35% over 5 minutes, from 35% to 55% over 20 minutes, from 55% to 95% over 2
minutes. 0.6 mL/minute flow rate was used during elution. Single chromatographic run was set
to 30 minutes. The eluting species were monitored using UV detector set at 226 nm wavelength.
α-synuclein from industrial source was used as a control to compare elution pattern of other
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samples.
3.16

Visualization of α-synuclein using transmission electron microscopy
Transmission electron microscopy (TEM) was used to physically image α-synuclein

monomer and modified species generated under different experimental conditions. TEM samples
were prepared on 400 mesh copper grids with carbon/formvar coating. 4 µL sample was loaded
on the grid for 4 minutes. Afterwards, it was wicked-off using whatman filter paper. Grid was
loaded with 4 µL distilled water 2 times and wicked off quickly to wash-off excess sample.
Before imaging, grid was loaded with 4 µL 2% Uranyl acetate (prepared in distilled water) for 30
seconds to negatively stain grid surface. The solution was wicked-off using whatman filter paper.
Grid was allowed to dry for 5-10 minutes before starting TEM imaging. JEOL (JEM-2010)
transmission electron microscope was used for imaging protein samples. All TEM images were
taken at 80000X magnification.
3.17

Generation of α-synuclein aggregates to assess extracellular toxicity in cell-culture
models
α-synuclein aggregates were generated with primary goal to evaluate the effect of various

extracellular α-synuclein species on cellular viability in PC12 cells. In this experiment, αsynuclein aggregates were formed by two different methods, either to yield β-sheet positive
fibrillar structure or to yield β-sheet negative dopamine-induced and co-valently modified
oligomeric structure of α-synuclein. All samples were prepared in 1X PBS. Shaking experiments
were conducted on Thermomix R shaker (Eppendorf, Hamburg, Germany) at 1400 rpm and
37°C. 1 mg α-synuclein was dissolved in 576.3 µL 1X PBS to yield 120 µM stock solution. 180
µM dopamine was prepared by dissolving 1mg dopamine hydrochloride in 29.24 mL 1X PBS.
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Protocol A: Generation of α-synuclein fibrils
250 µL α-synuclein (120 µM) was mixed with 250 µL 1X PBS to yield 60 µM αsynuclein. 70 µL aliquot was taken from the mixture and then the solution was shaken for 10
days. 70 µL aliquots were collected at day 2, day 4, day 6, day 8, and day 10. Aliquots were used
to assess cytotoxicity (40 µL), ThT assay (10 µL), and in some cases transmission electron
microscopy (10 µL).
Protocol B: Generation of α-synuclein oligomers co-valently modified with dopamine
250 µL α-synuclein (120 µM) was mixed with 250 µL 180 µM dopamine to yield the
mixture of 60 µM α-synuclein and 90 µM dopamine. 70 µL aliquot was taken from the mixture
and then solution was shaken for 10 days. 70 µL aliquots were collected at day 2, day 4, day 6,
day 8, and day 10. Aliquots were used to assess cytotoxicity (40 µL), ThT assay (10 µL), and in
some cases transmission electron microscopy (10 µL).
3.18

Evaluation of cytotoxicity of extracellular α-synuclein aggregates (pre-formed) in
cell-culture system
Aliquots obtained from experiments mentioned above were used to evaluate the effect of

(pre-formed) various species generated from α-synuclein aggregation experiments on PC12 cell
viability (extracellular toxicity). The main objective of this experiment was to optimize the timepoint and the aggregation environment that would induce desired cytotoxicity (in ideal
conditions, ~50% cell death). For cell-culture experiments, 40 µL aliquots (60 µM α-synuclein)
from various time-points were diluted with 200 µL PC12 cell media to make the final
concentration of α-synuclein 10 µM for cell culture experiments.
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Experimental protocol: Cell viability assay to assess extracellular toxicity of various αsynuclein aggregation species
Quantitative and colorimetric MTT assay was used to evaluate cytotoxic effects of αsynuclein. PC12 cells were seeded at 17000 cells/well density in 100 µL media in 96 well plate.
Cells were allowed to adhere to the surface for 24 hours. Media was removed and the adhered
PC12 cells were treated with 55 µL α-synuclein (10 µM) containing media. Control cells were
treated with appropriately diluted PC12 media. Treatment with extracellular α-synuclein was
conducted for 24 hours. After incubation, 6 µL 5 mg/mL MTT was added to the cells and the
plate was further incubated at 37°C in 95% air/5% CO2 atmosphere for 3 hours to produce dark
blue formazan crystals. Afterwards, the plate was centrifuged at 1500 rpm for 10 minutes and the
supernatants were carefully removed. The formazan crystals were dissolved by adding 100 µL of
DMSO/methanol (50:50) mixture to each well and shaking the plate gently at room temperature
at 400 rpm for 30 minutes at room temperature using a Thermomix R shaker (Eppendorf,
Hamburg, Germany). The absorbance values were measured using Epoch microplate reader
(Biotek, Winooski, VT, USA) at 570 nm with background correction done at 690 nm. Data from
at least 3 experiments were analyzed using Graphpad software (Version 4, San Diego, USA).
Cell viability was defined as a percentage reduction in absorbance compared to untreated
controls.
3.19

Assessment of some lead compounds and standard drug’s ability to alter
cytotoxicity induced by extracellular α-synuclein
α-synuclein alone (60 µM) was able to induce around ~ 40% cell death after shaking for

6 days. Therefore, we assessed the ability of some of our lead compounds (D-240, D-436, D-
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520) and a standard drug (rifampicin) to alter cytotoxicity induced by α-synuclein (60 µM) after
shaking for 6 days. All solutions were prepared in 1X PBS. Shaking experiments were conducted
on Thermomix R shaker (Eppendorf, Hamburg, Germany) at 1400 rpm and 37°C. 120 µM αsynuclein was prepared by dissolving 1 mg α-synuclein in 576.3 µL 1X PBS. 240 µM rifampicin
was prepared by dissolving 1mg rifampicin in 4.84 mL 1X PBS. 240 µM D-240 was prepared by
dissolving 1 mg D-240 in 6.25 mL 1X PBS. 240 µM D-436 was prepared by dissolving 1 mg D436 in 5.1 mL 1X PBS. 240 µM D-520 was prepared by dissolving 1 mg D-520 in 5.6 mL 1X
PBS.
Protocol for α-synuclein alone experiment
70 µL α-synuclein (120µM) was mixed with 70 µL 1X PBS to yield 60 µM α-synuclein.
50 µL aliquot was taken from the mixture and the remaining mixture was shaken for 6 days.
After 6 days, the mixture was frozen at -20°C until further use. From day 0 aliquot, 40 µL was
used for cell viability assay and 10 µL was used for ThT assay, whereas, from day 6 aliquot, 40
µL was used for cell viability assay, 10 µL was used for ThT assay, and remaining volume was
used for electron microscopy.
Protocols for rifampicin, D-240, D436, and D520 experiments
70 µL α-synuclein (120 µM) was mixed with 70 µL rifampicin (240 µM)/70 µL D-240
(240 µM)/70 µL D-436 (240 µM) or 70 µL D-520 (240 µM) to yield 60 µM α-synuclein and 120
µM rifampicin/D-240/D-436/D-520. 50 µL aliquot was taken from the mixture and the
remaining mixture was shaken for 6 days. After 6 days, the mixture was frozen at -20°C until
further use. From day 0 aliquot, 40 µL was used for cell viability assay and 10 µL was used for
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ThT assay, whereas, from day 6 aliquot, 40 µL was used for cell viability assay, 10 µL was used
for ThT assay, and remaining volume was used for electron microscopy.
Evaluation of ability of potential lead compounds’ and standard’s ability to alter
cytotoxicity induced by extracellular α-synuclein
The aliquots were diluted with PC12 media to get final concentration of α-synuclein to 10
µM in PC12 media. MTT assay was carried out as described in 3.18 with aliquots obtained from
experiments mentioned above.
3.20

Expression, isolation and purification of recombinant α-synuclein
We developed a method to purify recombinant α-synuclein in our lab to avoid the use of

α-synuclein from industrial source. Our protocol included expression of α-synuclein using
transformation of E.coli with a plasmid containing the amino acid sequence necessary to
generate wild-type α-synuclein, bacterial culturing protocol to yield maximum amount of αsynuclein that can be isolated, isolation of proteins from grown bacterial culture, and processing
of protein lysate to yield high purity α-synuclein protein.
Expression of α-synuclein and preparation of glycerol stocks
pET-3a plasmid (containing amino acid sequence to express wild-type α-synuclein) was
used to transform E.coli strain BL21(DE3). Heat-shock transformation protocol was used to
induce transformation. One vial of one-shot cells was thawed on ice. 10 ng pET-3a DNA (in
around ~2 µL) was added to the cells and the vial was mixed gently. Vial was incubated on ice
for 30 seconds. Heat shock was induced by incubating the vial for 30 seconds in 42°C water
bath. Afterwards, vial was quickly placed on ice. 250 µL SOC medium (supplied with bacteria)
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was added to vial. The vial was shaken in an incubator at 37°C for 1 hour at 225 rpm. 12.5 µL or
25 µL volumes from transformation reaction were streaked on LB plates containing ampicillin.
The plates were inverted and incubated overnight at 37°C.
Next morning, 2-3 transformants were collected (individual colonies were preferentially
selected) and added separately to 2.5 mL LB medium containing ampicillin in 14 mL vials. The
vials were shaken in an incubator at 37°C overnight. Next morning, 250 mL fresh LB medium
containing ampicillin was inoculated with overnight culture such that the optical density
OD600=0.05-.10. The medium was shaken in an incubator at 37°C and 225 rpm to reach an
OD600=0.8-1.0. 0.8 mL bacterial culture was mixed with 0.2 mL glycerol to generate glycerol
stock of bacteria expressing α-synuclein. Several vials generated by such method were stored at 80°C to use them for bacterial culturing experiments. Expression of α-synuclein from bacterial
cultures was verified by western blotting.
Bacterial culturing protocol
Transformed BL21(DE3) bacteria were scraped from glycerol stock and expelled into 3
mL LB media containing ampicillin in 14 mL vial. The bacteria were grown in an incubator
shaker at 37°C and 250 rpm for 6 hours. Afterwards, 400 µL of bacterial culture was added to 50
mL fresh LB medium containing ampicillin and bacterial culturing was continued overnight in
incubator shaker at 37°C and 250 rpm. Next morning, 50 mL bacterial culture was added to 700
mL fresh LB media containing ampicillin. Culturing was continued in an incubator shaker at
37°C and 250 rpm for 3 hours to reach OD600~0.8-1.0. Bacterial culture was induced with 0.1M
IPTG for 3 hours. The resulting bacterial culture was centrifuged at 6000 rpm for 10 minutes.
The supernatant medium was decanted and the pellet containing bacteria was resuspended in 7.5

68

mL buffer (50 mM tris pH 8, 10 mM EDTA, 150 mM sodium chloride). The resuspended
bacteria were stored at -80°C.
Purification of α-synuclein from bacterial pellet
Resuspended bacterial cells were directly placed on boiling water-bath for 7 minutes.
Afterwards, the tubes were centrifuged at 14000 rpm for 10 minutes. Resulting supernatant was
transferred to new tube and streptomycin sulphate (136 µL of 10% solution/mL of supernatant)
and glacial acetic acid (228 µL/mL of supernatant) were added. The mixture was centrifuged for
10 minutes at 14000 rpm. Resulting supernatant was transferred to new tube and precipitated
with ammonium sulphate (saturated ammonium sulphate at 4°C was used 1:1 v/v) on shaker for
1 hour at 4°C. Precipitated protein was collected by centrifugation for 10 minutes at 14000 rpm.
The protein pellet was washed once with 1mL ammonium sulphate solution (4°C, 1:1 v/v
saturated ammonium sulphate (4°C) and water). The washed pellet was resuspended in (900 µL)
100 mM ammonium acetate (to form cloudy solution) and precipitated by adding an equal
volume of ethanol at room temperature. Precipitation in ethanol was repeated twice, followed by
a final resuspension in 100 mM ammonium acetate. The resulting solution was dialyzed against
water overnight and frozen in liquid nitrogen before undergoing further purification.
Further purification of α-synuclein was carried out by anion exchange chromatography.
The whole protocol was carried out using a 10 mL syringe attached to the Q-sepharose HP
column (5 mL pre-packed column). Frozen protein solution was thawed slowly on ice and pH
was adjusted to pH 8. Q-sepharose HP column (5mL) was equillibriated with 25 mL buffer A
(tris 50 mM, EDTA 10 mM, sodium chloride 0 mM, pH 8.0). Protein solution was loaded into
the column slowly (< 1 mL/minute flow rate). Afterwards, the column was washed with 25 mL
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buffer A. Gradient elution was carried out using buffer A with sodium chloride concentrations
varying from 50 mM to 600 mM (pH 8.0) using total volume of 100 mL (20 column volumes) as
described in the table below. 5mL aliquots were collected for entire run and kept on ice. All
aliquots, the solution loaded into the column and the solution eluted from the column were
fractionated on 12% tris-glycine-SDS gel. Silver-staining was performed to visualize proteins
separated by gel electrophoresis. α-synuclein was found to be eluted in the fractions
corresponding to the sodium chloride concentrations of 250 mM-350 mM. The fractions were
combined and concentrated using Chemicon centrifuge filters. Concentrated samples were
dialyzed against 20 mM tris (pH 8.0) overnight. Next morning, dialyzed samples were divided
into several tubes and frozen at -80°C. Small aliquots were taken to determine final
concentration of protein and its purity.

mM NaCl

Total mL

mL (Tris-EDTA)

50
100
150
200
250
300
350
400
450
500
550
600

10
10
8
8
8
8
8
8
8
8
8
8

9.5
9
6.8
6.4
6
5.6
5.2
4.8
4.4
4
3.6
3.2

mL
(Tris-EDTA, 1M
NaCl)
0.5
1
1.2
1.6
2
2.4
2.8
3.2
3.6
4
4.4
4.8

Table 3-1. Gradient elution protocol for purification of α-synuclein using
Q-sepharose HP column
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CHAPTER 4
RESULTS
4.1

D-512 prevents cytotoxicity induced by 6-OHDA in PC12 cells
6-OHDA dose dependently induced toxicity on PC12 cells following exposure for 24

hours (figure 4-1). Cell viability was significantly decreased (~50%) when PC12 cells were
exposed to 75 µM 6-OHDA for 24 hours. Cells treated with D-512 alone (0.001 µM, 0.01 µM,
0.1 µM, 1 µM, 5 µM, and 10 µM concentrations) showed no significant toxicity when compared
to untreated control cells, whereas, D-512 at concentrations of 20 µM and 30 µM showed some
toxicity (~20-30%) to PC12 cells (figure 4-2).

Figure 4-1. MTT assay 6-OHDA dose dependence
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Figure 4-2. MTT assay D-512 dose dependence

Then, we evaluated the neuroprotective effect of D-512 on 6-OHDA induced toxicity using
two different treatment methods. In the first protocol, D-512 pre-treatment (various
concentrations) for 24 hours was followed by exposure to 6-OHDA (75 µM) and varied
concentration of D-512 for 24 hours. We observed that D-512 was able to significantly restore
the cell viability of PC12 cells at 1 µM, 5 µM, 10 µM and 20 µM concentrations (figure 4-3).
Our other protocol consisted of pre-treatment of PC12 cells with D-512 for 24 hours followed by
treatment with 6-OHDA (75 µM) for another 24 hours. Here, we observed that in either of the
protocols D-512 was able to significantly protect the PC12 cells against 6-OHDA-induced
toxicity to an extent of 20-40% at 5 µM, 10 µM, 20 µM and 30 µM concentrations (figure 4-4).
This suggests that D-512 has a neuroprotective effect on cell death induced by 6-OHDA in PC12
cells.
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Figure 4-3. Neuroprotective effect of D-512 pre-treatment and co-treatment
on 6-OHDA induced cell death in PC12 cells

Figure 4-4. Neuroprotective effect of D-512 pre-treatment on
6-OHDA induced cell death in PC12 cells
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4.2

D-512 partially restores free and total glutathione levels in 6-OHDA treated PC12 cells
Initially, we evaluated the effect of 6-OHDA alone in dose and time-dependent manner

on total glutathione levels in PC12 cells (figure 4-5 and figure 4-6). From our experiments
shown in figure 4-5 and figure 4-6, we observed an interesting trend in the level of total
glutathione in 6 hours and 24 hours treatment. 6 hours treatment with 25 µM 6-OHDA caused
around ~20% total GSH depletion, whereas, 24 hours treatment with 25 µM 6-OHDA caused
around ~65% increase in total GSH levels compared to untreated control cells. In case of 24
hours experiment, we observed an increasing trend for 12.5 µM, 25 µM, and 25 µM 6-OHDA
treatments, whereas, 6-OHDA concentrations of 75 µM and 100 µM showed decrease in total
glutathione levels compared to untreated control cells.

Figure 4-5. Effect of 6-OHDA on total glutathione levels in PC12 cells (6 hours)
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Figure 4-6. Effect of 6-OHDA on total glutathione levels in PC12 cells (24 hours)
NOTE: Higher dose of 6OHDA (75 µM and 100 µM causes significant amount of cell death
and this might be the reason that the apparent levels of glutathione seem to be decreasing.)
No normalization was performed for this experiment as it was done to select optimal dose
of 6OHDA for further studies.

To assess the effect of D-512 on free glutathione and total glutathione levels, we
employed 25 µM 6-OHDA as a toxin and 3 different concentrations of D-512 (10 µM, 5 µM and
1 µM) to assess its neuroprotective ability at 2 different time points, 6 hours and 24 hours. In the
6 hours treatment with 6-OHDA and D-512, we observed that D-512 at 10 µM concentration
was able to restore the free glutathione levels as well as total glutathione levels depleted by 25
µM 6-OHDA in PC12 cells (figure 4-7 and figure 4-8). However, 24 hour treatment with 6OHDA and D-512 showed that none of the doses of D-512 restored the increase in free
glutathione levels or total glutathione levels by 25 µM 6-OHDA alone in PC12 cells to control
level (figure 4.9 and figure 4.10). This suggests that D-512 may induce changes in free and total
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glutathione levels during earlier time-point of exposure to 6-OHDA in PC12 cells (6 hours).
However, D-512 doesn’t have ability to alter free or total glutathione level in PC12 cells treated
with 6-OHDA at higher time-point (24 hours).

Figure 4-7. Effect of D-512 on 6-OHDA induced changes in free glutathione levels (6 hours)
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Figure 4-8. Effect of D-512 on 6-OHDA induced changes in
total glutathione levels (6 hours)

Figure 4-9. Effect of D-512 on 6-OHDA induced changes
in free glutathione levels (24 hours)
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Figure 4-10. Effect of D-512 on 6-OHDA induced changes
in total glutathione levels (24 hours)
4.3

D-512 has an ability to restore total glutathione levels in BSO treated PC12 cells
Buthionine sulfoximine (BSO) is a well-known compound for the inhibition of enzyme γ-

glutamylcyteine synthetase, which has a key role in glutathione synthesis. Initially, we evaluated
the effect of BSO on total glutathione levels in PC12 cells in dose and time-dependent manner
(figures 4-11 and figure 4-12). Total GSH was depleted dose dependently at both 6 and 24
hours by BSO. It was observed that at 6 hours, 1.56 µM BSO causes ~20% total GSH depletion
(figure 4-11), while the same dose causes ~55% depletion at 24 hours compared to untreated
control cells (figure 4-12).
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Figure 4-11. Effect of BSO on total glutathione levels in PC12 cells (6 hours)

Figure 4-12. Effect of BSO on total glutathione levels in PC12 cells (24 hours)
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To evaluate the effect of D-512 against BSO induced glutathione depletion, PC12 cells
were pre-treated with 4 different concentrations of D-512 (20 µM, 10 µM, 5 µM and 1 µM) for
24 hours followed by co-treatment with 1.56 µM BSO and 4 different concentrations of D-512
for either 6 hours or 24 hours. In case of BSO and D-512 treatment for 6 hours (figure 4-13), D512 at 20 µM, 10 µM, and 5 µM concentrations partially restored total glutathione levels, which
were depleted by 1.56 µM BSO. In another experiment, which involved treatment of 1.56 µM
BSO and various D-512 concentrations for 24 hours (figure 4-14), D-512 concentrations of 20
µM and 10 µM provided statistically significant restoration of total glutathione levels in PC12
cells.

Figure 4-13. Effect of D-512 pre-treatment and co-treatment on BSO-induced
total glutathione depletion in PC12 cells (6 hours)
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Figure 4-14. Effect of D-512 pre-treatment and co-treatment on BSO-induced total
glutathione depletion in PC12 cells (24 hours)
4.4

D-512 is able to partially restore nuclear morphology changes in 6-OHDA treated PC12
cells
Nuclear morphology is one of the characteristic features of assessing the cell integrity.

Changes in nuclear morphology of PC12 cells treated with D-512 followed by exposure to 6OHDA were assessed by Hoescht 33342 staining. Control cells showed homogeneous staining of
their nuclei without any abnormalities, whereas, PC12 cells treated with 75 µM 6-OHDA
showed nuclear condensation. 10 µM D-512 alone didn’t cause any change in nuclear
morphology compared to control cells. However, when 10 µM D-512 treated PC12 cells were
exposed to 75 µM 6-OHDA, it reduced nuclear condensation significantly when compared to 6OHDA alone treated cells (figure 4-15).
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Figure 4-15. Nuclear morphology characterization of PC12 cells by Hoescht staining

4.5

D-512 partially prevents DNA fragmentation induced by 6-OHDA in PC12 cells
DNA fragmentation is a hallmark feature of apoptosis. We assessed the effect of D-512

treatment on 6-OHDA induced DNA fragmentation. Control cells and D-512 alone 10 µM
treated cells did not yield any fragmented DNA. However, PC12 cells treated with 75 µM 6OHDA yielded highly fragmented DNA. D-512 rescued the fragmentation of DNA in a dosedependent manner in PC12 cells treated with 75 µM 6-OHDA. D-512 10 µM was found to be
most effective concentration when compared with D-512 5 µM and 1 µM in preventing DNA
fragmentation upon exposure to 6-OHDA (figure 4-16).
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Figure 4-16. Determination of D-512’s ability to alter DNA fragmentation
induced by 6-hydroxydopamine.
1. Control cells; 2. Cells treated with 6-OHDA (75 µM); 3. Cells treated with D-512 alone
(10 µM); 4, 5, 6. Cells treated with 6-OHDA and D-512 10 µM/D-512 5 µM or D-512 1 µM,
respectively.

4.6

D-512 prevents sodium nitroprusside induced lipid peroxidation in PC12 cells
We utilized sodium nitroprusside (SNP) to generate lipid peroxidation as 6-OHDA did

not induce lipid peroxidation in PC12 cells (data not shown). We observed that SNP 200 µM was
able to induce ~90% increase in lipid peroxidation compared to untreated control cells. D-512
showed dose-dependent effect in preventing the lipid peroxidation induced by SNP. As shown in
figure 4-17, 1 µM of D-512 significantly prevented lipid peroxidation (~65%), whereas, 0.5 µM
D-512 showed ~42% decrease in lipid peroxidation induced by 200 µM sodium nitroprusside.
However, D-512 at 0.25 µM concentration wasn’t able to prevent lipid peroxidation in PC12
cells.
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Figure 4-17. Evaluation of ability of D-512 to protect against
lipid peroxidation induced by sodium nitroprusside

4.7

D-512 prevents temporal increase in phospho-ERK and phospho-JNK signaling
molecules induced by 6-OHDA in PC12 cells
We observed an upregulation in phospho-ERK1/2 and phospho-JNK levels in time-

dependent manner after exposure of PC12 cells to 6-OHDA (75 µM). Therefore, we evaluated
the effect of D-512 (10 µM) pre-treatment and co-treatment on these signaling molecules in
PC12 cells exposed to 75 µM 6-OHDA. Surprisingly, we found that D-512 at all three different
time points (30 minutes, 2 hours and 4 hours) was able to prevent an upregulation of phosphoERK1/2 and phospho-JNK induced by 6-OHDA (figure 4-18 and figure 4-19). It is possible
that the prevention of phospho-ERK and phospho-JNK upregulation by D-512 may be potential
molecular mechanism by which it is able to protect against 6-OHDA induced toxicity in PC12
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cells. As the time-points assessed preceded the time-point of any other assays, it can be inferred
that D-512 may act on these signaling molecules at early time-point which may prevent some
downstream signaling events leading to cell death at later time point.

Figure 4-18. Effect of D-512 on 6-OHDA induced changes in phospho-ERK

Figure 4-19. Effect of D-512 on 6-OHDA induced changes in phospho-JNK
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DISCUSSION
Surprisingly, the best available treatment for PD still remains to be L-DOPA, which was
discovered immediately following discovery of dopamine as a neurotransmitter (Birkmayer and
Hornykiewicz 1961). Approaches to develop a successful therapeutic for PD have failed to
achieve disease-modifying therapeutic, possibly because of multi-factorial nature of the disease
(Van der Schyf, Mandel et al. 2007, Youdim 2010, Youdim 2013). Although most of the PD
cases are sporadic in nature, cardinal clinical features of PD patients remain the same which
implies that a common pathological mechanism might be triggered by a variety of etiological
factors. Traditional therapeutics for PD are usually designed to act on single pathological target
(receptor, enzyme or protein), not considering the complex nature of the disease. However,
common PD therapy usually includes polypharmacy i.e. combination of two or more medications
(Swanson 1994). Polypharmacy is usually done to improve the effect of prescribed medication or
to treat other complications as PD progresses (Swanson 1994, Lemke, Fuchs et al. 2004). Most
of the PD medications used clinically are targeted towards restoring the imbalance in
neurotransmitter systems and usually provide symptomatic relief rather than addressing the
pathological factors involved in PD. Therefore, it is crucial to develop a therapeutic that can not
only restore the neurotransmitter system’s imbalance in PD patients but which can also act on
other common pathological targets of PD. Currently, very limited research has been done
towards the development of therapeutics that can target multiple pathological factors associated
with PD. Our ultimate goal is to develop a multifunctional therapeutic against PD which can
potentially act on multiple pathological targets and can also provide symptomatic relief from PD.
Based on various etiological, epidemiological, and biochemical studies increased
oxidative burden can be implicated as a common culprit in all PD patients. DA levels are
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substantially depleted in substantia nigra of patients with PD. DA has been shown to undergo
auto-oxidation more readily than any other catecholamines, which results in generation of toxic
products such as hydrogen peroxide, superoxide, and hydroxyl radicals. DA can also generate
quinone species which are transient in nature and can co-valently modify sulfhydryl groups of
various biomolecules (enzymes, proteins, and reducing environment). Thus, abnormal DA
metabolism may be potentially responsible for selective dopaminergic neuronal loss in PD.
Additionally, iron levels in substantia nigra have also been shown to be elevated. Iron catalyzed
Fenton’s reaction can yield hydroxyl radicals, which can potentially convert dopamine into 6hydroxydopamine. The generated 6-hydroxydopamine (6-OHDA) and other reactive oxygen
species might be responsible for vicious cycle of oxidative stress and the progression of PD.
Hence, it is quite convincing to develop therapeutics that can modify oxidative stress in PD.
Several clinical trials have been conducted in PD patients that show some convincing data for the
use of antioxidants as PD therapy. Interestingly, an open-label clinical trial showed that the rate
of PD progression can be decreased by 2.5 years by administration of high-dose α-tocopherol
and ascorbate in early stage PD patients (Fahn 1992). Historical DATATOP trial established
deprenyl (a MAO-B inhibitor) as a potent anti-oxidant that can delay the rate of PD progression
(Shoulson 1998). Youdim et al. have recently published some ground-breaking work on
multifunctional PD therapeutics which combine MAO-B inhibitory and iron-chelator activities
based on modification of Rasagiline (Youdim 2013). However, a potential drawback of their
drug design may be targeting the inhibition of dopamine metabolism, which still doesn’t address
the toxicity generated by dopamine auto-oxidation and may not be completely effective as a
disease-modifying therapy. We followed a similar approach as Youdim et al., but we designed
molecules that can act as dopamine agonist and anti-oxidant. We avoided designing molecules
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which can elevate dopamine levels or prevent dopamine metabolism possibly leading to
oxidative stress conditions in long-term therapy. We published work on some of our hybrid
templates that have iron-chelator, anti-oxidant, and neuroprotective activities in addition to their
dopamine D2/D3 receptor agonist activity (Gogoi, Antonio et al. 2011, Johnson, Antonio et al.
2012). We also established recently that 2 of our lead compounds possess multi-functional
activities which included dopamine receptor agonist, anti-oxidant, and anti-apoptotic properties
using murine mesencephalic dopaminergic cell-line (Santra, Xu et al. 2013).
Current experimental data reflects our efforts to further evaluate the mechanisms of
action of one of the lead compounds, D-512 from our hybrid template library. Specifically, we
evaluated the anti-oxidant activity of D-512 in PC12 cells against oxidative stress caused by 6OHDA and similar oxidants (or toxicants) after determining the ability of D-512 to prevent cell
death in PC12 cells. PC12 cells are rat adrenal medulla pheochromocytoma cell line. PC12
express tyrosine hydroxylase and possess higher levels of DA than any other catecholamines
(Greene and Tischler 1976). PC12 cells have also been shown to express dopamine D1 receptors,
D2 receptors, and DAT (Courtney, Howlett et al. 1991, Zhu, Conforti et al. 1997, Pothos,
Przedborski et al. 1998, Zachor, Moore et al. 2000). Thus, PC12 cells recapitulate dopaminergic
neurons and have been employed routinely in evaluation of PD therapeutics (Tatton, Ju et al.
1994, Abu-Raya, Blaugrund et al. 1999, Fujita, Izawa et al. 2006). 6-OHDA has been considered
to be a toxin which might be generated by abnormal metabolism of DA and has been implicated
as one of the factors that may cause PD (Linert and Jameson 2000). 6-OHDA is shown to be
increased significantly in patients with PD who administer L-DOPA (Linert and Jameson 2000).
It is well established that 6-OHDA causes its toxicity in PC12 cells by generation of ROS (Blum,
Torch et al. 2000, Hanrott, Gudmunsen et al. 2006). It has been also shown that extracellular
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oxidation of 6-OHDA is necessary to induce toxicity in PC12 cells and the toxicity is
independent of DA uptake blockade (Abad, Maroto et al. 1995, Yamada, Umegaki et al. 1997,
Blum, Torch et al. 2000, Hanrott, Gudmunsen et al. 2006). Non-enzymatic degradation of 6OHDA results in the generation of p-quinones and hydrogen peroxide extracellularly, which
enter PC12 cells and induce their apoptosis. Previously, we established that D-512 is a nonselective D2/D3 receptor agonist and two times potent compared to ascorbic acid as an
antioxidant using DPPH (2,2-diphenyl-1-picrylhydrazyl) radical quenching assay (Johnson,
Antonio et al. 2012). We also found D-512 to be neuroprotective in a dopaminergic cell-line
(MN9D) which doesn’t express dopamine receptors (Santra, Xu et al. 2013). Here, we employed
versatility of PC12 cells to partially recapitulate dopaminergic neurons and tested
multifunctional effects of D-512 using ROS generating toxin 6-OHDA.

Initially, we determined to assess the effect of various treatments on cell viability before
evaluating potential mechanisms of neuroprotection conferred by D-512. Our experiments to
optimize doses of 6-OHDA and D-512 for neuroprotection studies led us to use 75 µM 6-OHDA
for neuroprotection experiments, whereas, experiments with D-512 helped us conclude that D512 was toxic to PC12 cells at 20 µM and 30 µM concentrations. From our neuroprotection
experiments, we could conclude that D-512 treatment may not be necessary when cells are
exposed to 6-OHDA, and pre-treatment with D-512 alone is sufficient to confer similar extent of
protection against 6-OHDA induced cell death. This assay also provided us an insight that D-512
is a potential neuroprotective agent as it is able to rescue PC12 cells from 6-OHDA induced cell
death, which can be the effect of its dopamine agonist and/or anti-oxidant activity. Previously,
we observed similar neuroprotective effects of D-512 in MN9D cell line treated with 6-OHDA
(Santra, Xu et al. 2013).

89

We aimed our other experiments to determine potential mechanisms of action of D-512
by which it can act as an anti-oxidant. D-512 can be effective in preventing oxidative stress
induced by 6-OHDA in two different ways,

I.
II.

It may be able to prevent or decrease the generation of ROS;
It may be able to act via anti-oxidant defenses of PC12 cells to help them resist severe
oxidative stress conditions.

As ROS are usually unstable and transient, they are not easily detectable and may not
reflect the oxidative burden of cells effectively. However, ROS induced stress can be easily
detected by assessing oxidative status of various biomolecules. A potential mechanism of cell
survival may also include the alteration in its anti-oxidant defense systems such as glutathione
system, superoxide dismutase enzyme, and catalase enzyme. We carried out experiments to
evaluate neuroprotective ability of D-512 by estimating oxidized and total glutathione levels,
nuclear condensation, DNA fragmentation, and lipid peroxidation.

To evaluate the ability of D-512 to restore glutathione levels altered by 6-OHDA
treatment in PC12 cells, we determined the levels of free glutathione and total glutathione in
PC12 cells treated with 6-OHDA and D-512. Glutathione is a thiol tripeptide (glutamylcysteinyl-glycine), which is abundantly present in healthy cells and responsible for maintaining
reduced environment. Free glutathione is responsible for neutralizing any ROS generated as a
consequence of cellular metabolism. Initially, we carried out experiments to optimize the
concentration of 6-OHDA to carry out further experiments involving D-512. Surprisingly, we
observed an opposite trend in total glutathione levels following 6 hour and 24 hour treatment
with 6-OHDA in PC12 cells. 6 hour treatment caused a dose-dependent decrease in total
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glutathione levels. However, in case of 24 hour treatment of PC12 cells with 6-OHDA, we
observed significant increase in total glutathione levels for 25 µM and 50 µM concentrations,
whereas, total glutathione levels were significantly depleted after treatment with 100 µM 6OHDA compared to untreated control cells. These results corroborate with previous studies that
showed similar effects of relevant PD toxins on total glutathione levels in PC12 cells, other
similar cell lines, and primary neuronal cultures (Seyfried, Soldner et al. 2000, Shimizu,
Hashimoto et al. 2002, Takata, Yamaguchi et al. 2005, Zhang, Hu et al. 2005). For 6 hour
experiment, it can be concluded that before 6-OHDA exposed PC12 cells undergo cell death,
they are depleted of total glutathione either by corresponding increase in oxidized glutathione
(Seyfried, Soldner et al. 2000) or by efflux of glutathione out of the cells (Di Monte, Sandy et al.
1987). For 24 hour experiment, it can be inferred that lower doses of 6-OHDA (25 µM and 50
µM) may induce apoptosis in most of the cells and induce cell death in small percentage of cells
after 24 hours. After depletion of pre-existing glutathione, the remaining surviving cells may
increase glutathione levels as a protective mechanism before undergoing cell death at a later
time. Contrary to this, at higher doses of 6-OHDA (75 µM and 100 µM), most PC12 cells are
dead (as shown in MTT assay data) and very few surviving cells may decrease or lose their
ability to increase glutathione levels.

We utilized 25 µM 6-OHDA to evaluate effect of D-512 on free glutathione and total
glutathione levels in PC12 cells treated with 6-OHDA for 6 hours and 24 hours. Our experiments
suggested that there was no significant increase in oxidized glutathione at either time-point. This
suggests that glutathione levels in PC12 cells may decrease by efflux mechanism under apoptotic
condition rather than its oxidation under 6-OHDA treatment. We observed similar trend in the
levels of total glutathione and free glutathione at both time-points. In case of 6 hour experiment,
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we observed a dose-dependent restoration in free and total glutathione levels by D-512 in 6OHDA treated PC12 cells, which can be correlated to higher number of cells in healthy condition
and possibly less efflux of glutathione out of these cells. Surprisingly, in case of 24 hour
exposure to 6-OHDA, we didn’t see restoration effects of D-512 on free and total glutathione
levels in PC12 cells. Instead, we found the glutathione levels to be very similar to that observed
with 6-OHDA alone treated cells. This may possibly be due to inability of D-512 to protect
against 6-OHDA induced glutathione changes at a higher time point. An alternative explanation
can be a mild oxidative stress induced by D-512, which may result in increase in glutathione
content as has been observed with L-DOPA (Han, Mytilineou et al. 1996). Exposure to mild
oxidative stress may prevent PC12 cells from stronger oxidative burden induced by ROS formed
after 6-OHDA exposure.

As the mechanism by which 6-OHDA alters glutathione levels in PC12 cells is not fully
elucidated, we wanted to further verify the ability of D-512 to restore total glutathione levels in
PC12 cells using a toxicant with known mechanism of action on glutathione system. We
employed buthionine sulfoximine (BSO) which inhibits enzyme γ-glutamylcysteine synthetase,
which is involved in first step of glutathione synthesis. In case of BSO dose optimization
experiments, we observed a dose-dependent depletion of total glutathione levels in both 6 hour
and 24 hour time points. Our experiments involving D-512 and BSO led us to conclude that D512 has an ability to restore BSO-induced changes in total glutathione levels in a dose-dependent
manner at both the time points. Thus, we were able to verify that D-512 has a potential to restore
glutathione levels in PC12 cells treated with 6-OHDA or BSO. Therefore, D-512 must possess
broad mechanism of action by which it is able to protect against glutathione alteration induced
by toxins acting by different mechanisms of action.
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We intended to verify the ability of D-512 to protect against lipid peroxidation induced
by 6-OHDA in PC12 cells. However, we didn’t observe significant changes in lipid peroxidation
at different time points with different doses of 6-OHDA (data not shown). However, it is
important to assess the ability of D-512 to prevent lipid peroxidation as PD patient’s substantia
nigra show significant increase in lipid peroxidation. We were able to induce significant increase
in lipid peroxidation with 200 µM sodium nitroprusside (SNP). SNP is an ideal toxicant to
induce lipid peroxidation as it possesses iron as well as nitric oxide in its chemical structure,
which can generate lipid peroxides and simulate PD pathological condition. We found D-512 to
be dose-dependently effective in preventing lipid peroxidation induced by SNP. Thus, D-512
also possesses an ability to prevent damage to lipids induced by oxidative insult and excessive
iron accumulation. We observed similar results of toxins as well as D-512 in our previous study
using MN9D cell line (Santra, Xu et al. 2013).

Apoptotic cell death can cause nuclear condensation and DNA fragmentation. We
evaluated D-512’s ability to protect against apoptosis induced by 6-OHDA by Hoescht staining.
We found D-512 to be partially protective against 6-OHDA induced nuclear condensation.
However, nuclear condensation is a qualitative technique and we wanted to evaluate effect of D512 in dose-dependent manner using semi-quantitative technique. Therefore, we assessed D512’s ability to protect against DNA fragmentation, which is also the hallmark of apoptotic cell
death. We observed DNA laddering in case of 6-OHDA treatment, whereas, D-512 dosedependently prevented fragmentation of DNA induced by 6-OHDA. Thus, D-512 has an ability
to protect against apoptotic cell death and DNA as well as nuclear damage induced by 6-OHDA
in PC12 cells. Similar effect of D-512 to prevent apoptotic change has been reported by us
previously (Santra, Xu et al. 2013).
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We also wanted to understand the possible molecular mechanisms by which D-512 may
be able to protect PC12 cells against oxidative stress caused by 6-OHDA. Therefore, we
evaluated the ability of D-512 to alter 6-OHDA-induced changes in mitogen activated protein
kinases (MAPKs). As anticipated, we observed a time-dependent, sustained increase in
expression of phospho-ERK1/2 and phospho-JNK signaling molecules in presence of 6-OHDA
(Kim, Kim et al. 2011, Zhang, Xue et al. 2012). In case of D-512 alone, we observed a transient
increase in phospho-ERK1/2 at 30 minutes, whereas, at 2 hours and 4 hours time point we didn’t
observe significant differences compared to control PC12 cells. Interestingly, we observed a
significant down regulation of phospho-ERK at all the time-points compared to 6-OHDA treated
alone when D-512 pre-treated PC12 cells were exposed to 6-OHDA. Transient versus sustained
phosphorylation of ERK1/2 has been shown to be a determining step for cell signaling decisions
(Marshall 1995, Xia, Dickens et al. 1995). Abnormal activation pattern of ERK1/2 has been
shown to be responsible for 6-OHDA induced toxicity in various dopaminergic cell lines
(Kulich, Horbinski et al. 2007, Lin, Cavanaugh et al. 2008, Kim, Kim et al. 2011). Sustained
activation of ERK1/2 can cause the phospho-ERK1/2 to translocate into nucleus to modify other
transcription factors and may be responsible for cell death in case of 6-OHDA exposure
(Marshall 1995), whereas, in case of D-512 treatment, transient activation may not be sufficient
for phospho-ERK1/2 to translocate to nucleus and cause transcriptional changes. JNK is a stressactivated protein kinase (SAPK), which has been shown to be activated in response to stress
(serum withdrawal, growth factor withdrawal, hypoxia, 6-OHDA, H2O2) in various
dopaminergic cell lines(Xia, Dickens et al. 1995, Kang, Jang et al. 1998, Hou, Huang et al. 2003,
Fujita, Izawa et al. 2006, Zhang, Xue et al. 2012). 6-OHDA induces the generation of H2O2,
hydroxyl radical, and other ROS which may induce stress signals and activation of JNK. 6-
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OHDA has also been shown to cause mitochondrial activation of ERK1/2 (Kulich, Horbinski et
al. 2007) and inhibition of complex-I and complex-IV in isolated mitochondria (Glinka and
Youdim 1995), which may cause generation of more free radicals and result in increased stress to
the cells. D-512 also exhibited an ability to prevent phospho-JNK increase induced by 6-OHDA,
which further proves its ability to prevent development of stress signaling related pathways
following 6-OHDA exposure. 6-OHDA induced toxicity has been shown to be significantly
associated with the generation of H2O2 by auto-oxidation of 6-OHDA in PC12 cells (Kostrzewa
and Jacobowitz 1974, Saito, Nishio et al. 2007). Interestingly, Fujita et al. also observed very
similar results using hydrogen peroxide as a toxin in PC12 cells with Pramipexole (Fujita, Izawa
et al. 2006). Various studies have shown similar results using potent anti-oxidants (Kang, Jang et
al. 1998, Hou, Huang et al. 2003, Saito, Nishio et al. 2007). Previously, we also observed similar
effect of D-512 on signaling pathways using cell line devoid of dopamine receptors (Santra et al.,
2013).

Although not fully elucidated, significant features observed in PD pathology were able to
be recapitulated using 6-OHDA as a toxin for PC12 cells. From our current experimental data we
conclude that D-512 prevents the cell death induced by 6-OHDA in our two different
experimental paradigms as assessed by MTT assay. Detailed investigation into experiments
relevant to oxidative stress proves that D-512 is able to restore glutathione levels altered by
toxins acting by different mechanisms, prevents DNA fragmentation, inhibits significant changes
in nuclear morphology, and decreases lipid peroxidation to some extent. Further investigation
into molecular mechanism showed that D-512 prevents temporal changes in pERK1/2 and pJNK
induced by 6-OHDA, which might be some of the molecular mechanisms by which D-512 is
able to protect against ROS induced damage by 6-OHDA. As D-512 showed significant ability
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to restore cellular viability, various biochemical functions, and signaling pathways, it warrants
further study as a potential Parkinson’s disease therapeutic with multifunctional activity.
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CHAPTER 5
RESULTS
5.1

Dopamine induces SDS-resistant, ThT-negative, and morphologically distinct oligomers
of α-synuclein
Dopamine auto-oxidation has been shown to be involved in the formation of SDS-

resistant, soluble α-synuclein oligomers, which may be one of the culprits responsible for
dopaminergic neuronal death in PD. We developed a cell-free system to generate co-valently
modified aggregates of α-synuclein by dopamine. Our shaking experiments, which included αsynuclein (17.5 µM) and dopamine (200 µM) yielded α-synuclein aggregates that were resistant
to SDS, as determined by SDS-PAGE separation of various time-point samples from 0 day to 10
days. As shown in figure 5-1, dopamine induced formation of α-synuclein oligomers in timedependent manner and higher time-points resulted in SDS-resistant, high molecular weight
oligomers.

Figure 5-1. Silver staining of dopamine induced changes in α-synuclein
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We also determined the protein structure of aggregates formed at various time-points of
experiment. Thioflavin-T (ThT) is a dye which selectively binds to protein structures that have βsheet confirmation. α-synuclein aggregates known as fibrils (strongly ThT positive, β-sheet
structures) have been shown to be present in the brain of post-mortem PD patients. Our
experimental samples showed very less increase in ThT fluorescence. As shown in figure 5-2,
we observed ~4-fold increase in ThT signal in our experiment involving dopamine and αsynuclein.

Figure 5-2. ThT assay for α-synuclein and dopamine experiment
We also analyzed physical characteristics of the oligomers formed by shaking αsynuclein and dopamine for 4 days. We developed a transmission electron microscopy protocol
to determine morphology of aggregates formed after various experiments. As shown in figure 53, we observed heterogenous protofibrillar structures in case of α-synuclein and dopamine
experiment, whereas, we found α-synuclein monomer sample to be of homogenous spherical
structures.
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Figure 5-3. TEM images of α-synuclein and α-synuclein with dopamine experiments

5.2

α-synuclein at higher concentration (50µM) generates SDS-resistant, ThT positive, and
morphologically “fiber shaped” fibrils of the protein
α-synuclein locus duplication and triplication have been shown to be related to genetic

forms of PD. Therefore, α-synuclein concentration may play an important role in its aggregation
process. We have developed a cell-free system to assess the characteristics of α-synuclein
aggregates by shaking α-synuclein at higher concentration (50 µM). Our shaking experiments
yielded α-synuclein aggregates, which were resistant to SDS as determined by fractionation
using SDS-PAGE. We observed a time-dependent decrease in α-synuclein monomer and
corresponding increase in higher molecular weight aggregates of α-synuclein (figure 5-4).
Surprisingly, after 10 days of shaking we observed disappearance of higher molecular weight
structure and significant decrease in monomer (figure 5-4). This may be due to formation of
insoluble fibrils of α-synuclein, which do not enter the polyacrylamide gel.
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Figure 5-4. Silver staining of α-synuclein shaken at higher concentration

We analyzed samples collected at various time-points for determination of β-sheet
positive fibrillar structure of α-synuclein using ThT assay. ThT assay showed a significant
increase in fluorescence in time-dependent manner. As shown in figure 5-5, at day 10, we
observed ~110-fold increase in ThT signal compared to day 0.

Figure 5-5. ThT assay of α-synuclein (50µM) experiment

We also analyzed morphology of aggregates formed by α-synuclein after 10 days of
shaking. We utilized transmission electron microscopy to observe the physical structure of

100

aggregates formed after shaking α-synuclein at higher concentration (50 µM). As shown in
figure 5-6 (C), we found the aggregates of fibrillar morphology and significantly different than
aggregates formed by dopamine and α-synuclein experiment (figure 5-6 (B)).

Figure 5-6. TEM images of various α-synuclein experiments
(A) α-synuclein monomer; (B) α-synuclein (17.5 µM and dopamine 200 µM 10 days
sample); (C). α-synuclein (50 µM) 10 day sample.

5.3

Iron(III) induces SDS-sensitive and ThT positive fibrils of α-synuclein
Iron(III) concentration has been shown to be significantly increased in the substantia

nigra of patients with PD. Iron is also present in the Lewy bodies found in PD brain. We
developed a cell-free system to determine ability of iron to modify α-synuclein and induce its
aggregation. We performed shaking experiment with equimolar concentrations (17.5 µM) of αsynuclein and iron(III) for 6 days. We observed formation of SDS-sensitive α-synuclein
aggregates as determined by fractionation of samples using SDS-PAGE (figure 5-7). Iron(III)
has been shown to generate non-covalent aggregates of α-synuclein, which are sensitive to
detergent and fall apart into smaller forms of aggregates or monomers. We also determined the
structure of aggregates formed by ThT assay. We observed an increase in ThT fluorescence in
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time-dependent manner (figure 5-8). 6 days of shaking resulted in ~20 fold increase in ThT
signal compared to 0 day sample.

Figure 5-7. Silver staining of α-synuclein and iron experiment

Figure 5-8. ThT assay of α-synuclein and iron experiment
5.4

D-520 has an ability to modify α-synuclein aggregation in presence of dopamine relative
to ascorbic acid, rifampicin, and D-436
Various studies have shown that polyphenolic compounds have an ability to prevent/

modify aggregation of α-synuclein. Some studies have implicated oxidation of dopamine leads to
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generation of dopamine quinones and neuromalanin, which have strong tendency to co-valently
modify α-synuclein and bind to iron(III) respectively. Rifampicin was shown to decrease the
incidence of Lewy body related diseases in an epidemiological study.

Figure 5-9 (a)

Figure 5-9 (b)

Figure 5-9 (c)
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Figure 5-9 (d)

Figure 5-9 (e)

Figure 5-9. Silver staining images of effect of various compounds on dopamine induced αsynuclein aggregation
5-9 (a) α-synuclein (17.5 µM) and dopamine (200 µM); 5-9 (b) α-synuclein(17.5 µM),
dopamine (200 µM) and ascorbic acid (400 µM); 5-9 (c) α-synuclein (17.5 µM), dopamine
(200 µM) and rifampicin (400 µM); 5-9 (d) α-synuclein (17.5 µM), dopamine (200 µM), and
D-436 (400 µM); 5-9 (e) α-synuclein (17.5 µM), dopamine (200 µM), and D-520 (400µM).

Therefore, we developed a cell-free system including α-synuclein and dopamine with the
compounds of interest to compare our lead compounds’ ability to prevent/modify the aggregation
of α-synuclein. We used rifampicin as a polyphenolic drug and ascorbic acid as an anti-oxidant
of dopamine to evaluate the potential mechanism(s) of action of our lead compounds. We
conducted five different shaking experiments using cell-free system. Our experiments included,
i.

α-synuclein (17.5 µM) and dopamine (200 µM)

ii.

α-synuclein (17.5 µM), dopamine (200 µM), and ascorbic acid (400 µM) [anti-oxidant]

iii.

α-synuclein (17.5 µM), dopamine (200 µM), and rifampicin (400 µM) [polyphenolic
standard drug]

iv.

α-synuclein (17.5 µM), dopamine (200 µM), and D-436 (400 µM) [lead compound]

104

v.

α-synuclein (17.5 µM), dopamine (200 µM), and D-520 (400 µM) [lead compound]
We evaluated samples from different time points and different experiments using silver-

staining, TEM, and size-exclusion chromatography (SEC). As shown in figure 5-9 (a), we
observed time-dependent increase in formation of dopamine-induced co-valently modified
oligomers of α-synuclein. Surprisingly, we found ascorbic acid to be preventing the generation of
higher molecular weight oligomers of α-synuclein and dopamine (figure 5-9 (b)). We found
rifampicin to be partially effective in preventing generation of high molecular weight oligomers
induced by co-valent modification of α-synuclein by dopamine (figure 5-9 (c)). However, when
compared to ascorbic acid, rifampicin wasn’t very effective in preventing α-synuclein
aggregation, as it generated dimers, trimers and corresponding high molecular weight structures
of α-synuclein while decreasing the amount of monomer in time-dependent manner.
Interestingly, we found D-436 to be very distinct in modifying α-synuclein aggregation. D-436
caused a decrease in α-synuclein monomer in time-dependent manner (figure 5-9 (d)). However,
we didn’t observe any higher molecular weight structures formed by D-436. This may be due to
the generation of insoluble protein aggregates, which weren’t able to be fractionated by gel
electrophoresis. Surprisingly, D-520 showed an ability to prevent dopamine induced α-synuclein
aggregation partially (figure 5-9 (e)). We observed generation of well-structured aggregates in
presence of D-520. This suggests that, D-520 may be able to stabilize α-synuclein aggregates
such that it may prevent seeding phenomenon, by which dimers, trimers and corresponding
structures combine to form higher molecular weight fibrillar or oligomeric structures.
We further evaluated the experimental samples by transmission electron microscopy to
determine physical difference between samples from various experiments. We used samples
from 4th day of experiment to evaluate physical characteristics of aggregates. As shown in figure
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5-10 (A), α-synuclein monomers appeared as a small spherical homogeneous structures,
whereas, dopamine incubated α-synuclein appeared as a protofibrillar heterogeneous structure
(figure 5-10 (B)). Experiment involving ascorbic acid prevented generation of protofibrillar
structure (figure 5-10 (C)), but it generated homogenous spherical structures, which were of
increased radius compared to monomers (figure 5-10 (A) vs. figure 5-10 (C)). Rifampicin also
prevented the generation of protofibrillar structure (figure 5-10 (D)), but it formed somewhat
distinct shaped aggregates of α-synuclein, which were morphologically different compared to αsynuclein monomer. Our results of TEM corroborated with silver-staining results for D-436, as
we found D-436 to be forming α-synuclein aggregates of significantly higher dimensions in
presence of dopamine (figure 5-10 (E)). Interestingly, D-520 prevented the generation of
protofibrils and gave rise to heterogenous aggregates of α-synuclein ranging from apparent
monomers to aggregates of higher dimensions but smaller than protofibrils (figure 5-10 (F)).
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Figure 5-10. TEM images of various experiments conducted to evaluate effect of various
compounds on dopamine induced aggregation of α-synuclein
5-10 (a) α-synuclein day 0; 5-10 (b) α-synuclein, dopamine and ascorbic acid day 4; 5-10 (c)
α-synuclein, dopamine, and ascorbic acid day 4; 5-10 (d) α-synuclein, dopamine, and
rifampicin day 4; 5-10 (e) α-synuclein, dopamine, and D-436 day 4; 5-10 (f) α-synuclein,
dopamine, and D-520 day 4.
In our lab, we also have developed a size-exclusion chromatography (SEC) method to
determine the hydrodynamic radius of aggregates formed at various time-points of our
experiments. SEC is also alternatively called gel filtration chromatography when used to separate
macromolecules of different size. SEC separates macromolecules on the basis of the volume that
they see while passing through the analytical column. As small molecules can pass through
small pores as well as larger pores of the gel filtration column, they elute at a later time when
compared to molecules of relatively bigger size.
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Figure 5-11. SEC profile of biorad globular protein standards

Figure 5-12. SEC profile of industrial grade α-synuclein monomer
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As shown in figure 5-11, we initially ran bio-rad globular protein standard to determine
the elution pattern of protein mixture of known molecular weight. Afterwards, we ran fresh αsynuclein sample, which eluted at ~8 minutes (figure 5-12). Accordingly, we could determine
that the apparent molecular weight of α-synuclein is around ~44kda, which has been reported
previously. Afterwards, we ran samples from various experiments and various time-points to
determine the fraction of monomer left and the fraction of higher molecular weight (oligomer or
probably fibril) aggregates formed. As shown in figure 5-13, we observed almost complete
conversion of monomer into oligomeric form after 10 days of shaking in case of α-synuclein and
dopamine experiment, whereas, in case of experiment involving ascorbic acid and dopamine
(figure 5-14), we found that large amount of monomer was spared even after 10 days of
experiment. However, in the experiment involving rifampicin and dopamine (figure 5-15), we
found that the monomer was completely depleted after 10 days of shaking and corresponding
increase in oligomeric species was apparent. In case of D-436 and dopamine experiment, we
observed a significant decrease in monomeric fraction and corresponding increase in oligomeric
fraction (figure 5-16), whereas, in case of D-520 and dopamine experiment, we observed that
significant fraction of monomer was spared even after shaking for 10 days (figure 5-17). Figure
5-18 represents analysis of all experimental samples from different time-points. As shown in
figure 5-18, in experiments involving dopamine and dopamine and rifampicin, monomer was
significantly depleted (~88% and ~86%) after 2 days of shaking. However, experiment involving
ascorbic acid and dopamine showed significant fraction of monomer form (~24%) even after 10
days of experiment. Interestingly, in experiment involving D-520 and dopamine we observed
that after 10 days of shaking significant amount of protein was still retained in its monomeric
form (~40%), whereas, in case of D-436 and dopamine experiment fraction of monomer retained
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wasn’t significantly different after 10 days of shaking (~8%). Thus, from our experiments using
size-exclusion chromatography, we concluded that D-520 has a potential to retain α-synuclein in
its monomeric form even after long period of incubation with dopamine, which is very similar to
results obtained with ascorbic acid and dopamine experiment. Therefore, D-520 might be
potentially preventing the oxidation of dopamine, which can generate quinones to cause covalent modification of α-synuclein resulting in its oligomeric forms.

Figure 5-13. SEC profile of α-synuclein after 10 days shaking with dopamine
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Figure 5-14. SEC profile of α-synuclein after 10 days shaking with dopamine and ascorbic
acid

Figure 5-15.SEC profile of α-synuclein after 10 days shaking with dopamine and rifampicin
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Figure 5-16. SEC profile of α-synuclein after 10 days shaking with dopamine and D-436

Figure 5-17. SEC profile of α-synuclein after 10 days shaking with dopamine and D-520
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Figure 5-18. SEC profiles of various experiments
5.5

Extracellular fibrils of α-synuclein (60 µM) are more toxic to PC12 cells compared to
extracellular oligomers of α-synuclein (60 µM) and dopamine (90 µM)
We wanted to determine the cellular toxicity profile of α-synuclein aggregates by

incubating them extracellularly with PC12 cells. We generated aggregates of α-synuclein by two
different methods,
i.

Shaking α-synuclein (60 µM) for 10 days and collecting an aliquot at 2 days interval,

ii.

Shaking α-synuclein (60 µM) and dopamine (90 µM) for 10 days and collecting an
aliquot every 2 days.

Afterwards, we carried out cellular viability assay (MTT assay) by incubating aliquots obtained
from various time-points at a final concentration of 10 µM α-synuclein with PC12 cells. As
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shown in figure 5-19, we observed that in both cases, extracellular α-synuclein incubation
resulted in cell-death of PC12 cells. In case of α-synuclein alone (60 µM), we observed
statistically significant decrease in cell viability from day 2 to day 10 samples (P < 0.0001). It
was interesting to see that α-synuclein (60 µM) samples shaken for 8 days and 10 days were less
toxic to PC12 cells when compared to sample shaken for 6 days. We also observed statistically
significant decrease in cell viability in the experiment involving α-synuclein (60 µM) and
dopamine (90 µM) from samples shaken for 2 days to 10 days (figure 5-19). We observed
maximum cell death in PC12 cells incubated with α-synuclein (60 µM) shaken for 6 days
(~35%).

Figure 5-19. MTT assay to evaluate effect of extracellular α-synuclein on PC12 cell viability
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We also assessed the presence of β-sheet structure in our experimental samples by ThT
assay. As shown in figure 5-20, we observed significant increase in ThT signal in case of αsynuclein (60 µM), whereas, dopamine (90 µM) and α-synuclein (60 µM) experiment samples
didn’t show ThT signal. Interestingly, we observed ~350-fold in ThT signal in sample of αsynuclein (60 µM) after 4 days shaking. Surprisingly, the signal diminished at higher timepoints.

Figure 5-20. ThT assay results of α-synuclein (60 µM) and α-synuclein (60 µM) and
dopamine (90 µM) experiments

We also evaluated the physical appearance of aggregates formed after the experiment.
We utilized samples shaken for 6 days for TEM imaging. As shown in figure 5-21, we observed
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that α-synuclein (60 µM) shaken for 6 days formed aggregates with compact and branched
morphology [ThT-positive] (figure 5-21 (B)), whereas, dopamine (90 µM) and α-synuclein (60
µM) shaken for 6 days formed elongated protofibrillar structures [ThT-negative] (figure 5-21
(C)). Figure 5-21 (A) depicts α-synuclein in its monomer form.

Figure 5-21. TEM images of various α-synuclein experiments
5-21 (A) α-synuclein (60 µM) monomer day 0; 5-21 (B) α-synuclein (60 µM) and dopamine
(90 µM) day 6; 5-21 (C) α-synuclein (60µM) alone day 6.

5.6

D-240 and D-520 possess an ability to protect against cell-death induced by extracellular
α-synuclein in PC12 cells, whereas, D-436 doesn’t protect against the toxicity of
extracellular α-synuclein
As per our experiments in 5.5, we determined to assess the ability of our lead compounds

to protect against extracellular α-synuclein toxicity by shaking them with 60 µM α-synuclein for
6 days. We carried out 5 different experiments,
i.

α-synuclein (60 µM) alone shaken for 6 days (positive control experiment);

ii.

α-synuclein (60 µM) and rifampicin (120 µM) shaken for 6 days (standard drug);
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iii.

α-synuclein (60 µM) and D-240 (120 µM) shaken for 6 days (lead compound);

iv.

α-synuclein (60 µM) and D-436 (120 µM) shaken for 6 days (lead compound);

v.

α-synuclein (60 µM) and D-520 (120 µM) shaken for 6 days (lead compound).
Samples obtained from these experiments were used to assess the cellular viability by

MTT assay. Samples were incubated at a final concentration of 10 µM with PC12 cells for 24
hours. As shown in figure 5-22, α-synuclein (60 µM) after 6 days of shaking caused ~45%
decrease in cell viability, whereas, α-synuclein (60 µM) at 0 days didn’t alter cellular viability.
Surprisingly, rifampicin wasn’t able to rescue PC12 cells from α-synuclein (60 µM) induced
cell-death in case of 6 days experiment. Interestingly, D-240 and D-520 completely prevented
cell-death induced by α-synuclein (60 µM) after shaking for 6 days (P < 0.0001). We didn’t
observe any protection in case of D-436. It was interesting to observe that D-520 caused ~35%
decrease in cell viability when incubated with α-synuclein at 0 day time-point.
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Figure 5-22. MTT assay to evaluate the effect of various compounds on cell death induced
by extracellular α-synuclein

We also determined the structure of aggregates formed in various experiments by ThT
assay. As shown in figure 5-23, we observed a significant increase in ThT signal in case of αsynuclein shaken for 6 days. D-240 and D-520 incubation prevented the formation of ThT
positive β-sheet structure of α-synuclein aggregates. Surprisingly, D-436 seemed to enhance
generation of β-sheet structure of α-synuclein, as incubation of α-synuclein with D-436 showed
stronger ThT signal than α-synuclein (60 µM) alone (statistically non-significant) (figure 5-23).
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Figure 5-23. ThT assay of various experiments
We also evaluated the physical characteristics of α-synuclein aggregates formed in
various experiments that we carried out. As shown in figure 5-24 (B), α-synuclein (60 µM)
which was shaken for 6 days generated compact and branched fibrillar structures. Rifampicin
prevented the formation of fibrillar structure partially but it formed distinct branched aggregates
of α-synuclein (figure 5-24 (C)). D-240 and D-520 almost completely prevented the protofibril
formation induced by α-synuclein and formed heterogenous population of aggregates (figure 524 (D), 5-25 (F)). As expected, D-436 showed formation of aggregates with strikingly different
morphology, which consisted of huge amount of monomers and higher molecular weight
structures combined together (figure 5-24(E)). This may explain a strong ThT signal generated
by samples from D-436 experiment.
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Figure 5-24. TEM images of various experiments

DISCUSSION
Lewy bodies and Lewy neurites have been found to be accumulated in post-mortem
brains of PD patients. Various findings have established that α-synuclein aggregates constitute
significant filamentous portion of Lewy bodies and Lewy neurites. In addition, various genetic
mutations (point mutations and duplication or triplication of SNCA gene loci) have been also
shown to be responsible for genetic form of PD (usually juvenile PD). This has resulted in
significant amount of research to investigate the role of α-synuclein aggregation in the pathology
of PD. Various studies have shown that α-synuclein aggregates in a concentration dependent
manner and the aggregation process has been shown to be significantly enhanced in the presence
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of dopamine or iron, which have been also strongly implicated in the pathology of PD. αsynuclein aggregation has been shown to proceed in two steps. Initially, several α-synuclein
molecules form smaller aggregates (“protofibrils”) either in presence of dopamine or above a
critical concentration or due to presence of mutations that lower the critical concentration to
produce aggregates. Afterwards, these “protofibrils” act as seeds to generate higher molecular
weight aggregates known as “fibrils” (Goldberg and Lansbury 2000). These fibrillar structures
may coalesce together to generate Lewy bodies in PD. It is not unanimously concluded that
which α-synuclein species may play an important role in selective toxicity of dopaminergic
neurons but protofibrils have been shown to be more toxic compared to fibrillar structure of αsynuclein.
Some studies have shown that dopamine, under oxidizing conditions, prevents the
conversion of α-synuclein protofibrils to fibrils by generating co-valent adduct with α-synuclein
(Conway, Rochet et al. 2001, Cappai, Leck et al. 2005, Li, Lin et al. 2005, Illes-Toth, Dalton et
al. 2013). Amino acid residues 125-129 are shown to be essential for dopamine-induced
inhibition of fibril formation of α-synuclein (Norris, Giasson et al. 2005). Selective accumulation
of α-synuclein protofibrils in dopaminergic neurons might be responsible for selective
vulnerability of dopaminergic neurons in PD. A30P mutation of α-synuclein gene has been also
shown to prevent the conversion of protofibrils to fibrils and it may be responsible for
development of PD. α-synuclein induces apoptosis in dopaminergic neurons (but not in nondopaminergic cell line) without generation of detectable inclusion bodies, which further
corroborates the hypothesis that protofibrils may be the responsible species for dopaminergic
neuronal death (Xu, Kao et al. 2002). Addition of anti-oxidants in cell culture system or
prevention of dopamine synthesis prevents α-synuclein induced apoptosis of dopaminergic
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neurons, which implies that dopamine oxidation is necessary to generate toxic α-synuclein
protofibrils (Xu, Kao et al. 2002). Thus, dopamine may be directly involved in α-synuclein
induced apoptosis. Protofibrils have been shown to have ability to form pores in biological
membranes and cause leakage of small molecular weight biomolecules such as calcium and
dopamine, whereas, large molecular weight molecules such as cytochrome C are spared(Volles,
Lee et al. 2001, Volles and Lansbury 2002). In addition, as discussed in introduction, fetal
dopaminergic neurons grafted in PD patients also develop Lewy bodies, which further
corroborates prion-like phenomenon of α-synuclein. Some studies have shown that the structure
of protofibrils resemble some evolved pore-forming cytotoxins (Volles, Lee et al. 2001).
Therefore, not only intracellular protofibrillar forms of α-synuclein, but also the extracellular
species of protofibrillar α-synuclein may be involved in dopaminergic neuronal toxicity. Some
studies have shown that aggregation of α-synuclein into fibrils might be protective in nature
based on the observation that substantia nigra dopaminergic neurons containing Lewy bodies
appear healthier than their neighboring neurons. The protective role of fibrils can be further
supported by the fact that in many deceased elderly patients, incidental Lewy bodies are detected
without any relevant clinical symptoms of PD (Goldberg and Lansbury 2000).
As protofibrils are believed to be the culprits for α-synuclein induced toxicity, various
factors which can thermodynamically (stabilize) or kinetically (decrease the rate) favor the
generation of protofibrils and prevent (or decrease) the formation of fibrils may result in toxicity.
Dopamine has been shown to prevent the generation of fibrils of α-synuclein and stabilize αsynuclein in its protofibrillar form, whereas, structural analogs of dopamine such as catechol and
p-benzoquinone have been shown to stabilize α-synuclein in its monomer or dimer form and
prevent the generation of fibrils (Li, Lin et al. 2005). Ideal therapeutic agent,

122

i.

Should be able to prevent the formation of protofibrillar as well as fibrillar forms of
α-synuclein;

ii.

Should be able to disaggregate the existing fibrillar forms of α-synuclein into its
monomeric or lower molecular weight form;

iii.

Should have an ability to prevent against the cytotoxicity induced by extracellular
or intracellular form of aggregated α-synuclein species.

A study evaluated polyphenols, benzothiazoles, phenothiazines, polyene antibiotics,
rifamycin antibiotic, steroids, Congo red and its derivatives, and terpenoids to assess their ability
to prevent fibril formation and it was concluded that the most potent inhibitory compounds were
from polyphenolic class of compounds (Masuda, Suzuki et al. 2006). The study also showed that
the inhibitory compounds generated soluble oligomeric form of α-synuclein, which wasn’t toxic
to dopaminergic neuronal cultures when incubated extracellularly with neurons. Another study
showed potent anti-fibrillogenic and fibril-destabilizing effects of various antioxidant
compounds such as polyphenols, curcumin, rifampicin, and tetracycline (Ono and Yamada
2006). Very low concentration of baicalein, an anti-oxidant flavanoid, has been shown to inhibit
the formation of α-synuclein fibrils. It also has an ability to disaggregate preformed α-synuclein
fibrils (Zhu, Rajamani et al. 2004). In addition, baicalein has been also shown to possess ability
to prevent oligomer formation in living cells (Lu, Ardah et al. 2011). Rifampicin has been shown
to prevent generation of fibrils of α-synuclein by stabilizing monomeric and oligomeric form of
α-synuclein. Rifampicin also has an ability to disaggregate preformed α-synuclein fibrils (Li,
Zhu et al. 2004). Rifampicin has been also shown to decrease the expression of higher molecular
weight form of α-synuclein in PC12 cells treated with rotenone (Xu, Wei et al. 2007). In fact,
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epidemiological studies have shown that there is less incidence of Lewy body diseases in
population consuming rifampicin (leprosy patients) (Li, Zhu et al. 2004). Interestingly, most of
the compounds (including dopamine) which prevent the generation of fibrils, require oxidizing
conditions and their corresponding quinone forms exhibit more potent ability to prevent fibril
formation (Conway, Rochet et al. 2001, Li, Zhu et al. 2004, Zhu, Rajamani et al. 2004). Based on
literature evidence, two approaches can be taken to prevent α-synuclein toxicity. Toxicity can be
prevented by inhibiting the oxidation of dopamine (antioxidant compounds), which can prevent
the generation of protofibrillar form of α-synuclein by dopamine quinones. Another approach is
to develop compounds, which have similar functionality like dopamine (ability to generate
quinone and modify α-synuclein co-valently), which can stabilize various α-synuclein species
such that the resulting product is rendered non-toxic to the neurons.
In current experiments, we determined our ability to generate various species of αsynuclein under different conditions relevant to PD. Afterwards we evaluated the ability of some
of our potent anti-oxidant lead compounds to alter the aggregation of α-synuclein in presence of
dopamine. We also evaluated the capability of α-synuclein aggregates generated using higher
concentration of α-synuclein or aggregates generated using dopamine and α-synuclein to alter
cellular viability. In the end, we evaluated the ability of some of our lead compounds to alter the
aggregation of α-synuclein at higher concentration and also their ability to prevent cell death
induced by α-synuclein aggregates.
Our initial attempts in lab were to develop cell-free system assays to generate various
types of α-synuclein aggregates. Our efforts were to develop,
i.

Oligomers (protofibrils) of α-synuclein in presence of dopamine;
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ii.

Fibrillar structures in presence of higher concentration of α-synuclein;

iii.

Fibrillar structures of α-synuclein in presence of iron.

We were successfully able to develop dopamine-induced, SDS-resistant, co-valent
oligomers of α-synuclein. Characteristics of the oligomers were confirmed using silver-staining,
ThT assay, and TEM imaging. It was quite important to generate the oligomeric structures of αsynuclein as they have been hypothesized to be the major factor responsible for cytotoxicity of
dopaminergic neurons. Therefore, this assay would be highly relevant to assess the ability of
potential lead compounds to prevent or alter α-synuclein aggregation process. We observed that
α-synuclein alone shaken at lower concentration (17.5 µM) for longer time periods did not
generate ThT positive and SDS-resistant aggregates (data not shown). However, we observed
that α-synuclein, shaken at higher concentration (50 µM), was able to generate SDS-resistant,
ThT positive fibrillar structures (figure 5-4). Characteristics of these structures were determined
by silver-staining, ThT assay, and TEM imaging. Generation of fibrils using higher
concentrations of α-synuclein was quite interesting experiment as it would simulate genetic form
of PD in which SNCA gene duplication or triplication results in physiological increase in αsynuclein concentration resulting in early onset PD. Thus, this assay would be quite appropriate
to evaluate the ability of some of our lead compounds to prevent or alter α-synuclein aggregation
at higher concentration. Potential candidates from this experiment may poseess ability to prevent
aggregation of α-synuclein in genetic forms of PD. We were also able to generate iron-induced,
SDS-sensitive and ThT positive fibrils of α-synuclein (figure 5-7, 5-8). Characteristics of the
aggregates were evaluated using silver-staining and ThT assay. Iron-induced a rapid formation of
β-sheet positive fibrils and did not require higher concentrations of α-synuclein to induce
fibrilization. This assay was important to understand the ability of excess iron (observed in PD
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substantia nigra) to give rise to α-synuclein aggregates. This assay would also be quite relevant
to evaluate the ability of our iron-chelator lead compounds to alter α-synuclein aggregation
process.
We also evaluated the ability of our lead compounds to prevent α-synuclein protofibrils
generated by dopamine using cell-free system assay. We used ascorbic acid as a standard antioxidant and rifampicin as a model α-synuclein aggregation inhibitor to relatively compare our
lead compounds. We employed silver-staining, TEM imaging, and SEC methods to evaluate the
characteristics of aggregates. Interestingly, we observed that ascorbic acid was able to decrease
the kinetics of oligomer formation by dopamine, whereas, rifampicin did not seem to have
significant impact on oligomer formation by dopamine. Silver staining images clearly revealed
that ascorbic acid has an ability to alter the kinetics of α-synuclein aggregation (figure 5-9(a) vs.
figure 5-9(b)), whereas, rifampicin has an ability to stabilize various polymerized forms of αsynuclein (figure 5-9(a) vs. figure 5-9(c)). TEM images further corroborate that rifampicin
generated aggregates are morphologically different than aggregates generated in presence of
ascorbic acid (figure 5-10(d) vs. figure 5-10(c)). In addition, our evaluation by SEC profiling of
aggregates also proved that the monomer form of α-synuclein is quickly depleted in case of
rifampicin experiment, whereas, significant monomer fraction is retained in case of ascorbic acid
experiment (figure 5-18). Ideal compound should have an ability to prevent or alter the kinetics
of α-synuclein aggregation. It should be able to retain α-synuclein in its native monomeric form
and shouldn’t cause significant morphological changes in α-synuclein. We observed quite similar
results with ascorbic acid, most probably because of its potent anti-oxidant activity, which might
have prevented the formation of dopamine-quinones and corresponding modifications of αsynuclein. Out of the 2 lead compounds tested in this experiment, we observed that D-436 did
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not significantly affect dopamine induced α-synuclein oligomerization. Interestingly, in silverstaining experiments, we observed the disappearance of monomer without corresponding
increase in higher molecular weight aggregates of α-synuclein (figure 5-9(d)). Therefore, it
might be possible that D-436 may generate SDS-resistant insoluble fibrils of α-synuclein, which
do not enter the SDS-PAGE gel. Similar results were seen with TEM, which showed significant
increase in the size of α-synuclein aggregates in case of D-436 (figure 5-10(e)). Furthermore, D436 also exhibited very similar SEC profile, which helped us conclude that D-436 doesn’t
possess ability to prevent dopamine induced α-synuclein aggregation (figure 5-18). In fact, it
may be possible that D-436 might accelerate the formation of α-synuclein oligomers. In case of
D-520, we observed very interesting results in silver-staining experiments. Surprisingly,
incubation of α-synuclein and dopamine with D-520 generated well-structured and SDS-resistant
lower molecular weight aggregates as resolved by SDS-PAGE (figure 5-9(e)). TEM imaging
also corroborated with the interpretation from silver-staining (figure 5-10(f)), where we
observed smaller aggregates with heterogeneous morphology in case of D-520 experiment. In
addition, SEC profile of samples from the same experiments showed that the monomer fractions
retained in various samples were quite comparable to those observed with ascorbic acid
experiment (figure 5-18). Therefore, it can be concluded that D-520 should be able to
significantly alter dopamine induced α-synuclein aggregation and it holds a potential to prevent
cytotoxicity induced by oligomeric α-synuclein.
We aimed to evaluate the extracellular toxicity of α-synuclein aggregates (generated
using cell-free system) in dopaminergic neuronal culture. We generated β-sheet positive fibrils
(60µM α-synuclein alone) and β-sheet negative protofibrils (60 µM α-synuclein and 90 µM
dopamine) of α-synuclein using cell-free system assay. The characteristics of the aggregates
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were evaluated by use of ThT assay and TEM imaging (figures 5-20, 5-21). TEM imaging
revealed that dopamine generated elongated protofibrillar structures, whereas, α-synuclein alone
generated compact and branched fibrillar structures. MTT assay was carried out using PC12
cells, which were incubated with 10 µM final concentration of α-synuclein aggregates from both
the experiments (figure 5-19). Surprisingly, in case of α-synuclein (60 µM) alone, we observed
that from day 0 to day 6, there was a decrease in cellular viability. For day 8 and day 10, we
observed somewhat restoration in cellular viability. This may be potentially due to the
conversion of protofibrillar species (toxic) into fibrillar (relatively less toxic) structure of αsynuclein. In an experiment involving α-synuclein (60 µM) and dopamine (90 µM), we observed
a decrease in cellular viability from day 0 to day 4. However, the cellular toxicity of aggregates
from day 6 to day 10 remained similar. This might imply that the chemical interaction of
dopamine with α-synuclein is completed by day 4 leaving no dopamine molecules to interact
with ASN further. Thus, further incubation doesn’t alter the structural features of the aggregates
significantly when compared to aggregates produced after 4 days. Thus, we achieved the
maximum amount of cytotoxicity from aggregates generated using α-synuclein alone (60 µM)
shaken for 6 days.
Our ultimate goal was to evaluate the ability of some of our lead compounds to prevent
the cytotoxicity induced by α-synuclein (60 µM) alone shaken for 6 days. We tested rifampicin
as a standard compound and D-240, D-436, and D-520 (lead compounds) to evaluate their ability
to alter α-synuclein aggregation in cell-free system. We characterized the aggregates of αsynuclein from various experiments using ThT assay and TEM imaging (figure 5-23, 5-24). We
observed that rifampicin altered the morphology of aggregates significantly, when compared to
aggregates generated by α-synuclein alone. Interestingly, D-240 and D-520, significantly
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reduced the size of aggregates and the morphology of aggregates appeared to be comparable to
small molecular weight polymeric forms of α-synuclein. Surprisingly, D-436 again generated
aggregates with significantly increased size and distinct morphology. ThT assay revealed that
rifampicin, D-240 and D-520 inhibited β-sheet formation, whereas, D-436 significantly enhanced
the formation of β-sheet structure. Thus, D-436 failed to alter the aggregation of α-synuclein
fibrils. MTT assay using the samples generated from these experiments provided insightful
results (figure 5-22). We observed that extracellular incubation of α-synuclein shaken for 6 days
significantly decreased cellular viability. Incubation of protein with rifampicin altered the
characteristics of aggregates but the toxicity was not altered. Incubation of protein with D-240 as
well as D-520 resulted in prevention of cell-death. As expected, incubation of protein with D-436
resulted in further decrease in cellular viability. From MTT assay results, it can be interpreted
that as D-240 and D-520 are able to protect against extracellular toxicity induced by α-synuclein
(60 µM), they hold potential to prevent α-synuclein induced toxicity in genetic form of PD where
increased physiological concentrations of α-synuclein is a major concern. As D-436 accelerated
the fibril formation process and caused a further decrease in cellular viability, it may not be an
ideal candidate of choice to prevent extracellular toxicity of α-synuclein. From the study of
chemical structure of compounds investigated in this experiment, it can be concluded that dihydroxyl aromatic groups are essential for a compound to alter the aggregation of α-synuclein
(rifampicin, D-240, D-520 vs. D-436). Adjacent hydroxyl groups may generate structures that
have ability to prevent cytotoxicity induced by dopamine induced oligomers (D-240 and D-520).
Further investigation into the structural-activity relationship may help generate some potential
therapeutic molecule.
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CHAPTER 6
INTRODUCTION
6

Amphetamine
Amphetamine (AMPH) is derived from α-methyl-phenylethyl-amine structure (figure 6-

1). AMPHs naturally occur in ephedra and khat plants (Sulzer, Sonders et al. 2005). Ephedra
(Ephedra sinica) contains natural AMPHs called ephedrine and pseudoephedrine. Khat (Catha
edulis) contains natural AMPHs called cathine and cathinone (Sulzer, Sonders et al. 2005). The
first synthetic amphetamine was synthesized in 1887 by Lazar Edeleanu. However, its
sympathomimetic activities were not realized until concept of sympathomimetics developed.
AMPH was independently synthesized by Gordon Alles in 1927 in an effort to develop synthetic
sympathomimetics. Figure 6-1 shows the structural similarities of various AMPHs.

Amphetamine

Ephedrine

Pseudoephedrine

Cathine

Cathinone

Figure 6-1. Chemical structures of amphetamines
AMPH was introduced commercially by Smith, Kline and French as Benzedrine, which
was a free base administered in inhaler form to treat nasal congestion (Sulzer 2011, Vearrier,
Greenberg et al. 2012). Myron Prinzmetal is credited for the first clinical use of AMPH in the
treatment of narcolepsy. AMPH was made available by prescription only in 1939. By 1945, the
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drug industry promoted 30 different uses of AMPH including the treatment of schizophrenia,
opiate addiction, infantile cerebral palsy, etc. During World War II, AMPH was highly promoted
by the militaries of Japan, Germany and Britain to increase alertness in soldiers. AMPH’s
addictive potential and neurotoxic effects were not widely accepted until the mid-1960s.
Various synthetic AMPHs have been developed as potential therapeutics including
fenfluramine (appetite suppressant) and deprenyl (anti-Parkinson’s drug). Some of the most
widely abused AMPHs are methamphetamine (METH) and methylene dioxymethamphetamine
(MDMA) (Sulzer, Sonders et al. 2005) (figure 6-2).

Fenfluramine

Deprenyl

Methylene Dioxy
Methamphetamine (MDMA)

Methamphetamine

Figure 6-2. Chemical structures of synthetic amphetamines
6.1

Legal status of amphetamine
Amphetamine is classified by the U.S. Drug Enforcement Agency (DEA) as a schedule II

controlled substance, characterizing it as having limited therapeutic value but high abuse
potential. Several prescription AMPHs are currently available including Ritalin or Ritalin SR
(methylphenidate),

Adderall

(amphetamine

and

dextroamphetamine),

and

Dexedrine
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(dextroamphetamine). All of these prescription drugs are non-refillable. Interestingly, it has been
demonstrated that therapeutic doses used in the treatment of Attention Deficit Hyperactivity
disorder (ADHD) can cause significant neurotoxicity (Ricaurte, Mechan et al. 2005).
6.2

Methamphetamine (METH)
METH is an amphetamine derivative which has a very high abuse potential and has been

proven highly neurotoxic in various rodent, non-human primate, and human studies
(Woolverton, Ricaurte et al. 1989, Thomas, Walker et al. 2004, Berman, O'Neill et al. 2008).
METH acts as a stimulant in the central nervous system (CNS). METH is highly abused, in part,
due to its ease of synthesis - including easy access to its precursors: ephedrine and
pseudoephedrine. METH is usually consumed by smoking, resulting in an initial rush that lasts
for several minutes followed by a prolonged high that includes an extended period of euphoria.
METH’s half-life is 10-30 hrs based on the amount administered, pH of urine, and purity of the
drug (Russell, Dryden et al. 2008). As METH is easily accessible, relatively cheap, and has
reinforcing properties, its chronic use can pose significant dangers. METH is also known as
Chalk, Crank, Crystal, Glass, Go-Fast, Ice, Methlies Quick, Speed, etc. As of 2000, the U.S.
DEA stated that METH is the most prevalent illicitly manufactured controlled substance. The
single largest METH seizure to date was 208 pounds of METH confiscated in Las Vegas in July,
2011 near the U.S.-Mexico border. Therefore, it is very important to maintain vigilance in
preventing METH trafficking from other countries.
6.3

METH statistics
METH is highly abused by the teenage population. Initially METH abuse was limited to

Hawaii and western states of the U.S., but has become more widespread including all rural and
urban areas. In 2000, 6394 clandestine METH labs were seized. Illicit METH production
operations have been uncovered in all 50 states of U.S. Approximately 13 million people aged 12

132

years or older, have abused METH in their lifetimes. In 2010, approximately 353,000 people
were current users (NIDA report, November, 2011). The 2009 World Drug Report suggested that
the global prevalence of METH use is second only to cannabis, with estimates suggesting that up
to 51 million individuals (1.2% of the global population aged 15–64 years) have used METH at
least once in the past 12 months (World Drug Report, 2009).
6.4

Legal status of METH
METH is classified by DEA as Schedule II drug, which means that it has limited

therapeutic use but high abusive potential. METH is available by prescription under the trade
name Desoxyn. Desoxyn is used in the treatment of morbid obesity and ADHD. METH
prescriptions can’t be refilled.
6.5

Risk factors for METH abuse in youth
According to the 2004 national survey on drug use and health, 0.6% of the U.S.

population had used METH in the previous 12 months. In 2002, street youth aged 14-30 years
were surveyed and 71% of respondents reported using amphetamine-type stimulants. Therefore,
identification of risk factors for METH abuse can help to prevent or at least decrease METH
abuse. An excellent review article by Russel et al. examined risk factors of METH abuse in
youth with low risk (youth who did not use illicit drugs) and youth with high risk (youth who had
abused illicit drugs other than METH or were recruited from juvenile detention center) (Russell,
Dryden et al. 2008).
6.5.1 Risk factors in low risk youth
6.5.1.1 Gender
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Two cross-sectional studies examined sex as a risk factor. Both have shown that males are more
likely to use METH than females (Oetting, Deffenbacher et al. 2000, Sattah, Supawitkul et al.
2002).
6.5.1.2 Ethnicity
One cross-sectional study examined ethnicity as a risk factor. The study concluded that
Caucasian youth are more likely to abuse METH than African American or Asian youth.
However, Caucasian youth are significantly less likely to use METH than Hispanic or Native
American youth (Oetting, Deffenbacher et al. 2000).
6.5.1.3 Years of education
Three different studies concluded that METH users had significantly less years of
education than non-METH users (Sattah, Supawitkul et al. 2002, Yen 2004, Yen, Yang et al.
2006).
6.5.1.4 Sexual behavior
Two different studies examined associations between previously engaging in risky sexual
behaviors and METH use (Green and Halkitis 2006). It concluded that people who had engaged
in unprotected sex, engaged in unplanned sex under the influence of alcohol,or engaged in sexual
intercourse with an alcohol-intoxicated-partner were more likely to abuse METH.
6.5.1.5 Alcohol, cigarette and opiate use
Two studies independently found significant association with alcohol use, cigarette
smoking, and heroin/opiate use (Yen, Yang et al. 2006).
6.5.1.6 Psychiatric disorders
The presence of any psychiatric disorder, adjustment disorder, conduct disorder, or
attention deficit hyperactivity disorder (ADHD) significantly increased the risk of METH abuse.
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6.5.1.7 Other factors
Other factors including homosexuality or bisexuality, having experienced disruptive
parenting, having peers who use or provide METH, and having a family history of drug use all
increase the likelihood of METH abuse in low risk youth.
6.5.2 Risk factors in high risk youth
6.5.2.1 Gender
Three studies concluded that female gender was significantly associated with METH
abuse than male gender (Kim and Fendrich 2002, Rawson, Gonzales et al. 2005, Miura, Fujiki et
al. 2006).
6.5.2.2 Ethnicity
Caucasian youth were significantly more likely to use METH than African-American or
Asian youth. However, there was no difference between Caucasian, Hispanic, and Native
American youth.
6.5.2.3 Family history
One cross-sectional study reported that a family history of crime or drug use was
significantly associated with METH use (Miura, Fujiki et al. 2006).
6.5.2.4 Other factors
Youth receiving psychiatric treatment, youth with greater than two admissions to a
juvenile home, and youth with a history of violence were all more prone to METH abuse.
Thus, a history of engaging in various risky behaviors was significantly associated with
METH abuse in low risk youth. Being homosexual or bisexual is another risk factor as METH is
known to enhance sexual pleasure. In high risk youth, females are more prone to METH abuse,
as are youth who have grown up in unstable family environments. Youth who have received
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psychiatric treatment were more likely to abuse METH. However, strict parental monitoring was
found to decrease the risk of METH abuse.
6.6

Consequences of METH abuse
METH is abused primarily by younger individuals. As it is neurotoxic, it is extremely

important to understand the associated mental and physical disorders that develop because of
METH addiction. It is particularly important to understand the neurotoxic effects of METH in
the younger population as the CNS is still undergoing development during exposure (Marshall
and Werb 2010, Vearrier, Greenberg et al. 2012).
6.6.1 Mental and behavioral disorders
Suicidal ideation and eating disorders are more likely in youth abusing METH. Chronic
METH users experience paranoia and hallucinations. Hallucinations have been found to be a
common problem among METH abusers. METH-induced psychosis has also been well
documented. Individuals that undergo treatment for METH abuse are very likely to have major
depressive disorders and it is specifically diagnosed in youth who have abused METH by the age
of 15.
6.6.2 Dermatological disorders
METH abuse predisposes one to repetitive, stereotypical skin picking, resulting in
excoriations on the face and extremities. METH related skin infections may take the form of
cellulitis or cutaneous abscess.
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6.6.3 Hematological disorders
METH use may increase the risk of contracting Human Immunodeficiency Virus (HIV)
because of sharing non-sterile needles for injecting METH. METH users also engage in unsafe
sexual practices and usually report more sex partners than non-users. METH users are more
likely to participate in sexual activities that may increase the risk of HIV transmission, such as
anal sex, unprotected sex, and sex with known injection drug users. METH abuse is also
associated with necrotizing angiitis. Macroscopically, affected arteries can display segmental
narrowing with aneurysm formation.
6.6.4 Gastrointestinal disorders
METH use is known to increase Hepatitis C infection in needle and non-needle users.
Even in the absence of hepatitis, METH use has been known to cause hepatic necrosis and
centrilobular degeneration.
6.6.5 Genitourinary disorders
METH users are more likely to have Sexually Transmitted Diseases (STDs) because they
are more likely to engage in risky sexual behaviors. Prolonged sex while on METH can cause
soft tissue injury which can further increase the risk of STDs.
6.6.6 Musculoskeletal disorders and “METH mouth”
METH induces dental decay through multiple mechanisms. It causes xerostomia by
sympathetic overstimulation. It also causes bruxism, resulting in multiple dental caries. Dental
decay can also occur from an addict’s poor hygiene and malnutrition. METH abusers also report
rhabdomyolysis. Pott’s puffy tumor (osteomyelitis of the frontal bone) has been associated with
intranasal METH use.
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6.6.7 Neurological disorders
Intracranial hemorrhage is a devastating side-effect of METH abuse. It may occur due to
METH-induced hypertension and tachycardia. METH induced necrotizing angiitis may also
cause intracerebral hemorrhage. Intraparenchymal bleeds in various brain regions have been
reported in METH addicts which may be due to prolonged cardiovascular effects of METH.
Fatal intraventricular hemorrhage has been also reported with METH use. METH abuse has been
also known to cause ischemic stroke, seizure, and cognitive impairment. METH abstinence in
chronic users shows persistent improvement in various cognitive tests.
HIV-positive and hepatitis C patients show more cognitive impairment due to METH
abuse. Comorbid patients show additional glial activation and neuronal injury in the frontal
cortex and basal ganglia compared to non-disease METH abusers.
6.6.8 Prenatal METH exposure
METH is increasingly a drug of choice in substance dependent women. Prenatal METH
use has been associated with fetal growth restriction and premature delivery. Animal studies
have shown that prenatal METH exposure may affect the myelination process. Prenatal METH
exposure in humans has been shown to decrease inhibitory control in children. Prenatal METH
exposure may cause structural damage to frontal-subcortical circuits which may be changing
behavior among affected children (LaGasse, Derauf et al. 2012). Heavy METH exposure is
known to be associated with lower arousal and excitability in children. Prenatal exposure also
results in poor quality of movement and increased stress signs when METH is taken in first
trimester, whereas third trimester exposure can be associated with increased lethargy and
hypotonicity (LaGasse, Wouldes et al. 2011). A study carried out to understand the outcome of
prenatal METH exposure has shown that in 3 and 5 year old children, METH exposure is
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associated with increased emotional reactivity and anxiety/depression. Heavy METH exposure
was associated with attention problems and withdrawn behavior. In 5 year old children, there is
decreased externalizing behavior and ADHD problems (LaGasse, Derauf et al. 2012).
6.6.9 Adverse effects of METH on Brain
METH is known to cause significant toxicity in the brain. Acute METH intoxication has
been shown to cause significant hyperthermia, which is potentiated by associated physiological
activation - especially in warm environments which prevent proper heat dissipation (Kiyatkin
and Sharma 2009). METH induces structure-specific leakage in the blood-brain barrier (BBB)
which can cause water, ions, and various potentially neurotoxic substances contained in plasma
to enter the brain (Zlokovic 2008). METH induced BBB leakage is attributed to the hyperthermia
induced by it. METH is also known to cause metabolic activation which results in more
oxidative species being produced than the body can tolerate. Thus, it induces abnormal levels of
oxidative and nitrosative stress in the brain and elsewhere. As METH causes BBB leakage, it can
result in brain edema. METH toxicity is also related to the ambient temperature at which it is
administered. Higher ambient temperatures can enhance METH toxicity, whereas, lower ambient
temperatures can protect from METH-induced toxicity.

Various brain regions show significant overexpression of GFAP in astrocytes after
METH intoxication (Thomas, Dowgiert et al. 2004). METH causes morphological changes in
neuronal structure in hippocampus, thalamus, hypothalamus, and cortex. The METH “high” is
induced by the massive dopamine (DA) released following its administration. As discussed later,
METH significantly affects the nigrostriatal pathway, particularly in the striatum, where the DA
nerve terminals lie. METH administration results in significant DA depletion and decreased
tyrosine hydroxylase (TH) activity in the striatum. METH administration also results in striatal-
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specific activation of microglia cells, which are equivalent to the systemic macrophages of the
immune system. Surprisingly, the vast majority of microglial activation following METH
exposure occurs only in the striatum and not other parts of brain (Thomas, Walker et al. 2004).

6.7

Possible mechanisms of actions responsible for neurotoxicity of METH
METH structurally resembles dopamine. It has been well-established that METH acts on

the nigrostriatal pathway to release massive amount of DA. METH-induced DA release is critical
for inducing its addiction potential. To understand the mechanisms of actions of METH, it is
essential to understand dopaminergic pathways in brain (figure 6-3).

6.7.1 Dopaminergic pathways in brain
There are four dopaminergic pathways in brain,
i. Nigrostriatal pathway
ii. Mesolimbic pathway
iii. Mesocortical pathway
iv. Tuberoinfundibular pathway
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Figure 6-3. Dopaminergic pathways in brain
(Adapted from: http://en.wikipedia.org/wiki/File:Dopamine_pathways.svg)
Dopaminergic neurons originate in the substantia nigra pars compacta (SNPc), ventral
tegmental area (VTA) and hypothalamus. They project their axons to other brain areas and
constitute the dopamine neurotransmitter system.

1. The nigrostriatal pathway is formed by neurons which project from substantia nigra to
neostriatum. The terminals end in caudate nucleus and putamen which form striatum.
Nigrostriatal pathway is involved in movement and motor control. PD is caused by
destruction of neurons in nigrostriatal pathway.
2. The mesolimbic pathway is formed by neurons projecting from the VTA to the nucleus
accumbens, and is mainly involved in the “reward system.” Food, sex, and pleasure of
any kind (including METH administration) involve activation of this pathway, resulting
in reward.
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3. The mesocortical pathway is formed by neurons projecting from the VTA to the
prefrontal cortex, hippocampus and amygdala. This pathway is involved in motivation,
emotion, memory and cognition. Dysfunction of this pathway is sometimes associated
with schizophrenia.
4. The tuberoinfundibular pathway is formed by neurons projecting from the hypothalamus
to the pituitary gland. It is mainly involved in prolactin release and is associated with
maternal behavior, hormonal regulation, and pregnancy.

6.7.2 Components of the Dopaminergic neuronal system

METH-induced toxicity can easily be detected in the striatum of METH addicts.
Understanding the components of the dopaminergic system can help explain the possible
mechanisms of METH action (figure 6-4).

DA is synthesized from tyrosine by tyrosine hydroxylase, which converts tyrosine to 3,4dihydroxy phenylalanine (L-DOPA). L-DOPA is converted to DA through decarboxylation by
dopa decarboxylase. Once synthesized, DA is transported from the cytosol into synaptic vesicles
by VMAT-2. Upon appropriate stimulus, these vesicles fuse to the presynaptic membrane and
release DA. Post-synaptically, DA binds to D1 and D2 receptors. DA also binds to presynaptic
DA receptors which are auto-inhibitory and prevent further DA release. Once DA has elicited the
appropriate response, it dissociates from its receptors and can be recycled back into the presynaptic neuron by the dopamine transporter (DAT). Some of the cytoplasmic DA is then
transported back into synaptic vesicle by VMAT-2.
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Figure 6-4. Components of Dopaminergic neuronal system

Another fraction of cytoplasmic DA is metabolized by MAO and COMT enzymes.
Different metabolites of DA include dihydroxyphenyl acetaldehyde (DOPAL), dihydroxyphenyl
acetic acid (DOPAC), 3-methoxytyramine (3-MT), and homovanillic acid (HVA).

6.7.3 Proposed Mechanisms of action of METH
Several studies have shown that METH is a strong substrate for DAT. Other studies
support that other components of the dopaminergic neuronal system may be responsible for
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METH-induced neurotoxicity (Fleckenstein and Hanson 2003, Yamamoto, Moszczynska et al.
2010).

6.7.3.1 Dopamine transporter blocker and dopamine transporter reverse transport
facilitator
METH has been shown to be a strong substrate for the DAT. METH and similar weak
bases not only block the reuptake of DA by DAT but it also facilitates the reverse transport of
DA (Sulzer, Chen et al. 1995). This results in excessive DA accumulation in the synaptic cleft.
Thus, excessive DA in the synapse continuously binds to post-synaptic DA receptors, resulting
in its euphoric effect. DAT expression has been shown to be persistently depleted in METH
addicts, even after long term abstinence. However, the DAT alone doesn’t cause massive DA
release following METH administration. The VMATs also appear to play an important role in
METH action.

6.7.3.2 Vesicular monoamine transporter-2 blocker
METH is a substrate for VMAT-1 and VMAT-2. METH has 10 times more affinity for
VMAT-2 than VMAT-1 (Peter, Jimenez et al. 1994). VMAT-2 knock-out animals do not
survive. However, VMAT-2 knock-out animal derived cell-culture data has shown that, in the
absence of VMAT-2, the METH-induced release of DA is significantly decreased. METH is also
known to block VMAT-2 once inside the neurons, which results in high cytoplasmic
concentrations of DA. METH has been shown to deplete two different types of dopaminergic
vesicles. At low doses, METH depletes vesicles that are large in size; whereas, at high doses,
METH depletes small size vesicles (Anderson, Chen et al. 1998).
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6.7.3.3 Tyrosine hydroxylase inhibitor
METH at lower concentrations enhances DA synthesis and TH activity. This requires
extracellular calcium. At higher concentrations, METH inhibits TH activity (Sulzer, Sonders et
al. 2005). Inhibition of TH activity results in lower DA levels in the striatum following METH
administration.

6.7.3.4 Monoamine oxidase inhibitor
METH prevents deamination of DA most potently by acting at the DAT to block
reuptake and by facilitating the efflux of DA from the cytoplasm. In addition, METH is also a
direct inhibitor of MAO, which results in more DA available for release into the synaptic space.

6.7.3.5 Dopamine transporter and vesicular monoamine transporter trafficking alteration
METH has been shown to promote DAT redistribution. METH administration results in a
decrease in the expression of cell surface DAT and increased redistribution of DAT on cellular
endosomes (Saunders, Ferrer et al. 2000).Western blot analysis has shown that neurotoxic
METH regimen causes decreases in DAT monomers and a corresponding increase in higher
weight DAT complexes.

METH has been shown to decrease vesicular DA transport by promoting the
redistribution of VMAT-2. METH also accumulates in synaptic vesicles because of its structural
similarity to DA and its ability to collapse the pH gradient across synaptic vesicle membranes.
METH-induced VMAT-2 dysfunction causes high concentration of DA in cytoplasm, which can
cause increases in reactive species generated by DA metabolism.
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Figure 6-5. Adverse consequences of METH administration
6.7.3.6 Significant increase in reactive oxygen species and inflammation
METH treatment results in striatal microglia activation, which in turn can produce ROS.
In addition to microglia, METH treatment can increase ROS in several ways (Riddle,
Fleckenstein, and Hanson 2006). METH treatment can:
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i)

significantly increase cytoplasmic DA which can then undergo auto-oxidation

ii)

cause glutamate release, subsequent mitochondrial dysfunction, and glutamateinduced NO production

iii)

activate D1 dopaminergic receptors, which increases nNOS expression

iv)

induce inhibition of mitochondrial function which increases mitochondriamediated reactive species generation.

Using various approaches, our lab has shown that METH-induced striatal microglial
activation precedes dopaminergic neuronal damage. Microglia forms key immune system of
central nervous system (CNS) and their persistent activation has been widely accepted to
represent CNS pathology.

6.8

Microglia cells
CNS is separated from peripheral parts of body by BBB. BBB prevents the entry of

various potentially pathological substances into CNS. Thus, brain is immunologically privileged
organ. Microglia cells are considered resident macrophages of brain and are known to be most
effective sensors of brain pathology. The exact function of microglia is unknown. However,
massive amount of activated microglia are shown to be present in various brain regions of
patients with neurodegenerative diseases such as Parkinson’s disease (PD), Alzheimer’s disease
(AD), Kreutzfeldt-Jacob disease, multiple sclerosis (MS), etc. As dysfunction of microglia
results in mostly all pathologies of CNS, they must be playing an important role in maintenance
of homeostasis in CNS. Microglia were first introduced as a cellular element of CNS by Pio del
Rio-Hortega in 1932. He used a modified silver carbonate impregnation to label the microglia
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cells. Most of the description that was given by Rio-Hortega about microglia still holds true. He
advocated that,

i) Microglia enter the brain during early development;
ii) These cells have amoeboid morphology and are mesodermal in origin;
iii) They transform into a branched, ramified morphological phenotype in matured brain;
iv) In mature brain, they are found almost evenly dispersed throughout the CNS and display
little variation;
v) After a pathological event, these cells undergo a transformation;
vi) Transformed cells acquire amoeboid morphology similar to that observed early in
development;
vii) These cells have the capacity to migrate, proliferate, and phagocytose.

Figure 6-6. Microglia morphology as depicted by Rio-Hortega
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6.8.1 Microglia cells- Morphology and response to native environment
Elegant in-vivo 2-photon imaging studies show that microglia continuously monitor their
native environment using their cellular processes (Davalos, Grutzendler et al. 2005, Nimmerjahn,
Kirchhoff et al. 2005, Raivich 2005). Previously, when it was not known that microglia actively
survey their surrounding environment, native state of microglia was termed as “resting” state.
However, because of their active search for and reading of signals from neighboring
environment, microglia’s native state is termed “surveying” state. In healthy CNS, “surveying”
microglia have ramified morphology i.e. small soma with fine processes. Because of wide
diversity of receptors for various molecules, microglia can immediately sense signs of change in
homeostasis. Various insults such as infection, trauma, ischemia, neurodegenerative disease,
neurotoxin exposure or altered neuronal activity i.e. disturbance or loss of homeostasis in brain
can induce rapid changes in microglia cell shape, gene expression, and the functional behavior
which can be termed “activated” microglia. Phenotypically, “activated” microglia have ramified
morphology and the complexity of its processes is reduced. Microglia can engulf foreign
molecules (activated state), but they also remove dead or dying cells (surveying state). Activated
microglia release inflammatory molecules upon bacterial invasion, whereas, in response to dead
or dying cells microglia release anti-inflammatory molecules (“surveying” microglia). Hence, it
is very important to understand the role of microglia under “surveying” state versus under
“activated” state and also understand how they transform from one state to another.

Microglia should have some function in healthy brain. They can act to maintain
homeostasis in CNS as they form immune system of CNS. In healthy state, minor damages in
CNS can happen such as ischemic event, minor capillary rupture, or small damage to BBB which
can cause entry of plasma components into brain. Microglia respond to these types of damages
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and react to prevent further damage in CNS because of them. They are also known to remove
dead cells or debris by phagocytosis. However, very few functions of “surveying” microglia
have been reported in literature. Interestingly, there is plethora of literature showing “activated”
microglia in various chronic neurodegenerative diseases.
There is increasing evidence that microglial activation is not an “all-or- none” process,
neither is it a linear path with a fixed uniform outcome (figure 6-7). To the contrary, activated
microglia can acquire distinct functional states. Transformation of microglia to reactive state in
response to pathology is very diverse and dynamic process. Chronic pathology in CNS can lead
to persistently activated state of microglia which can harm their neighbor environment.

Figure 6-7. Activation States of Microglia

As shown in figure 6-7 (Hanisch and Kettenmann 2007), in healthy tissue, microglia are
in a surveying state. In this state, neurons may be continuously emitting signals which keep them
in that state. However, upon minor changes in the state of the CNS, microglia respond by
reorganizing their processes toward the site of insult. Neighboring astrocytes can support
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microglia by releasing appropriate ligands such as purinoceptor ligands. During minor injuries,
microglia release anti-inflammatory and neurotrophic molecules which can protect endangered
neurons from insult. Neurons can cause microglial transformations by preventing or altering the
release of “calming signals” that are present under normal conditions. Small local damages
usually go unnoticed as it is very difficult to distinguish transformed microglia from surveying
microglia after some period following injury. Significant infections, neurotoxic challenges or
significant tissue injury can cause a large insult to the CNS. These drastic changes can alter the
functional phenotype of microglia. These types of chronic or disruptive insults significantly
damage the normal functions of microglia and neurons. Under these circumstances, microglia
adopt an “activated” state which can result in damage to neighboring neurons and induce chronic
pathology.

6.8.2 Microglia cells-Role in various neurodegenerative disorders
Activated microglia have been found in various chronic neurodegenerative disorders such
as Parkinson’s disease (PD), Alzheimer’s disease (AD), Amyotrophic lateral sclerosis (ALS),
multiple sclerosis (MS), Kreutzfeldt-Jacob disease, etc. It is important to note there is no specific
single activated state of microglia. Activated microglia can have diverse profiles of chemokines,
cytokines, or cell-surface receptor expression patterns based on their exposure to native chemical
or cell-based environmental cues. A positive feedback loop has been hypothesized in which
microglia become activated by neuronal degeneration, then secrete neurotoxic molecules which,
in turn, promote further neurodegeneration. Neurodegenerative diseases progress slowly and the
morphology of activated microglia under these conditions is not well defined. A variety of
receptors known as “Damage Associated Molecular Patterns” (DAMP) have been shown to be
present on the microglial membranes.
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Microglial morphology may be different in neurodegenerative disease such as AD in
which misfolded proteins accumulate extracellularly, whereas in diseases such as PD, ALS, and
Huntington’s disease, accumulations of misfolded proteins occur inside microglia, neurons, and
astrocytes. The morphology of activated microglia may vary widely in the latter diseases
compared to AD. Peripheral benzodiapzepine receptors have been shown to upregulate in
activated microglia. A benzodiazepine ligand, C-R-PK11195 has been developed to image
activated microglia in living brain. PET-imaging using C-R-PK11195 has shown that cognitive
function in AD patients is inversely proportional to C-R-PK11195 signal.

Figure 6-8. Possible cues that can activate (or “switch”) microglia

6.8.3 Microglia cells- Effect of acute injury
Acute exposure to endotoxins or neurotoxins (including METH) can also activate
microglia. Acute injury can expose microglia to serum proteins such as albumin. It can also
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cause increased local concentrations of glutamate, ATP, and ADP. These types of signals are
sensed by microglia as dangerous. In response, they transform into an activated state. The
response of microglia is not a linear process; rather, it is highly dependent on the nature of
stimulus, the receptors involved, and the prior state of the microglia.

There is some evidence showing that the number of microglia in mouse substantia nigra
is highest followed by striatum. Various acute neurodegeneration models involving
dopaminergic toxins have been widely studied. 6-OHDA, MPTP, rotenone, and METH have
been shown to cause dopaminergic neurodegeneration and microglial activation. The
inflammatory agent lipopolysaccharide (LPS) has been shown to cause selective death of
dopaminergic neurons when injected into the substantia nigra. LPS also causes microglial
activation in brain. However, dopaminergic neurons may be undergoing selective degeneration
because of a distinct local population of microglia and astrocytes present in substantia nigra.

Using 2-photon imaging technique, two independent studies have shown that acute tissue
injury causes neighboring microglia to re-orient their processes toward the site of injury and
increases their capability to phagocytose the foreign material being introduced into the CNS.
Minor acute injuries can trigger the transformation of microglia such that they would protect the
neighboring environment from toxic insult and shield the injured site. Massive injury can release
overwhelming amounts of foreign material into the CNS, causing microglia to overreact and
resulting in their persistent activation - a potentially harmful state.

6.9

Microglia activation- Possible molecular mechanisms
To understand how microglia transform from a surveying to an activated state, it is of

utmost importance to understand the molecular mechanisms involved in this process. To
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understand the molecular mechanisms, it is essential to know which type of surface receptors,
chemokines, cytokines, and other secretory molecules are released from microglia under normal
and pathological states.
6.9.1 Microglia molecular expression under healthy and “pathological” states
As discussed previously, microglia continuously survey their environments using their
fine processes and quickly respond to potential harm. This implies that microglia must have a
complex communication network of molecules through which they can continuously integrate
environmental inputs and respond appropriately. As such, microglia should have molecular
machinery by which they can interact with the surrounding neurons and astrocytes. Microglia
signaling can be distinguished as an “ON” or “OFF” process. The "OFF” signal may be inferred
as a “healthy” environment, where the neighboring environment is under homeostatic conditions.
Detection of foreign molecules can trigger the “ON” signal, causing expression of distinct
molecules instructing the microglia to neutralize the foreign molecule, protecting the susceptible
cell population.
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Figure 6-9. Neuronal inhibitory influences on parenchymal microglia
(Ransohoff and Cardona 2010)
One particular hypothesis is based on the “OFF” signal. It assumes that if the “OFF”
signal has been terminated, it causes microglia to transform into the activatedstate. This
hypothesis is important to understand as microglia which are very similar cells to mononuclear
phagocytes, express ion channels, neurotransmitter receptors, and have very high expression of
purinergic receptors.
Microglia continuously receive “OFF” signals from neurons via a contact-dependent
receptor interaction as well as soluble factor/cytokine based signals, which under normal
conditions keep microglia in the surveying state. Contact-dependent inhibition occurs by CD200CD200R, HSP60-TREM2-DAP12, CD22-CD45, and CD47-CD172A, whereas, ICAM5
(Intracellular Adhesion Molecule-5) and LFA-1 (Lymphocyte Function Associated antigen-1),
CX3CL1-CX3CR1, IL-10- IL-10 receptor, and TGF-β-TGF-β receptor signals are soluble
factor/cytokine mediated signals.
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Microglia also possess neurotransmitter receptors on their surface and thus may react to
abrupt changes in concentration of the respective neurotransmitters. Various neurotransmitter
receptors such as GABA receptors, glutamate receptors, adrenergic receptors and DA receptors
have been shown to be present on the microglial cell surface. Purinergic receptors are also
present in high abundance. The activation of microglial receptors has been shown to alter the
immunological functioning of microglia. Therefore, extra-synaptic neurotransmitter receptors
may play important roles in various regulatory functions.

6.9.2 Microglial pattern recognition receptors for sensing neighbor environment

Microglia can enter an activated state in response to environmental toxins and
endogenous proteins. Diverse toxin signals are thought to be translated into microglial ROS
production through pattern recognition receptors (PRR). A variety of PRRs have been shown to
be present on the microglial surface, which can identify diverse arrays of molecular
determinants. Therefore, a wide range of foreign or toxic molecules can also be readily
recognized, and microglia can respond to protect the native environment - when the insult is
small and controllable. Various molecules such as estrogen, glucocorticoids, neuropeptides, and
anti-inflammatory cytokines such as IL-10 and TGF-β can inhibit microglial activation under
small insult condition. However, massive insult by foreign molecules or toxic components can
cause over-activation of microglia. This over-activation can result in the over-expression of
iNOS and COX-II which cause ROS generation. In addition, microglia can also release proinflammatory cytokines such as IL-1β and TNFα. Over-activation of microglia can also cause
overexpression of NADPH oxidase, generating massive amounts of ROS inside microglia cells
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as well as in their immediate environment. Chronic over-activation of microglia can even result
in neuronal death, which is observed in various neurodegenerative diseases.

Figure 6-10. Microglial PRRs identify neurotoxic and pro-inflammatory ligands
(Block, Zecca et al. 2007)
Microglial PRRs identify and bind pathogen associated molecular patterns by PRRs.
Toll-like receptors (TLRs) are one of the widely studied PRRs. Microglia have been shown to
express 9 different types of TLRs. TLR4 is primarily responsible for LPS-induced neurotoxicity.
Various TLRs have been shown to be responsible for microglia-induced immune responses.
Activation of TLRs mainly induce microglial response resulting in the production of NO.
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Another class of PRRs are scavenger receptors, which recognize various modified lipoproteins
and polyanionic ligands. The activation of scavenger receptors has been shown to result in ligand
internalization and/or the production of extracellular superoxide by microglia. Macrophage
antigen complex-1 (MAC-1) functions as an adhesion molecule and PRR that recognizes a
variety of ligands. MAC-1 receptors are located on microglia and have been shown to be part of
a primary mechanism by which toxins activate microglia to produce extracellular superoxide,
inducing subsequent neurotoxicity. It has also been demonstrated that multiple PRRs can identify
a single neurotoxin, implying that combinations of receptors may be involved in the recognition
of some neurotoxic ligands. NADPH oxidase is known to be responsible for the generation of
ROS following microglia activation. MAC-1 receptors may be crucial for microglial NADPH
oxidase activation in response to neurotoxic insult. NADPH oxidase has also been shown to
generate extremely high levels of ROS under neurotoxic stimuli, which can cause microglia to
generate various proinflammatory molecules, causing inflammation in surrounding areas.
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CHAPTER 7

HYPOTHESES

Our lab initially carried out a microarray analysis on striatum of METH-treated animals
and observed significant changes in genes related to inflammatory or immune responses,
receptor/signal transduction components and ion channel/transport proteins. Subsequently, we
established that microglial activation is induced specifically in striatum following a neurotoxic
METH regimen (Thomas, Dowgiert et al. 2004). We were also able to verify that other brain
areas displayed a normal microglial phenotype (Thomas, Walker et al. 2004). We also
demonstrated that NMDA receptor antagonists such as MK-801 and dextromethorphan were able
to attentuate METH-induced microglial activation in striatum (Thomas and Kuhn 2005),
suggesting excitotoxicity must be involved. Furthermore, striatal gene expression studies and
knockout mouse studies indicated that cyclooxygenase-2 (COX-2) is essential for METHinduced dopaminergic neurotoxicity. From the same study we concluded that the peroxidase
activity of COX-2, which leads to the formation of ROS including dopamine quinones, is
responsible for METH-induced neurotoxicity in striatum (Thomas and Kuhn 2005). Microarray
analysis of cultured microglia treated with DA quinones demonstrated that various genes
associated with microglial protective and phagocytic functions decreased in expression, whereas,
genes associated with inflammatory and cytokine functions increased in expression (Kuhn,
Francescutti-Verbeem et al. 2006). Thus, increased oxidative stress may play an important role in
microglial activation, especially by increasing DA’s oxidation to DA quinones. Our additional
findings using LPS and HIV-tat protein to activate microglia also showed similar genetic
expression changes in cultured microglia cells (Thomas, Francescutti-Verbeem et al. 2006).
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From our previous studies, we hypothesized that, as METH causes striatal-specific activation of
microglia, METH should induce significant alterations in protein expression of striatal microglia,
and understanding these changes will elucidate the mechanisms of neurotoxicity induced by
METH. In addition, we also hypothesized that either the unique striatal environment or the
differential protein expression by microglia in other brain regions may be responsible for striatal
specific microglial activation. Quite possibly, the elucidation of protein expression profiles might
assist in the understanding of METH addiction and its treatment.

RATIONALE AND STUDY DESIGN

The main objective of the first part of this project was to develop a cell-culture model for
METH-induced neurotoxicity using cultured microglia cells. We focused on determining the
proteomic expression changes in BV2 murine microglial cells after their treatment with low dose
METH, high dose METH, and LPS in presence or absence of MN9D cells. We used the BV2
microglial cell line because it is well-established, widely used, and is derived from murine
mesencephalic microglia. BV2 cells retain many of the functions and features of in vivo
microglia, thus they serve as an ideal celll model system (Henn, Lund et al. 2009). We planned
to co-culture MN9D and BV2 cells if unable to observe significant protein expression changes in
BV2 cells with METH treatment. We planned to use MN9D cells as they possess tyrosine
hydroxylase and DA, and can partially recapitulate dopaminergic neurons to assess the direct
effect of METH on microglia as well as indirect effects of METH treated dopaminergic neurons
on microglial protein expression. We determined to use two different doses of METH because of
the possibility that METH might alter microglial protein expression in different manners at low
(50 µM) and high doses (500 µM). We used LPS, as we successfully carried out microarray
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analysis of BV2 microglia following LPS treatment and had possession of their gene expression
profile (Thomas, Francescutti-Verbeem et al. 2006). We planned to determine protein expression
changes of microglia (as opposed to gene expression changes), as proteins are ultimately
responsible for the phenotypic changes under pathological conditions.

To achieve the objectives of this project, I determined cellular viability of BV2 cells
following their exposure to low dose METH, high dose METH, and LPS. I also determined the
effect of each treatment on dopaminergic levels in MN9D cells. Proteomic expression profiles
for each treatment were evaluated to understand the effects of each treatment. To accomplish my
objectives, I proposed to:
 Test the ability of low dose METH, high dose METH or previously used doses of
LPS to alter the viability of BV2 cells.

This analysis was crucial to evaluate the data obtained from proteomic study. If METH
significantly altered cellular viability, it may manifest as an alteration in protein expression may
or may not be important for METH-induced neurotoxic damage and/or its addictive properties.
The interpretation of data from the proteomic studies would be more conclusive after
understanding each treatment’s direct effect on cell viability.
 Test the ability of different drug treatments to alter DA levels in the dopaminergic
cell line MN9D.

This experiment was carried out to determine if METH or LPS have the ability to deplete
DA levels from the dopaminergic MN9D cell line. As we previously carried out microarray
analysis of cultured microglia cells using DA quinones, it would be highly relevant to understand
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the direct effect of DA and probably other molecules released from MN9D cells following their
treatment with METH or LPS. Therefore, it is important to understand the effect of each
treatment on DA levels in MN9D cells.
 Test the proteomic expression change of BV2 cells following their treatment with low
dose METH, high dose METH, and LPS.

This experiment was important as there are not many findings that have measured the
effect of METH on cultured microglia cells. At the very least, our findings would provide us an
understanding as to whether or not any significant protein expression changes take place in the
cellular proteome following exposure to different doses of METH or LPS.
 Verify the proteomic expression changes of BV2 cells exposed to low dose METH,
high dose METH, and LPS following growth in an environment where they have had
access to various secretory molecules (including DA) from the MN9D cell line.

This experiment was carried out to understand the possible influence of secretory factors
(including DA) released from MN9D cells upon exposure to low dose METH, high dose METH,
and LPS, in addition to the drug’s direct influence on protein expression changes induced on
cultured microglia cells. This experiment could be highly relevant to an in vivo state as it would
involve two cell types (dopaminergic neurons and microglia cells), both of which have been
shown to be affected by exposure to METH.

The main objective of the second part of this study was to evaluate the proteomic
expression changes in microglia isolated from the striatum of animals treated with METH and
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compare to the microglial profile from untreated controls. To achieve these objectives, I
proposed to:

Compare various methods of microglia isolation and determine the most suitable method
for isolation of highly pure microglial fractions from various brain tissues of the transgenic
mouse strain B6.129P- Cx3cr1tm1Litt/J.

The rationale behind using the transgenic mouse strain (B6.129P- Cx3cr1tm1Litt/J) was
to have the ability to readily isolate microglia from all other brain cells. In this transgenic strain,
the fractalkine receptor gene of microglia has been knocked out and a gene encoding enhanced
green fluorescent protein (eGFP) knocked-in, resulting in microglia that express eGFP (Thomas,
Francescutti-Verbeem et al. 2008). The rationale behind comparing various methods of microglia
isolation was to determine the best possible method to isolate microglia. It was of utmost
importance to optimize a rapid isolation protocol that could be used downstream of our animal
experiments. We compared fluorescence activated cell sorting (FACS), magnetic activated cell
sorting (MACS), and density gradient centrifugation procedures. Subsequently, we optimized a
density gradient centrifugation protocol to isolate microglia from various brain regions. Flow
cytometry and fluorescence microscopy were used to verify microglia purity. These methods
were ideal as all microglia expressed eGFP and could be easily distinguished from nonmicroglia. We also performed microglial isolation on wild-type mice (C57BL6), and labeled
them with CD11b (a microglia-specific antigen) antibody to compare their purity with those
isolated from the eGFP mice.
 Isolate microglia from the striatum of non-treated control animals (C57BL6 mice)
and animals treated with METH and determine changes in their protein expression.
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The purpose of this experiment was to compare the striatal microglia protein expression
profiles from METH-treated and untreated animals. Due to the specificity of their activation,
only striatal microglia examined. Evaluating the differences in protein expression between
striatal microglia isolated from control animals and METH-treated animals might assist us in
identifying specific proteins involved in the neurotoxic and/or addictive processes following
METH administration.
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CHAPTER 8
MATERIALS AND METHODS

8.1

Materials
Methamphetamine hydrochloride, methyl thiazolyl blue tetrazolium bromide (MTT), LPS

(from E.coli serotype 055:B5), dimethyl sulfoxide (DMSO), poly-L-lysine, and dopamine
hydrochloride were purchased from Sigma. Methanol, sodium phosphate (monobasic), sodium
citrate, ethylene diamino tetraacetic acid (EDTA), sodium hydroxide, tris, glycine, sodium
dodecyl sulfate (SDS), fetal clone-III bovine serum, and perchloric acid were purchased from
Fisher Scientific. Heptane sulfonic acid was purchased from TCI. BCA protein assay kits were
purchased from Pierce. Nano orange protein quantification kits, DPBS, 1X PBS, DMEM media,
penicillin/streptomycin, trypsin, and 8-16% tris-glycine gels were purchased from Invitrogen.
CD11b microbeads, CD11b-FITC antibody, LS columns, and column adapters were purchased
from Miltenyi Biotech. Percoll was purchased from GE Healthcare. 6 well plates with 0.45µM
inserts and CD11b-APC antibody were purchased from BD Biosciences.

Cell culture and treatments
The hybridoma dopaminergic MN9D cells are derived from the somatic infusion of
rostral mesencephalic neurons from embryonic C57BL/6J (E14) mice with N18TG2 mouse cells.
MN9D cells were obtained from Dr. Michael Zigmond’s laboratory. They were cultured in T-75
flasks (Greiner Bio One, Frickenhausen, Germany) coated with 1 mg/ml poly-L-lysine and
maintained in DMEM (high glucose with phenol red) supplemented with 10% fetal Clone III
serum, penicillin (50 units/ml) and streptomycin (50 µg/ml) at 37°C under 5% CO2 atmosphere.
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Murine microglia BV2 cells were grown in DMEM (high glucose with phenol red)
supplemented with 5% fetal calf serum, 1mM sodium pyruvate, and 100 U/ml
penicillin/streptomycin in T-75 flask. Cells were maintained at 37°C under 5% CO2.

For co-culture experiments, BV2 and MN9D cells were incubated with their
corresponding media in 1:1 proportions. Methamphetamine hydrochloride and LPS were
dissolved in media as stock solutions. Methamphetamine hydrochloride solutions were prepared
fresh every time, whereas LPS aliquots were prepared and stored at -20°C.

Animals

Female C57BL/6 mice (Harlan, Indianapolis, IN, USA) were primarily used for
proteomic expression experiments and, in some instances, additional protocols to verify the
reproducibility of microglia isolation. For the optimization of microglial isolation protocol, mice
in which the CX3CR1 gene was deleted and replaced with a cDNA of eGFP (Jung, Aliberti et al.
2000) were purchased as breeding pairs from The Jackson Laboratory (Bar Harbor, ME; strain
B6.129P- Cx3cr1tm1Litt/J). Mice homozygous for the deletion of the CX3CR1 gene were used
to establish a colony of male and female offspring for use in these studies. All mice were housed
five per cage in large shoebox cages in a light- and temperature-controlled room and were
approximately 8-10 weeks old at the time of experimentation. Mice had free access to food and
water. The Institutional Animal Care and Use Committee of Wayne State University approved
the animal care and experimental procedures. All procedures were also in compliance with the
NIH Guide for the Care and Use of Laboratory Animals.

8.2

Measurement of BV2 cell viability
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To determine the effect of each treatment on BV2 cell viability, quantitative and
colorimetric MTT assays were used. BV2 cells were plated at a density of 10,000 cells/well in 96
well plates and afforded 24 hours of growth to ensure adherence. BV2 cells were treated with the
above mentioned treatments for 6 hours, 12 hours or 24 hours. After incubation, MTT was added
to each well at final concentration of 0.5 mg/mL and the plate was further incubated at 37°C in
95% air/5% CO2 atmosphere for 3 hours to produce dark blue formazan crystals. The
supernatants were carefully removed and the formazan crystals dissolved by adding 100 µL of a
DMSO/methanol (50:50) mixture to each well and shaking the plate gently at room temperature
for 30 minutes. The absorbance values were measured using a microplate reader at 570 nm with
a background correction done at 690nm. Data from 3 experiments were analyzed using
GraphPad software (Version 4, San Diego, USA). Cell viability was defined as a percentage
reduction in absorbance compared to untreated controls.
8.3

Measurement of dopamine levels in MN9D cells
Two different protocols were followed to determine DA levels in MN9D cells.
I.

To determine the direct effect of each treatment on dopaminergic neurons, DA
levels of MN9D cells were determined using HPLC coupled with electrochemical
detection. MN9D cells were plated at 5X105 cells/well in 6 well plates for 48
hours to allow their attachment. Adherent MN9D cells were treated with 50 µM
METH, 500 µM METH or LPS (100 ng/mL) for 12 hours. After incubation, the
media was removed and cells washed with 1X PBS. 50 µL 0.16N perchloric acid
was added to each well and cells were harvested with a rubber policeman and
sonicated 3 times for 5 seconds each. Cell lysates were centrifuged at 14000 rpm
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for 10 minutes at 4°C. The resulting supernatant was diluted 1:4 with 0.16N
perchloric acid. 50 µL of the resulting mixture was used to determine DA levels
using a Shimadzu HPLC system equipped with an electrochemical detector and
reverse phase C18 column. The mobile phase consisted of 50 mM sodium citrate,
50 mM sodium phosphate, 200 μM EDTA, 1.5 mM heptane sulphonic acid, and
14% methanol. Concentrations of DA were quantified by interpolating peak areas
relative to those generated by a range of DA standards that were run in parallel.
DA levels were adjusted by determining protein concentrations of cell pellets by
BCA protein assay, which were dissolved by boiling at 95°C for 5 minutes in 50
µL 0.5M sodium hydroxide.
II.

To determine the direct and indirect effects of each treatment on dopaminergic
neurons, DA levels of MN9D cells cultured with BV2 cells were determined
using HPLC. MN9D cells were plated at a density of 2X105 cells/well in a 6 well
plate insert, and BV2 cells were plated at 5X105 cells/well density in 6 well plate.
The plate was incubated for 48 hours to allow the attachment of both cell lines.
Adherent MN9D and BV2 cells were treated with 50 µM METH, 500 µM METH
or LPS (100 ng/mL) for 12 hours. After incubation, the media was removed and
cells were washed with 1X PBS. MN9D cells were harvested by adding 50 µL
0.16N perchloric acid to each well. Cells were harvested with a rubber policeman
and sonicated 3 times for 5 seconds each. Cell lysates were centrifuged at 14000
rpm for 10 minutes at 4°C. The resulting supernatant was diluted 1:4 with 0.16N
perchloric acid. 50 µL of the resulting mixture was used to determine DA levels
using a Shimadzu HPLC system equipped with an electrochemical detector and
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reverse phase C18 column. The mobile phase consisted of 50 mM sodium citrate,
50 mM sodium phosphate, 200 μM EDTA, 1.5 mM heptane sulphonic acid, and
14% methanol. Concentrations of DA were quantified by interpolating peak areas
relative to those generated by a range of DA standards that were run in parallel.
DA levels were adjusted by determining the protein concentrations of cell pellets
by BCA protein assay, which were dissolved by boiling at 95°C for 5 minutes in
0.5M sodium hydroxide.

8.4

Determination of changes in protein expression in BV-2 cells
To determine changes in protein expression, BV-2 cells were plated at 5X105 cells/well

in 6 well plates for 24 hours to allow their attachment. Adherent BV-2 cells were treated with 50
µM METH (low dose METH), 500 µM METH (high dose METH), or LPS (100 ng/mL) for 12
hours. After incubation, media was aspirated and cells were washed twice with 1X PBS. Washed
cells were lysed with 1% SDS and protein concentrations were determined using a BCA protein
assay kit. 15µg of protein from each treatment were fractionated on 8-16% tris-glycine gradient
gels. Gels were stained with SYPRO-ruby dye. Each lane was cut into 20 pieces, reduced,
alkylated and digested. The resulting peptides were separated by reverse phase chromatography
(Magic C18 column, Michrom), followed by ionization with ADVANCE ion source (Michrom),
and introduced into an LTQ-XL mass spectrometer (Thermo Electron). The data was analyzed
using scaffold (Proteome software).

8.5

Determination of changes in protein expression in BV-2 cells in the presence of
secretory factors released by MN9D cells
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To determine the effect of various soluble factors (including DA) released from MN9D
cells upon exposure to various treatments as well as the direct effects of the treatments, 6 well
plates with cell-culture inserts were used. MN9D cells were plated at 2X105 cells/well on cell
culture inserts and BV-2 cells were plated at 5X105 cells/well in the wells of the same plate. The
inserts were made of a 0.45 µM semi-permeable membrane which allowed various soluble
factors (including DA) released from MN9D cells to pass the membrane and come into contact
with BV-2 cells. 48 hours after plating, the cells were treated with 50 µM METH, 500 µM
METH or 100 ng/mL LPS for 12 hours. After incubation, the media was aspirated and the inserts
containing MN9D cells were removed (they were used for HPLC determination of DA levels)
and BV-2 cells were washed twice with 1X PBS. Washed cells were lysed with 1% SDS and
protein concentrations determined using a BCA protein assay kit. 15µg of protein from each
treatment were fractionated on 8-16% tris-glycine gradient gels. Gels were stained with SYPROruby dye. Each lane was cut into 20 pieces, reduced, alkylated and digested. The resulting
peptides were separated by reverse phase chromatography (Magic C18 column, Michrom),
followed by ionization with ADVANCE ion source (Michrom), and introduced into an LTQ-XL
mass spectrometer (Thermo Electron). The data was analyzed using Scaffold (Proteome
software).

8.6

Development of a protocol to isolate purified fractions of microglia from brain tissue
For this experiment, we used a transgenic mouse strain (B6.129P- Cx3cr1tm1Litt/J)

which harbor eGFP labeled microglia. We evaluated 3 different isolation protocols designed to
produce highly purified fractions of microglia from various brain regions. The first step is to
prepare a single cell suspension of tissue before isolating microglia.
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8.6.1

Preparation of single cell suspension from mouse brain tissue
8-10 mice (B6.129P-Cx3cr1tm1Litt/J) were used for this experiment. Mice were

sacrificed after briefly anesthetizing them with isoflurane. The brain was immediately isolated
and regions of interest (striatum, hippocampus or prefrontal cortex) were pooled together in a
petri-dish containing 3 mL 1X DPBS supplemented with 0.02% glucose. Tissues were minced
using a sterile surgical blade before transferring to a 7 mL Dounce tissue homogenizer for further
dissociation. The tissue homogenate was passed several times through a fire-polished Pasteur
pipette before filtering through a 30 micron filter to remove non-dissociated cells. This filtrate
represented the heterogeneous single cell suspension. The resulting single cell suspension was
subjected to 3 different microglia-isolation methods to evaluate the best method to isolate highly
pure fraction of microglia from different brain regions.
8.6.2 Evaluation of fluorescence assisted cell sorting to isolate microglia
As microglia isolated from the mice expressed eGFP, we evaluated fluorescence
activated cell sorting (FACS) to separate microglia from other cell types in the single cell
suspension. The single cell suspension was subjected to FACS using FACSDiva (BD
Biosciences). Microglia cells were sorted based on their green fluorescence because of their
eGFP expression.

8.6.3

Evaluation of magnetic-activated cell sorting to isolate microglia
The number of cells in the single cell suspension was determined and the cells were

centrifuged at 300g for 10 minutes at 4°C. The cell pellet was resuspended in 180 µL buffer (1X
PBS, 0.5% BSA, 2 mM EDTA, pH 7.2) then incubated with 20 µL CD11b microbeads for 15
minutes at 4°C. Cells were washed with 2 mL buffer then centrifuged at 300g for 10 minutes.
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The supernatant was removed and cells resuspended in 500 µL buffer. The labeled cell
suspension was applied to an LS column (Miltenyi Biotech) in the presence of a strong magnetic
field. Unlabeled cells were collected as a pass through, and the column was washed three times
with 3 mL ice-cold buffer. The column was removed from the magnetic field and 5 mL buffer
was used to elute the retained, labeled cells. Microglia were isolated based on their expression of
CD11b receptors and the ability of CD11b microbeads to selectively bind to the receptors and be
retain in column due to the strong magnetic field.
8.6.4 Evaluation of density gradient centrifugation to isolate microglia
The single cell suspension was centrifuged at 300g for 10 minutes at 4°C and the
supernatant aspirated. The cell pellet was resuspended in 1 mL freshly prepared 70% sterile
isotonic percoll (SIP). Resuspended cells were passed through a fire-polished Pasteur pipette
several times to make a homogenous cell suspension. 2 mL freshly prepared 50% SIP was gently
layered on top of 70% SIP layer using a fire-polished Pasteur pipette (without disturbing the 70%
SIP layer). 1 mL 1X DPBS was gently layered on top of 50% SIP (without disturbing the 50%
SIP layer). The resulting density gradient tube was centrifuged in a swinging bucket rotor
centrifuge at 1200g for 45 minutes. After centrifugation, 2 distinct layers appeared at the
interface of 1X PBS and 50% SIP as well as at the interface of 50% SIP and 70% SIP. Both the
layers were removed and used for FACS analysis to determine the percentage of eGFP
expressing microglia cells. The purity of the isolated fraction was also determined using
fluorescence microscopy.

8.7

Identification of protein expression profile of pure microglial fraction isolated from
various brain regions following METH treatment
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After optimizing the density gradient protocol to yield highly pure fractions of microglia,
we used this method to isolate pure microglia from the striatum of control and METH-treated
wild-type animals (C57BL6 mice). We used our previously established METH administration
protocol which induced maximum neurotoxicity. 40 animals were injected 4X with 5mg/kg
METH (once every 2 hours) and another 40 animals were used as untreated controls. Microglia
were isolated from the striata of from both groups. We performed triplicate experiments to yield
purified microglia fractions (as shown in figure 8-1).

Figure 8-1. Experimental protocol to isolate murine microglia
The density gradient centrifugation protocol was followed as described in 8.6.4 and the
isolated microglial fraction centrifuged at 500g for 10 minutes. The supernatant was removed
and the cell pellet lysed with 35 µL 1% SDS. The cell lysate was boiled at 95°C for 5 minutes.
Denatured samples were frozen at -80°C until further analysis. After completion of triplicate
experiments, protein concentrations of each sample were determined using a nano orange protein
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assay kit. 5 µg proteins from each treatment were fractionated using 8-16% tris-glycine gradient
gels. Gels were stained with SYPRO-ruby stain. Each lane was cut into 20 pieces, reduced,
alkylated and digested. The resulting peptides were separated by reverse phase chromatography
(Magic C18 column, Michrom), followed by ionization with ADVANCE ion source (Michrom),
and introduced into an LTQ-XL mass spectrometer (Thermo Electron) The data was analyzed
using Scaffold (Proteome software).

174

CHAPTER 9
RESULTS
9.1

Methamphetamine causes time-dependent and dose-dependent decreases in BV2 cell
viability
After exposure to various treatments for 6 hours, higher concentration of METH (500

µM) significantly altered BV-2 cell viability. However, lower concentrations of METH (50 µM)
or LPS treatment did not alter BV-2 cell viability significantly as shown in figure 9-1. The
toxicity profile of various treatments remained quite similar to 6 hours profile after exposure of
BV2 cells for 12 hours (figure 9-2). We observed dose dependent reductions in cellular viability
with METH in the case of the 24 hour treatment of BV-2 cells, whereas LPS treatment did not
seem to affect cellular viability even after that longer exposure (figure 9-3).

Figure 9-1. MTT assay BV2 cells (6 hours post-treatment)

175

Figure 9-2. MTT assay BV2 cells (12 hours post-treatment)

Figure 9-3. MTT assay BV2 cells (24 hours post-treatment)

9.2

Methamphetamine treatment causes a decrease in DA levels in MN9D cells
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We observed significant reductions in DA levels in the dopaminergic neuronal cell line
MN9D following their exposure to 50 µM METH and 500 µM METH for 12 hours. However,
treatment with LPS induced a non-significant increase in DA levels of MN9D cells (figure 9-4).

Figure 9-4. Dopamine levels of MN9D cells (12 hours post-treatment)
9.3

Methamphetamine treatment induces a decrease in DA levels of MN9Dcells cultured in
the presence of BV2 cells
The experiment utilizing cell-culture inserts to allow MN9D cells to be in indirect contact

with BV-2 cells (to simulate tissue microenvironment) showed that both concentrations of
METH caused a significant decrease in DA levels of MN9D cells. In the case of LPS treatment,
we observed a non-significant reduction in DA levels of MN9D cells (figure 9-5).
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Figure 9-5. Effect of various treatments on dopamine levels of MN9D
Cells cultured in presence of BV-2 cells

9.4

Treatment of BV-2 cells with different agents results in significant protein expression
changes compared to untreated control cells
We observed significant alterations in protein expression following treatment of BV-2

cells with various treatments. Some proteins were induced upon treatment with LPS, METH 50
µM or METH 500 µM treatment, whereas expression of some proteins was completely
attenuated following treatment. As shown in figure 9-6, we found 3061 proteins were expressed
in both control and LPS-treated BV-2 cells, whereas, LPS-treated BV-2 cells expressed 119
proteins that were exclusive, and untreated BV2 cells expressed 90 exclusive proteins.
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Figure 9-6. Protein expression changes between control and LPS-treated BV-2 cells
Statistical analysis (p-value <0.05) revealed the expression of 161 proteins as
significantly altered following LPS treatment of BV-2 cells. Upon further examination, it was
observed that significantly altered proteins represented molecules associated with cell survival
and cell death, cell function and cell maintenance, cellular compromise, cell morphology, and
protein synthesis. The most significantly altered proteins included inducible nitric oxide
synthase, poly [ADP-ribose] polymerase 14, immune-responsive gene 1 protein, pyruvate kinase
isozymes M1/M2, heme oxygenase 1, macrophage migration inhibitory factor, interferoninduced very large GTPase 1, histone H4, interferon-activatable protein 204, prostaglandin G/H
synthase 2, prolow-density lipoprotein receptor-related protein 1, signal transducer and activator
of transcription 1, intercellular adhesion molecule 1, profilin-1, integrin alpha-5, heat shock
cognate 71 kDa protein (p-value < 0.0001).
With 50 μM METH treatment, we observed that 3062 proteins were expressed in
untreated and 50 μM METH treated BV-2 cells. However, 89 proteins were exclusively present
in untreated BV-2 cells and 95 proteins were exclusively expressed in BV-2 cells treated with 50
μM METH (figure 9-7). Statistical analysis (p-value < 0.05) revealed that expression levels of
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36 proteins were significantly altered following the treatment of BV-2 cells with 50 μM METH.
Significantly altered molecules were associated with dermatological diseases, developmental
disorders, neurological disorders and connective tissue disorders. Significantly altered proteins
included keratin family proteins, talin-1, talin-2, UDP-N-acetylhexosamine pyrophosphorylase,
histone-H2A, serine-threonine protein phosphatase 6, heat-shock related 70 kda protein, pyruvate
kinase isozymes M1/M2, mitochondrial 10-formyltetrahydrofolate dehydrogenase, and
melanoma inhibitory activity protein (p-value < 0.01).

Figure 9-7. Protein expression changes between control and
50 μM METH-treated BV2 cells

With the 500 μM METH treatment, we observed that 3083 proteins were expressed in
untreated and 500 μM METH treated BV-2 cells. Interestingly, 68 proteins were exclusively
present in untreated BV-2 cells and 93 proteins were exclusively expressed in BV-2 cells treated
with 500 μM METH (figure 9-8). Statistical analysis (p-value < 0.05) revealed that expression
levels of 62 proteins were significantly altered following treatment of BV-2 cells with 500 μM
METH. Significantly altered molecules were associated with cell morphology, cell death, cell
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survival, cellular proliferation, nucleic acid metabolism, and small molecule biochemistry.
Significantly altered proteins included keratin family proteins, heat-shock related 70kda protein,
ATP synthase, E3- ubiquitin protein ligase, serine/arginine repetitive matrix protein, perilipin,
endoplasmic reticulum resident protein, bi-functional purine biosynthesis protein, Rab GDP
dissociation inhibitor (p-value < 0.01).

Figure 9-8. Protein expression changes between control and
500 μM METH-treated BV-2 cells

9.5

Treatment of BV-2 cells (cultured in the presence of MN9D cells) with different agents
resulted in significant protein expression changes compared to untreated control cells
We observed significant alterations in protein expression following treatment of BV-2

cells (cultured in the presence of MN9D cells) with various treatments. Some proteins were
induced upon treatment with LPS, METH 50 µM or METH 500 µM treatment, whereas the
expression of some proteins was completely attenuated following treatment. As shown in figure
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9-9, we found 2886 proteins were expressed in both control and LPS-treated BV-2 cells, whereas
LPS-treated BV-2 cells expressed 126 proteins that were exclusive and untreated BV-2 cells
expressed 114 exclusive proteins.
Statistical analysis (p-value < 0.05) revealed that expression of 273 proteins was
significantly altered following LPS treatment of co-cultured BV-2 cells. Upon further
examination, it was observed that significantly altered proteins represented molecules associated
with carbohydrate metabolism, immunological disease, RNA post-transcriptional modification,
molecular transport, nucleic acid metabolism, metabolic disease, energy production, neurological
disease, cell growth and proliferation, cell survival. The most significantly altered proteins
included inducible nitric oxide synthase, cytoplasmic dynein, alpha-enolase, filamin, talin-1,
ADP-ribosylation factor 2, elongation factor-2, immune-responsive gene-2, histone H2A type 1F, interferon-activable protein 204, signal transducer and activator of transcription 1, interferoninduced protein with tetratricopeptide repeats 1, mitochondrial ATP synthase, histone H2Ax,
hemoglobin subunit alpha, interferon-induced very large GTPase, histone H2A type-2, E3
ubiquitin-protein ligase, UMP-CMP kinase 2, ubiquitin-like protein, vimentin, and flavin
reductase (p-value < 0.0001).

182

Figure 9-9. Protein expression changes between control and
LPS-treated co-cultured BV-2 cells
With 50 μM METH treatment, we observed that 2911 proteins were expressed in
untreated and 50 μM METH treated BV-2 cells. However, 89 proteins were exclusively present
in untreated BV-2 cells and 119 proteins were exclusively expressed in BV-2 cells treated with
50 μM METH (figure 9-10). Statistical analysis (p-value < 0.05) revealed that expression levels
of 208 proteins were significantly altered following treatment of co-cultured BV-2 cells with 50
μM METH. Significantly altered molecules were associated with RNA post-transcriptional
modification, cell-to-cell signaling and interaction, inflammatory response, nucleic acid
metabolism, energy production, cellular assembly and organization, cellular function and
maintenance, developmental disorder, and neurological disease. Significantly altered proteins
included talin-1, elongation factor 2, vimentin, myosin-9, Ras-related protein Rab-11A, keratin
(type II cytoskeletal 6A), pyruvate kinase isozymes M1/M2, fatty acid synthase, cytoplasmic
dynein 1 heavy chain 1, alpha-enolase, E3 ubiquitin-protein ligase, histone H2A type 1-F,
hemoglobin subunit alpha, and hemoglobin subunit beta-2 (p-value < 0.0001).
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Figure 9-10. Protein expression changes between control and
50 μM METH-treated co-cultured BV-2 cells
With 500 μM METH treatment, we observed that 2926 proteins were expressed in
untreated and 500 μM METH treated BV-2 cells. Interestingly, 74 proteins were exclusively
present in untreated BV-2 cells and 125 proteins were exclusively expressed in BV-2 cells
treated with 500 μM METH (figure 9-11). Statistical analysis (p-value < 0.05) revealed that
expression levels of 264 proteins were significantly altered following treatment of BV-2 cells
with 500 μM METH. Significantly altered molecules were associated with RNA posttranscriptional modification, cell death and survival, post-translational modification, protein
folding, cellular movement, DNA replication, recombination and repair, protein trafficking and
developmental disorder. Significantly altered proteins included alpha-enolase, ADP/ATP
translocase 2, fatty acid synthase, ATP synthase subunit alpha, beta-enolase, elongation factor 2,
talin-1, ADP/ATP translocase 1, pyruvate kinase isozymes M1/M2, ATP synthase subunit beta,
myosin-9, phosphoglycerate kinase 1, hemoglobin subunit alpha, hemoglobin subunit beta-2,
vimentin, cytoplasmic dynein 1 heavy chain 1, heat shock 70 kDa protein 1A, 78 kDa glucoseregulated protein (p-value < 0.0001).
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Figure 9-11. Protein expression changes between control and
500 μM METH-treated co-cultured BV-2 cells
9.6

Density gradient centrifugation yields significantly pure fraction of microglia compared
to fluorescence activated cell sorting or magnetic activated cell sorting
Our initial attempts to isolate GFP expressing microglia using FACS did not yield

significant number of cells. In addition, as the FACS facility was not available in-house, it took
significant amount of time from the time of animal sacrifice to obtaining the pure microglial
fraction. As shown in figure 9-12, it was very difficult to separate GFP expressing microglia
because of the presence of a significantly high number of other cell types as well as cell debris,
(which also possessed some auto-fluorescence).
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Figure 9-12. Microglia isolation using fluorescence activated cell sorting
We also used magnetic activated cell sorting to isolate microglia based on their
expression of CD11b receptors by incubating the single cell suspension with anti-CD11b
antibody conjugated to iron beads. The labeled cells were passed through a column in the
presence of a strong magnetic field which removed all the unlabeled cells. The retained labeled
cells were collected by removing the column from the magnetic field. The FACS analysis
revealed that the microglia fraction obtained using MACS technique was ~80% pure and the
unlabeled fraction did not contain significant numbers of microglia cells.
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Figure 9-13. Evaluation of effectiveness of MACS as a technique to isolate microglia
We also attempted to perform density gradient centrifugation to yield purified fraction of
microglia. As different cells vary in their density, appropriate gradients can help in isolating cells
of interest from mixture of cells. We evaluated the purified fraction and non-purified remnants
for the presence of GFP expressing microglia cells. We observed ~90-95% pure fraction of
microglia from striatum, hippocampus, and prefrontal cortex (figure 9-14, 9-15). We also
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observed the pure microglia fraction via fluorescence microscopy. Interestingly, all the cells
from the fractions appeared to be green fluorescent microglia cells (figure 9-16).

GFP+

GFP+

Tube: _001
Gate: single cells
Gated Ev ents: 4747
Total Ev ents: 403155

Tube: _002
Gate: single cells
Gated Ev ents: 12903
Total Ev ents: 27681

Marker Ev ents % Gated % Total
All
4747 100.00
1.18
GFP+
656
13.82
0.16

Mean
124.98
892.11

Marker Ev ents % Gated % Total
All
12903 100.00 46.61
GFP+
11901
92.23 42.99

Mean
872.78
946.10

Figure 9-14. FACS analysis of striatal microglia fraction isolated by
density gradient centrifugation
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GFP+

GFP+

Tube: _003
Gate: single cells
Gated Ev ents: 17659
Total Ev ents: 22614
Marker Ev ents % Gated % Total
All
17659 100.00 78.09
GFP+
16325
92.45 72.19

Tube: _004
Gate: single cells
Gated Ev ents: 22583
Total Ev ents: 26300
Mean
863.84
934.26

Marker Ev ents % Gated % Total
All
22583 100.00 85.87
GFP+
21743
96.28 82.67

Mean
938.31
974.47

Figure 9-15. FACS analysis of hippocampal and prefrontal cortical microglia fractions
isolated by density gradient centrifugation

A

B

Figure 9-16. Fluorescence microscope images of eGFP expressing microglia
A. GFP microglia under blue filter; B. GFP microglia stained with nuclear stain DAPI.
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We also tried to isolate microglia from wild-type animals (C57BL6 mice) and labeled
them with CD11b antibody to specifically recognize microglia cells. We evaluated the purity of
microglia cells isolated from various brain regions of wild-type animals by FACS. As shown in
figure 9-17, we observed > 90% microglia cells in purified fractions.

Figure 9-17. Evaluation of microglial fraction isolated from wild-type animals

9.7

METH significantly alters expression of some essential proteins in microglia isolated
from striatum
We observed significant alterations in protein expression in microglia isolated from

animals following their treatment with METH compared to microglia isolated from untreated
control animals. Some proteins were induced upon treatment METH, whereas, expression of
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some proteins was completely attenuated following treatment. As shown in figure 9-18, we
found 1613 proteins were expressed in both control and LPS-treated BV-2 cells, whereas,
microglia from untreated animals expressed 25 proteins that were exclusive and microglia
isolated from METH-treated animals expressed 88 exclusive proteins.

Figure 9-18. Proteomic expression changes between microglia isolated from
striata of METH-treated animals and untreated control animals
Statistical analysis (p-value < 0.05) revealed that expression of 141 proteins was
significantly altered following treatment of animals with METH. Upon further examination, it
was observed that significantly altered proteins represented molecules associated with RNA
post-transcriptional modification, cellular growth and proliferation, cellular development,
neurological disease, psychological disorders, nucleic acid metabolism, developmental disorders,
hematological disease, DNA replication, recombination and repair. The proteins were directly
associated with hematological diseases, immunological disease, inflammatory disease, and
inflammatory response. Most significantly altered proteins included clathrin heavy chain-1, ATP
synthase, malate dehydrogenase, dihydropyrimidinase related protein 2, glyceraldehyde-3-
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phosphate dehydrogenase, aconitate hydratase, fructose bisphosphate aldolase A, gamma
enolase, microtubule associated protein 1A and 6, elongation factor-1, ADP/ATP translocase,
pyruvate kinase isozymes M1/M2, tubulin beta-2A, heat shock protein HSP-90 alpha, and
histone H2A type 2-A (p-value < 0.0001).
DISCUSSION
METH is highly abused drug that is popular among or youth, and requires immediate
attention because of its highly addictive properties. As the precursors of METH (e.g.
pseudoephedrine, red phosphorus, anhydrous ammonia, etc.) are readily available in the U.S. and
many other countries, it is difficult to control the illicit manufacture of METH. Previous attempts
to restrict the distribution of METH precursors have resulted in an increase in METH trafficking
from neighboring countries. As METH causes severe neurotoxic effects, and most of the
addicted people are among the young, it can significantly damage the development of the CNS.
Because of METH’s ability to cause massive DA release and subsequent euphoric effects, its
addictive potential is extremely high. Surprisingly, METH is also used as a medication for
ADHD. Thus, the understanding of the mechanisms underlying METH’s addictive and
neurotoxic properties is very critical. In-depth analyses of factors responsible for addictive and
neurotoxic properties of METH may provide important targets to ease METH addiction and the
neurotoxicity induced by it.
Various studies have evaluated the ability of anti-inflammatory molecules, radical
scavenger molecules, and molecular inhibitors of excitotoxicity that prevent the neurotoxicity
induced by METH. Some of these studies also evaluated the ability of potential therapeutics to
prevent the self-administration of METH, which simulates addictive behavior. The non-steroidal
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anti-inflammatory drug (NSAID) ibuprofen has been shown to prevent neurotoxicity of METH
because of its agonistic activity on PPARγ (Tsuji, Asanuma et al. 2009). Another study
established the ability of the NSAID indomethacin to prevent METH induced microglia and
astrocyte activation (Goncalves, Baptista et al. 2010). This same study implicated significant
alterations in the tumor necrosis factor system as a cause of METH-induced neuroinflammation.
Ketoprofen is another NSAID that has been shown to attenuate METH-induced neurotoxicity by
preventing the loss of DAT and decreasing the accumulation of activated microglia in striatum
(Asanuma, Tsuji et al. 2003). Surprisingly, several studies showed that aspirin, also an NSAID,
does not prevent neurotoxicity induced by METH (Asanuma, Tsuji et al. 2003, Tsuji, Asanuma
et al. 2009). Therefore, the prevention of METH-induced neurotoxicity appears to be
independent of its effect on the COX-2 enzyme and may be related to the agonistic potency of
NSAIDs as PPARγ agonists (Tsuji, Asanuma et al. 2009). This is further supported by a study
showing that endogenous PPARγ might play an essential role in the prevention of METHinduced neurotoxicity in vivo (Yu, Airavaara et al. 2012). The sigma-receptor antagonist SN79
has been shown to block METH-induced microglia activation. SN79 has also been shown to
attenuate the release of IL-6 family cytokines following METH treatment (Robson, Turner et al.
2013). We observed prevention of striatal microglia activation and prevention of damage to
dopaminergic

nerve

terminals

by

the

NMDA

receptor

antagonists

MK-801

and

dextromethorphan, which implicate excitotoxicity as a possible causative factor for METHinduced striatal microglia activation (Thomas and Kuhn 2005). The radical scavenger edaravone
has been shown to partially protect against METH-induced neurotoxicity by blocking
peroxynitrite production in astrocytes. However, edaravone doesn’t prevent microglial activation
or METH-induced decreases in striatal DA levels (Kawasaki, Ishihara et al. 2006). This implies
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that METH might be activating microglia independent of its ability to generate free radicals.
Another study focusing on the mechanism of action of minocycline concluded this antibiotic is
able to prevent METH as well as MPTP-induced microglia activation, but doesn’t protect
dopaminergic neurons from toxicity as it doesn’t affect TNF-α signaling. Therefore, TNF-α may
not be essential for METH-induced microglial activation, but it is responsible for METHinduced dopaminergic neuronal damage (Sriram, Miller et al. 2006). METH-induced increases in
iNOS and the release of inflammatory cytokines in microglia cell lines has been shown to be
inhibited by melatonin through the inhibition of NFκB transcription factor (Sriram, Miller et al.
2006).
METH self-administration experiments ideally replicate the behavior-based addictive
properties of METH. Therefore, molecules that are able to reverse such behavior can be ideal
candidates to prevent METH addiction and the potential neurotoxicity associated with it.
Lobelane and lobeline have been shown to prevent METH self-administration because of their
ability to block VMAT-2 and DAT (Harrod, Dwoskin et al. 2001, Neugebauer, Harrod et al.
2007). METH self-administration is also decreased by minocycline, ibudilast, and AV1013 (an
amino analog of ibudilast) which have the ability to modulate glial cell responses (Snider,
Hendrick et al. 2013). Minocycline has been shown to exert its effect by inhibition of various
mitogen-activated protein kinase family proteins and IkappaBalpha degradation in microglia
(Nikodemova, Duncan et al. 2006). A study on Ibudilast and AV1013 concluded that, although
their ability to modulate glial reactivity to METH plays an important role in decreasing METH
self-administration, their phosphodiesterase inhibition activity also plays an important role in
decreasing addictive behaviors induced by METH (Snider, Hendrick et al. 2013). Several other
studies have shown that various compounds which have an ability to inhibit the
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phosphodiesterase-4 enzyme (elevating cAMP levels) prevent METH induced behaviors (Iyo, Bi
et al. 1996, Iyo, Bi et al. 1996, Mori, Baba et al. 2000, Yan, Mizuno et al. 2004). Modafinil,
buproprion, naltrexone, varenicline, and disulfiram are being tested, or have been tested in
clinical trials to prevent METH dependence in addicted individuals. Ibudilast, which prevents the
neuroinflammatory effects of glial cells has been fast-tracked in clinical trials to treat METH
addiction. In addition, minocycline, which has been shown to prevent glial responses to METH,
has also been shown to prevent METH use disorders (Tanibuchi, Shimagami et al. 2010). Thus,
some molecules which target particular pathways associated with METH-induced responses in
glial cells may help develop potent molecules which can prevent METH addiction or METH
associated behavioral changes.
In the aforementioned studies, we attempted to develop an in vitro model of METHinduced microglia activation by utilizing the murine BV-2 microglia cell line, which was treated
with METH or LPS. Our initial experiments examined the effects of our treatments on cell
viability and subsequent proteomic expression studies. However, our experiments showed
relatively non-significant alterations in protein expression of BV-2 cells in case of METH
treatment, whereas, BV-2 cells treated with LPS exhibited significant alterations in their protein
expression. We then evaluated the ability of METH to deplete DA levels in the dopaminergic
MN9D cell line. We used a unique approach by employing culture inserts which exposed
microglia to various molecules released by the dopaminergic neuronal cells (MN9D) while being
exposed to METH. These experiments seemed to partially recapitulate the in vivo environment,
as permitted some interactions between the different cell types. Furthermore, we optimized a
protocol to isolate microglia from the striata of animals and determined their protein expression
changes in order to identify key molecules that might be involved in addictive and behavioral
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properties associated with METH dependence. Various studies have evaluated the ability of
diverse molecules to prevent or decrease METH dependence. We intended to obtain a list of
targets which might have been involved in METH addiction and/or neurotoxicity. Appropriate
drug design approaches to restore the protein signatures of microglial cells might ameliorate the
inflammation and neurotoxicity associated with METH abuse.
We observed time- and dose-dependent toxicity in BV-2 cells when treated with METH.
Surprisingly, LPS did not induce a decrease in BV-2 cell viability at any of the examined timepoints (figures 9-1, 9-2, and 9-3). It is important to note that the dose of LPS used was
significantly lower than the concentrations of METH tested. LPS is an endotoxin from gram
negative bacteria and has been well-established as a potent agent that can induce microglia
activation in different brain regions. METH is an amphetamine class of drug, which is known to
cause striatal-specific microglia activation. Therefore, METH-induced microglia activation may
require a unique environment and may involve modulators from other cell types which may
promote striatal-specific microglia activation. As METH administration evokes massive DA
depletion in striatum, we evaluated the ability of METH to deplete DA levels from the MN9D
dopaminergic cell-line. We observed a dose-dependent decrease in DA following METH
treatment,whereas LPS treatment seemed to induce a non-significant increase in DA levels
(figure 9-4). As MN9D cells possess DAT and have been shown to be depleted of DA in the
presence of MPP+ in a dose-dependent manner, it is possible that METH may also induce the
depletion of DA from MN9D cells in a DAT-dependent manner (Choi, Won et al. 1991). As
some studies have investigated the effects of various molecules derived from neurons on
microglia upon neurotoxic damage, it seemed appropriate to verify the changes in protein
expression of BV-2 cells cultured in an environment where they would be exposed to various
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secretory factors of dopaminergic neurons in presence of METH (Glanzer, Enose et al. 2007,
Reynolds, Glanzer et al. 2008, Dutta, Barber et al. 2012). To determine how co-culture
experiments alter METH-induced depletion of DA in MN9D cells, we determined DA levels in
MN9D cells co-cultured with BV-2 cells. We observed a dose-dependent depletion in DA levels
in MN9D cells in the presence of METH, which was very similar to the DA depletion observed
in the absence of BV-2 cells (figure 9-5). Therefore, co-culturing did not seem to affect DA
levels in dopaminergic neurons. Interestingly, we observed a non-significant reduction following
LPS treatment in co-cultured MN9D cells. This result was the opposite of what we observed with
LPS treated MN9D cells cultured alone. This implies that secretory molecules released from
LPS-treated BV-2 cells may alter dopaminergic neurons such that it induces a non-significant
reduction in DA levels in MN9D cells (figure 9-5).
The LPS treatment of BV-2 cells caused significant changes in protein expression (figure
9-6). The most significantly altered protein was inducible nitric oxide synthase (iNOS), which
was completely absent in untreated BV-2 cells. The significant induction of prostaglandin G/H
synthase 2 (PGS2) was also observed in LPS treated BV-2 cells but not expressed in untreated
cells. PGS2 produces COX-2 enzyme. Both COX-2 and iNOS have been strongly implicated in
the inflammatory response of microglia following LPS treatment (Thomas, FrancescuttiVerbeem et al. 2006). We also observed a strong induction of the oxidative stress responsive
protein poly (ADP-ribose) polymerase-14. A significant up-regulation of proteins related to
inflammatory and cytokine cascades was also observed (TNF-system proteins, IFN-system
proteins, macrophage migration inhibitory factor). A strong up-regulation of heme oxygenase-1
was also observed which may play a protective role against the toxicity induced by LPS. The upregulation of various proteins important for microglial migration was also observed (integrin
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alpha-5, intercellular adhesion molecule-5, filamin-B, and cytoplasmic dynein 1 heavy chain 1).
Significantly altered signaling molecules included: STAT-1, STAT-2, NFκB, MAPKKK4, and
PI3K adapter protein. Thus, most of the significantly altered signaling molecules are the cause or
consequence of interferon release induced by LPS treatment. Our experiments involving cocultured microglia and dopaminergic cell lines also yielded significant protein expression
changes in BV-2 cells (figure 9-9). In this experiment, we also observed the most significant
change in induction: that of inducible nitric oxide synthase. A similar induction of PGS2 was
also observed. Therefore, in co-culture conditions, iNOS and COX-2 induced inflammatory
signaling seemed to remain unaltered. Poly (ADP-ribose) polymerase-14 was also induced
following LPS treatment. Significant expression changes were observed in inflammatory and
cytokine cascade related proteins (TNF-system proteins, IFN-system proteins). Significant overexpression of proteins related to the glycolytic pathway was also observed (alpha-enolase,
pyruvate kinase, phosphoglycerate kinase, phosphoglyceratemutase, hexokinase). A significantdown regulation was observed in mitochondrial oxidative phosphorylation related proteins (heatshock
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kDa,

glycerol-3-phosphate

dehydrogenase,

NADH
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mitochondrial Rho GTPase 2, mitochondrial 2-oxoglutarate/malate carrier protein, apoptosisinducing factor 1, succinate dehydrogenase, NADH ubiquinone oxidoreductase, ATP synthase),
whereas, mitochondrial UMP-CMP kinase which is required for pyrimidine biosynthesis by
mitochondrial DNA was up-regulated following LPS treatment. These changes can be explained
as injury to BV-2 cell mitochondria (affecting mitochondrial complex-I, II, and V), resulting in a
switch from oxidative phosphorylation to glycolysis (similar to that observed in cancer cells) and
mitochondrial DNA damage requiring the generation of pyrimidine to repair the damage.
Proteins related to microglial migration and cell-cell contact were also significantly up-regulated
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(cytoplasmic dynein 1 heavy chain, filamin-B, talin-1). Important signaling molecules that were
significantly up-regulated included STAT-1, STAT-2, dual-specificity mitogen activated protein
kinasekinase 1, protein tyrosine kinase 2-beta, phosphatidylinositol 3,4,5-trisphosphatedependent Rac exchanger 1 protein. Thus, important signaling molecules altered in co-culture
condition involved response to cytokines or inflammation as well as anti-viral responses which
may promote cell survival.
50 µM METH did not induce significant protein expression changes in BV-2 cells
compared to LPS or 500 µM METH (figure 9-7). However, significant up-regulation was
observed in heat-shock related 70kDa protein and serine/threonine protein phosphatase 6
regulatory subunit.. Interestingly, significant alterations in protein expression were observed in
BV-2 cells co-cultured with MN9D cells treated with 50 µM METH (figure 9-10). We observed
significant alterations in proteins associated with glycolysis (alpha-enolase, beta-enolase,
pyruvate kinase, triosephosphateisomerase, L-lactate dehydrogenase A chain, fructose
bisphosphate aldolase, glyceraldehyde-3-phosphate dehydrogenase). Vimentin, which is
implicated in glial cell differentiation was significantly down-regulated by 50 µM, which may
cause decreased glial reactivity to infectious or injurious stimuli. Various proteins related to
intracellular protein trafficking were altered such that it would result in inefficient membrane
trafficking of proteins (ras-related protein rab-11A, ras-related protein rab-35, rab GDP
dissociation inhibitor beta). Mitochondrial dysfunction was observed as alterations of key
proteins required for oxidative phosphorylation (ADP/ATP translocase, ATP synthase, succinate
dehydrogenase iron-sulphur subunit, NADH ubiquinone oxidoreductase, trifunctional enzyme
subunit alpha, apoptosis-inducing factor-1, succinate dehydrogenase). Heat-shock protein HSP90 alpha was significantly up-regulated, which may help in chaperone functions to generate
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protein assemblies. E3 ubiquitin-protein ligase was also up-regulated which may assist in the
degradation of dysfunctional proteins. Significantly altered cell signaling molecules include
STE-20

line

serine/threonine

protein

kinase,

serine/threonine

protein

kinase,

1-

phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta-3, c-JUN amino-terminal kinase
interacting protein 4, serine/threonine protein kinase N1. Thus, significant protein expression
changes were observed related to apoptosis and cellular stress signaling.
500 µM METH significantly altered protein expression in BV-2 cells (figure 9-8). The
most significantly altered protein was heat-shock related 70kDa protein 2. Its up-regulation may
be a cellular response to stress, stabilizing various protein against aggregation to maintain their
appropriate function. We observed down-regulation of mitochondrial enzymes following 500
µM METH treatment (ATP synthase and NADH dehydrogenase). Serine/arginine-repetitive
matrix (SRRM) and E3 ubiquitin-protein ligase were significantly down-regulated which may
explain the toxic effects of 500 µM METH as SRRM is involved in the generation of appropriate
functional proteins and E3 ubiquitin-protein ligase is responsible for the destruction of
dysfunctional proteins. Interestingly, when BV-2 cells were co-cultured in the presence of
MN9D cells, the protein expression was significantly changed, involving many other proteins
that were not changed when BV-2 cells were exposed to 500 µM METH in monoculture (figure
9-11). A significant up-regulation of glycolytic enzymes was observed (alpha enolase, beta
enolase,

pyruvate

kinase,

phosphoglycerate

kinase,

fructose

bisphosphate

aldolase,

glyceraldehyde-3-phosphate dehydrogenase). As observed in the case of 50 µM METH,
mitochondrial dysfunction was also observed for higher concentrations of METH as the
expression of many mitochondrial proteins was altered (ADP/ATP translocase, ATP synthase,
apoptosis-inducing factor 1, NADH dehydrogenase, cytochrome C1, succinate dehydrogenase).
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500 µM METH may induce the reduction in oxidative phosphorylation and subsequent increases
in glycolysis to generate ATP. Significantly altered signaling molecules included serinethreonine protein kinase mTOR, 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase
beta-3, phosphoinositide 3-kinase regulatory subunit, STE20-like serine/threonine-protein
kinase, serine/threonine protein kinase, 1-phosphatidylinositol-3-phosphate 5-kinase. In addition,
many members of ras-related protein rab family were down regulated. Thus, METH may be
altering proteins critical for membrane trafficking, vesicular trafficking and neurotransmitter
release.
We explored several different techniques to isolate microglia from various brain regions.
A significant amount of work has been published using primary microglia cultures, but there is
limited evidence in which microglia are used for experimental purposes immediately following
their isolation (Parvathenani, Tertyshnikova et al. 2003, Moussaud and Draheim 2010, Ohtaki,
Tsumuraya et al. 2013). Our objective was to determine the effect of METH on striatal
microglia. Hence, it was essential to follow a protocol that could yield microglia that could be
used for proteomic experiments without extended culturing, which would alter microglial protein
expressions extensively. In our effort to yield purified microglia fraction, we avoided the use of
enzymes such as trypsin which are known to disturb microglial homeostasis (Park, Jeon et al.
2010). We optimized a protocol to generate single-cell suspension using a mechanical
dissociation method to verify the ability of 3 different methods to yield pure microglia fractions
from various brain regions. We found the density gradient centrifugation protocol to be the most
efficient in yielding purified microglia fractions from single-cell suspensions, regardless of the
brain region examined. Our verification of isolated microglia fractions confirmed the purity of
isolated microglia (figures 9-14, 9-15, and 9-16). Density gradient centrifugation has been
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previously used to isolate pure microglia fraction from a variety of brain regions and seemed
compatible with our downstream experiments (Frank, Wieseler-Frank et al. 2006, Hussain, Yang
et al. 2006, Frank, Barrientos et al. 2010, Olah, Raj et al. 2012).
Microglia isolated from the striatum of METH-treated animals also exhibited significant
alterations in protein expression compared to striatal microglia isolated from untreated control
animals (figure 9-18). The most significantly altered protein was junction plakoglobin, which
was almost completely absent in microglia isolated from the striatum of METH-treated animals.
It is shown to be essential for cell migration and cell-cell adhesion. Heat shock 70 kDa protein
1A was significantly up-regulated in microglia isolated from the striatum of METH-treated
animals and corroborates that there is significant protein aggregation or dysfunction induced by
METH in striatal microglia. Interestingly, mitochondrial stress-70 protein and heat shock protein
75 kDa were also up-regulated in METH-treated microglia, which implies the presence of
dysfunctional proteins in mitochondria. Several essential proteins involved in protein transport
were significantly up-regulated (clathrin heavy chain 1 and spectrin beta chain), which implies
increased protein transport due to increased transcription and translation in response to stress
induced by METH. Subsequent increases in clathrin-coated pits associated protein required for
endocytosis was also observed (epidermal growth factor receptor substrate 15-like 1).
Mitochondrial proteins were significantly up-regulated in microglia isolated from METH-treated
animals (ATP synthase subunit alpha, NADH dehydrogenase, mitochondrial inner membrane
protein, ADP/ATP translocase 1 and ADP/ATP translocase 2). Many mitochondrial enzymes
associated with tricarboxylic acid cycle were also up-regulated in microglia isolated from
METH-treated animals. Significant increases in endoplasmic reticulum quality control protein
UDP-glucose:glycoprotein glucosyltransferase 1 and 78 kDa glucose-regulated protein were also
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observed, which implies protein misfolding or dysfunction following METH exposure.
Significant over-expression of DNA damage binding protein and proliferating cell nuclear
antigen in striatal microglia isolated from METH implies significant DNA damage following
METH exposure. There was a down-regulation of 1-phosphatidylinositol-4,5-bisphosphate
phosphodiesterase beta-1 and subsequent up regulation of diacyl glycerol kinase beta. Therefore,
the intracellular signal transduction machinery might alter based on METH induced protein
alterations. Surprisingly, no significant alterations in any inflammatory or cytokine related
proteins were observed. Except for the heat-shock protein family and some mitochondrial
proteins, no similarity was observed when comparing proteomic data obtained from BV-2 cells
(in monoculture or co-culture systems). Therefore, the native environment of the striatum, in
which many different types of neurons, astrocytes, etc. exist, certainly plays a critical role in the
striatal-specific activation of microglia following METH exposure.
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ABSTRACT
PROGRESS TOWARDS UNDERSTANDING OF MECHANISMS OF ACTION OF
POTENT MULTIFUNCTIONAL DISEASE MODIFYING
THERAPEUTICS FOR PARKINSON’S DISEASE
by
MRUDANG MANOJKUMAR SHAH
May 2014
Advisor: Dr. Aloke Dutta
Major: Pharmaceutical Sciences
Degree: Doctor of Philosophy
Our long term goal is to design and develop potent multifunctional disease modifying
therapeutics for Parkinson’s disease. The objective of my dissertation was to understand the
mechanisms of action of some potent small molecules (synthesized in our lab) as a disease
modifying Parkinson’s disease therapeutic. The objective was achieved by pursuing the
following two specific aims:
1. Investigating anti-oxidant and neuroprotective effects of a lead molecule (D-512) generated
in our lab.
2. Assessing the ability of some of our potential lead compounds (D-240, D-436, and D-520) to
prevent the aggregation of α-synuclein.
Oxidative stress is one of the major factors implicated in the pathogenesis and
progression of Parkinson’s disease. To investigate the neuroprotective effects of D-512 in
Parkinson’s disease, we determined the ability of D-512 to rescue against 6-hydroxydopamine
induced cell death in dopaminergic cell line PC12 under two different protocols. Once it was
established that D-512 is able to prevent/rescue the cell death induced by 6-hydroxydopamine in
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PC12 cells, various other assays to determine its ability to confer neuroprotection were
performed.
As Parkinson’s disease patients have elevated levels of oxidative stress and subsequent
damage of their glutathione system, excessive lipid peroxidation, and DNA damage, we
evaluated D-512’s ability to protect against 6-hydroxydopamine induced changes in glutathione
levels and DNA damage. We also evaluated the ability of D-512 to protect against the lipid
peroxidation induced by sodium nitroprusside. In addition, we also evaluated the possible
molecular mechanism by which D-512 may be able to confer neuroprotection against 6hydroxydopamine induced cell death.
α-synuclein aggregation has been shown to be present in post-mortem brains of
Parkinson’s disease patients and SNCA gene mutations as well as gene duplication and
triplication results in familial form of Parkinson’s disease. To assess the ability of some of our
lead compounds against α-synuclein aggregation, we developed a cell-free system assay. We
simulated different Parkinson’s disease associated factors to generate different types of αsynuclein aggregates. We also developed various assays to determine the type of aggregates
formed following our experiments. After optimizing assays to generate α-synuclein oligomers
and fibrils, we evaluated the ability of some standard compounds (ascorbic acid and rifampicin)
and some of our lead compounds (D-436 and D-520) to prevent α-synuclein aggregation in
presence of dopamine. We employed numerous assays to verify the morphology and structural
characteristics of the aggregates formed under various conditions.
α-synuclein aggregates have been known to transfer from one neuron to another by their
ability to form pores in biological membranes. Therefore, we developed an in-vitro assay to
determine the extracellular toxicity of α-synuclein aggregates generated under high concentration
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of α-synuclein and α-synuclein in presence of dopamine by cell-free system assay. Afterwards,
we evaluated the ability of a standard compound (rifampicin) and our lead compounds (D-240,
D-436, and D-520) to prevent α-synuclein aggregation and subsequent cytotoxicity of
extracellular α-synuclein aggregates. We also evaluated the ability of our compounds to prevent
α-synuclein aggregation and the morphological changes induced in presence of our lead
compounds.

INVESTIGATING THE METHAMPHETAMINE-INDUCED
STRIATAL MICROGLIA ACTIVATION
by
MRUDANG MANOJKUMAR SHAH
May 2014
Advisor: Dr. David Thomas
Major: Pharmaceutical Sciences
Degree: Doctor of Philosophy
Methamphetamine is a highly abused, addictive and neurotoxic drug which causes
striatal-specific activation of microglia cells. Our long term goal is to identify the potential
molecular targets of methamphetamine induced neurotoxicity and addiction. The objective of my
dissertation was to develop a cell-culture model of methamphetamine neurotoxicity and
determine

proteomic

expression

changes

in

microglia

isolated

from

striatum

of

methamphetamine treated animals. I achieved my objective by pursuing following two specific
aims:
1. Identifying the proteomic expression changes of cultured microglia cells after exposure to
methamphetamine or similar insult.
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2. Optimization of a protocol to isolate highly purified fraction of microglia from various
regions of brain and identification of protein expression changes in striatal microglia isolated
from control and methamphetamine treated animals.
The addictive property of methamphetamine is because of its ability to cause release of
dopamine from striatum, which cause euphoria. Dopamine quinones have been shown to cause
significant changes in gene expression profile of culture microglia cells (BV2 cells). We
determined to evaluate the effect of different concentrations of methamphetamine and
lipopolysaccharide (gram negative endotoxin which causes strong immune response) on cultured
microglia cells alone and cultured microglia cells which have access to various soluble factors
secreted by cultured dopaminergic cell line (MN9D cells). We also verified the differences in
protein expression profile of BV2 cells alone or BV2 cells co-cultured with dopaminergic
neuronal cell line to determine if either of the cell-culture systems can be used as a model to
determine methamphetamine-induced neurotoxicity in striatal microglia.
As striatum is a region where all dopaminergic nerve terminals of nigrostriatal tract end
and methamphetamine has been shown to cause significant alterations in dopaminergic neuronal
system, we determined to isolate microglia from striatum. We compared and optimized various
protocols for microglial isolation to achieve method to isolate highly pure fraction of microglia
cells. Afterwards, we also isolated microglia from striatum of untreated animals and animals
treated with methamphetamine to determine protein expression changes between them. We
analyzed the differences in protein expression between isolated microglia to understand the
molecular mechanisms or pathways which are altered or affected by methamphetamine which
might be responsible for addictive and neurotoxic properties of methamphetamine.
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